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Abstract 
 
 
At the initial stages of tumourigenesis, transformation occurs in a single cell within a 
healthy epithelial sheet. Competitive interactions between normal and Ras-
transformed cells can drive the elimination of mutant cells from tissues to protect from 
carcinogenesis. Moreover, we have previously demonstrated that normal cells detect 
and eliminate Ras-transformed cells via differential EphA2 signalling. KrasG12D 
expressing cells (KrasG12D cells) initiate and drive the earliest stages of pancreatic 
cancer yet it is unclear if normal pancreatic cells can eliminate oncogenic cells. Here 
we use low level, stochastic induction of KrasG12D mutations in the pancreas to model 
the interaction of normal and transformed epithelial cells. We show that Ras-
transformed cells adopt a contractile morphology and are eliminated from healthy 
tissue when present at low numbers. When surrounded by normal cells, KrasG12D cells 
become segregated, increase in compactness and are often extruded. We find that E-
cadherin-based cell-cell contacts are downregulated and internalised in mutant cells 
when surrounded by normal neighbours in an EphA2-dependent manner. Our 
evidence also suggests that normal cells suppress progression of Ras-transformed 
cells to an early disease state. Together, this study suggests that non-transformed 
pancreatic epithelial cells can eliminate KrasG12D cells from the tissue via EphA2 
signalling. These data identify a novel putative tumour-suppressive mechanism in the 
adult pancreas that mutant cells must first overcome to drive tumourigenesis. 
Understanding the earliest stages of pancreatic carcinogenesis will provide insight into 
how risk factors promote disease and may elucidate how pancreatic cancer spreads 
around the body. 
 
 1 
Chapter 1: Introduction 
 
1.1 The Mammalian Pancreas 
 
 The pancreas is a glandular organ that forms part of both the digestive 
and endocrine system (Jain and Lammert, 2009). It is located in the upper left 
part of the abdomen behind the stomach and is divided into four regions: head, 
neck, body and tail. The exocrine pancreas consists of acinar and ductal cells 
(Figure 1.1A). The acinar cells form the bulk of the pancreas and generate 
digestive enzymes that are stored in zymogen granules. They are organised into 
grape-like clusters at the termini of a branching ductal system (Bardeesy and 
DePinho, 2002). The ducts form a network of tubes of increasing size that add 
mucous and bicarbonate to the acinar-secreted enzyme mix and empty into the 
duodenum (Grapin-Botton, 2005). The endocrine pancreas is made up of four 
cell types that are organised into Islet of Langerhans and secrete hormones into 
the bloodstream (Figure 1.1B). The a- and b- cells regulate the usage of glucose 
by producing glucagon and insulin, respectively. Pancreatic polypeptide and d-
cells produce pancreatic polypeptide and somatostatin to modulate the secretory 
properties of other pancreatic cell types (Jain and Lammert, 2009). To control 
and carry out these functions the pancreas is highly innervated and contains a 
network of blood vessels (Brunicardi et al., 1995). 
 
1.2 Epithelial Biology 
 
 The pancreas, as with most organs, consists of layers of cells termed 
epithelia and have several functions such as: form a physical barrier to protect 
tissues, regulate the exchange of chemicals between the underlying tissue and 
lumen, secretion of hormones into the circulatory, enzymes and other products 
into ducts and also provide sensation (Alberts, 2013). The role of epithelial 
tissues is closely associated with the junctional complexes formed between cells 
and the polarity of epithelial tissues (Figure 1.2). 
 Epithelial cell polarity is established by complex but coordinated events 
involving the multiprotein complexes: Par, Crumbs and Scribble (Rodriguez-
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Boulan and Macara, 2014). This generates spatially distinct domains at the apical 
surface, the tight junction, and the lateral and basal surfaces (St Johnston and 
Ahringer, 2010). Stable cell polarity also relies on the asymmetric delivery of 
apical and basolateral proteins to the correct surface (Apodaca et al., 2012). 
 The orientation of epithelial polarity requires extrinsic signals that arises 
from the extracellular matrix (ECM) (Gumbiner, 1996). Most cells also contact a 
supporting matrix with a large variety of cell surface proteins interacting with the 
underlying extracellular matrix (ECM) for structure and cell migration (Bonnans 
et al., 2014). The integrin family is central to these cell-matrix interactions. 
Between cells, tight junctions link epithelial cells closely together to form a barrier 
and enable regulation of ion transport across epithelial layers. The mechanical 
attachment between adjacent cells is carried out by adherens junctions that 
consist of cadherins, such as E-cadherin, and catenins such as p120-, a- and b- 
catenin and are linked to the actin cytoskeleton (Alberts, 2013). This linkage to 
the actin cytoskeleton can generate force and the linkage of cadherins to the 
actin network is finely regulated. Desmosomes are another class of cell-cell 
junction that confers mechanical resilience on cell layers. Together these 
junctions mediate cell-cell and cell-ECM adhesion and allow epithelial layers to 
act as a coherent dynamic sheet (Trepat and Sahai, 2018). Epithelial integrity 
and homeostasis are central to survival with alterations to these systems 
resulting in cancer. 
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Figure 1.1: Exocrine and endocrine compartments of the pancreas. 
Grape-shaped acinar cells produce enzymes stored in zymogen granules 
that travel down ducts to the intestine. The hormone-secreting islets are 
found scattered throughout the tissue. Figure based on Bardeesy & 
DePinho, 2002. 
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Figure 1.2 Epithelial Polarity and Junctional complexes. Several junctional 
complexes perform different functions within epithelial tissues. Tight junctions 
perform a barrier function and enable active regulation of ions. Adherens 
junctions generate cell-cell adhesion and can transmit force through the linkage 
with the actin cytoskeleton. Cell-matrix interactions are facilitated through 
integrins. The basement membrane provides directional cues that allows the 
establishment of polarity. 
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Pancreatic Cancer 
 
1.2.1  Incidence 
 
 Pancreatic cancer is one of the most deadly forms of the disease. An 
estimated 9,921 new cases were diagnosed in the UK in 2015 and associated 
with 9,263 deaths in 2016 (Cancer Research UK, 2017). It is currently the fourth 
highest cause of cancer death in developed countries and is predicted to become 
the second leading cause of cancer-related mortality by 2030 (Rahib et al., 2014). 
Less than 5% of patients survive for at least five-years after diagnosis in the UK 
and this survival rate has remained unchanged for the last 40 years (Cancer 
Research UK, 2017).  
  
1.2.2 Risk factors 
 
  One of the major determinants of pancreatic cancer risk is age with over 
90% of patients diagnosed >50 years old (Deutsch et al., 1999). With regards to 
preventable risk factors, tobacco smoking is the most characterised. It has been 
estimated that smoking is attributable to 15-30% of cases. Smoking tobacco can 
increase the risk of pancreatic cancer by up to threefold and a dose-risk 
relationship has been identified (Bosetti et al., 2012). Other factors such as 
obesity and low physical activity have also been linked to development of this 
disease (Behrens et al., 2015).Obesity is thought to promote a chronic pro-
inflammatory state and hyperinsulinaemia that may increase risk (Raimondi et 
al., 2009; Xu et al., 2018). Chronic pancreatitis, an inflammatory disease of the 
pancreas, is believed to increase risk of pancreatic cancer by more than tenfold. 
Diabetes can be both a consequence of early-stage pancreatic cancer and a risk 
factor for the disease with long-term diabetes approximately doubling the risk of 
pancreatic cancer (Bosetti et al., 2014). However, the precise mechanism for 
increased likelihood of developing the disease cause by different risk factors is 
not well understood.  
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1.2.5 Diagnosis of Pancreatic cancer 
 
 One of the major contributors to the dismal prognosis of pancreatic cancer 
is due to late diagnosis. Pancreatic cancer is difficult to diagnose in part because 
the clinical manifestations are non-specific and occur late in disease progression. 
Symptoms include unexplained weight loss, nausea, new-onset diabetes and 
jaundice (Freelove and Walling, 2006).Diagnosis typically requires expensive 
and invasive techniques such as contrast-enhanced computed tomography and 
endoscopic ultrasound with needle biopsy. At the time of diagnosis around 80% 
of patients have advanced, metastatic disease that is not suitable for surgical 
intervention (Siegel et al., 2016). However, patients diagnosed with localised 
disease are eligible for surgery which increases the 5-year survival by >5-fold to 
25%.  
 Being able to diagnose the disease earlier would markedly improve patient 
survival but faces a number of challenges. Although the lifetime risk for 
developing PDAC is 1.5%, and only 1 in 8000 individuals will be diagnosed each 
year (Siegel et al., 2016). This low incidence in the general population in 
combination with expensive and invasive tests demands that any screening 
technology is highly sensitive with a low false positive rate. Use of biomarkers is 
a promising area of research for diagnosis and disease monitoring of pancreatic 
cancer. Currently, in individuals known to have a high risk for developing PDAC, 
the blood biomarker cancer antigen 19-9 (CA-19) can be used to aid diagnosis 
and monitor disease. However, it has a number of limitations with low sensitivity 
(78.2%), specificity (70%) and false positive (5-10%) limiting its use (Becker et 
al., 2014; Poruk et al., 2013). Furthermore, it is difficult to differentiate between 
pancreatic cancer and other non-malignant diseases such as liver cirrhosis 
(Duffy et al., 2010) and CA-19 is not expressed in all patients (Poruk et al., 2013). 
Circulating tumour DNA (ctDNA) encoding mutant KRAS have shown 
encouraging results with detection in 43% of patients before metastasis. Efforts 
to use mutant KRAS has also been hampered by the finding that Kras-mutations 
are common in an age-dependent manner even in people devoid of pancreatic 
malignancy (Lu et al., 2002; Parsons and Meng, 2009; Yakubovskaya et al., 
1995; Yan et al., 2005). Similarly, the presence of circulating tumour cells from 
may also provide a fruitful diagnostic but both ctDNA and circulating cells are 
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only detected in a subset of pancreatic cancer patients (Sausen et al., 2015). 
More recently, the EphA2 receptor has been identified as a potential extracellular 
vesicle biomarker for pancreatic cancer (Liang et al., 2017). Although promising, 
it is imperative to understand how biology impacts biomarkers in disease initiation 
and progression. 
 
1.3 Biology of Pancreatic Cancer 
 
 Pancreatic ductal adenocarcinoma (PDAC); the most common form of 
pancreatic cancer accounts for 95% of cases and arises from the exocrine 
compartment of the pancreas.  
 Multiple studies have identified Kirsten rat sarcoma viral oncogene 
homolog (KRAS) mutations as the initial event in the development of human 
PDAC (Almoguera et al., 1988; Habbe et al., 2008; Hingorani et al., 2003). 
Outside of KRAS mutations the genetic landscape of pancreatic cancer primarily 
consists of only a handful of other mutations: CDKN2A, TP53, and SMAD4. 
Activating mutations in KRAS are found in up to 95% of patients with inactivating 
mutations in TP53, CDKN2A and SMAD4 occurring in 50-80% of cancers 
(Biankin et al., 2012; Jones et al., 2008; Waddell et al., 2015; Witkiewicz et al., 
2015). PDAC is associated with several distinct precursor lesions including 
pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous 
neoplasm (IPMN) and mucinous cystic neoplasm (MCN) (Morris et al., 2010a). 
The stepwise progression of PanIN lesions to invasive PDAC has been most well 
characterised, summarised in Figure 1.3. They are classified based on histology 
into three stages of increasing cellular and nuclear atypia (Bardeesy and 
DePinho, 2002; Hruban et al., 2004; Morris et al., 2010a) (Figure 1.2): PanIN 1A 
(flat duct lesions), PanIN 1B (papillary duct lesions), PanIN 2 (papillary duct 
lesions with dysplasia) and PanIN3 (also known as carcinoma-in-situ). Support 
for the stepwise model comes from increasing PanIN stage associated with 
increasing mutational burden. For example, loss of p16INK4A protein is associated 
with PanIN 2 and PanIN 3, with a higher frequency in PanIN 3 (Wilentz et al., 
1998). Nuclear accumulation of TP53 or SMAD4 loss is also most commonly 
observed in PanIN-3, with higher frequency of somatic mutation of both genes in 
invasive cancer (DiGiuseppe et al., 1994; Wilentz et al., 1998, 2000). Moreover, 
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although KRAS mutations are present in all PanIN stages and PDAC, the 
proportion of cells containing KRAS mutations increase with PanIN grade (Kanda 
et al., 2012). This suggests that in humans early PanIN lesions expand clonally 
and contain KRAS wild-type cells that are lost as disease advances. The 
mutational burden of Kras-transformed cells in PanIN lesions then increases, 
lesions become higher grade and eventually develop into PDAC. Recently, a 
revised 2-tier classification system has recommended for patients which 
describes current PanIN-2 and neoplasms with intermediate grade dysplasia as 
low grade (Basturk et al., 2015). With the term ‘high grade’ lesion reserved for 
the uppermost end of the spectrum including carcinoma in situ. 
 Another key feature of pancreatic cancer is an abundant and dense 
collagenous stroma and accounts for up to 90% of the tumour volume (Neesse 
et al., 2015). The stroma consists of both cellular elements: pancreatic stellate 
cells, infiltrating immune cells, endothelial cells and neuronal cells and 
extracellular matrix (ECM) proteins: collagens, fibronectin and laminin as well as 
non-collagenous proteins like glycoproteins and glycosaminoglycans (Von 
Ahrens et al., 2017; Neesse et al., 2015; Sousa and Kimmelman, 2014; Stromnes 
et al., 2014). This results in restricted nutrients and oxygen gradients with 
complex cross-talk between the stroma and cancer (Tape et al., 2016). 
 Pancreatic cancer is an extremely deadly disease and one reason for this 
is the highly invasive and metastatic capabilities of PDAC. It has been 
demonstrated in murine models that cells can disseminate from the earliest 
stages of pancreatic carcinogenesis (Hendley et al., 2016; Rhim et al., 2012, 
2014). Before frank metastasis could be detected, mutant cells were able to seed 
the liver with circulating tumour cells widely associated with epithelial-to-
mesenchymal (EMT) characteristics (Rhim et al., 2012)(Figure 1.2). 
Furthermore, genetic analysis has indicated that precancerous neoplastic cells 
migrate through the ductal system and seed precursor lesions in the pancreas 
(Makohon-Moore et al., 2018), suggesting cells can spread early in disease 
progression but not necessarily to seed other organs. Recently, livers from PDAC 
patients were found to harbour single disseminated cancer cells that can grow 
following resection of the primary tumour (Pommier et al., 2018). Strikingly, these 
cells were found to be cytokeratin-19 (CK19) negative. Expression of CK19 in 
acinar cells is thought to follow KrasG12D mutations as the initial event in 
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pancreatic cancer. In acinar cells, expression of oncogenic KrasG12D results in a 
CK19, duct-like progenitor via a process known as acinar-ductal metaplasia 
(ADM), that gives rise to precursor lesions (Houbracken et al., 2011). 
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Figure 1.3: Progression of PDAC. Activating mutations to Kras in acinar cells are 
sufficient to initiate pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal 
adenocarcinoma (PDAC). PanINs are classified on morphology with increasing 
cellular atypia and mutations burden as disease progresses. Oncogenic cells can 
escape basally from PanIN-1 lesions to metastasise to the liver. In addition to 
epithelial changes desmoplastic changes occur in the stroma. Figure is based on 
Morris et al., 2010. 
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1.3.1 Acinar-Ductal Metaplasia  
 
 Histologically, PDAC resembles the exocrine ductal compartment of the 
pancreas, however, mouse models using lineage-specific oncogene activation 
suggested that the ductal compartment is refractory to Kras mutations (Brembeck 
et al., 2003; Guerra et al., 2007). It was later observed that oncogenic KrasG12D 
can convert acinar cells into duct-like cells and PanINs and this leads to PDAC 
(Carriere et al., 2007; Guerra et al., 2007; Habbe et al., 2008; Morris et al., 2010a; 
Shi et al., 2013). This acinar-ductal-metaplasia (ADM) process has been an 
intense area of study in recent years. In the absence of activating Kras mutations 
ADM is a common and reversible process to protect the pancreas and help 
regenerate the organ following inflammation (e.g. pancreatitis) or damage 
(Houbracken et al., 2011; Liou et al., 2013). ADM can also result from loss of cell-
cell contact signalling; with several studies demonstrating that loss of cell-cell 
junctions and E-cadherin based cell-cell adhesions capable of driving ADM (Hall 
and Lemoine, 1992; Hendley et al., 2016; Hezel et al., 2008; Shi et al., 2013). 
Oncogenic KrasG12D expression also facilitates ADM, but in contrast to the 
damage response, this is irreversible and can lead to PanIN lesion formation 
(Baer et al., 2014; Collins et al., 2014; Kopp et al., 2012; Storz, 2017). A summary 
of ADM can be found in Figure 1.4. 
 During the process of ADM, a number of transcription factors associated 
with mature acinar fate are turned off, with increased expression of factors 
typically found in both mature ductal cells and embryonic pancreatic progenitors 
(Kopp et al., 2012; Krah et al., 2015; Prévot et al., 2012; Zhu et al., 2007). 
Specifically, acinar genes such as Mist1, Cpa1 or those encoding elastase and 
amylase are silenced (Shi et al., 2013). With induction of genes such as CK19 
and Sry-related high-mobility group box 9 (Sox9) (Liou et al., 2013). ADM can 
then lead to the formation of early PanIN lesions but to progress to more invasive 
carcinoma, it is thought another insult in the form of a secondary mutation 
(Bardeesy and DePinho, 2002; Hingorani et al., 2005), or inflammation (Guerra 
et al., 2011) is required to progress to PDAC. 
 Although the use of acinar-specific Cre promoters has demonstrated that 
mutant acinar cells can give rise to PDAC in animal models (Habbe et al., 
2008), the progression of pancreatic cancer in humans is less well understood. 
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Human acinar cells can undergo ADM (Liu et al., 2016) but a variety of 
pancreatic lesions have been identified in humans and whether PDAC occurs 
via a stepwise process is not clear. Indeed, PanIN-like lesions can be induced 
by PDAC in normal, adjacent tissue (Ferreira et al., 2017). This suggests that 
lesions could arise from a variety of cellular origins. It is also conceivable that 
PanIN lesions are a protection mechanism from the progression of 
tumourigenesis by confining aberrant cells into proliferative-restricting cysts 
similar to the intestine (Cortina et al., 2007). 
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Figure 1.4: Acinar-ductal metaplasia (ADM) in the pancreas. A number of insults 
to pancreatic cells such as KrasG12D expression, loss of cell-cell contacts or 
inflammation can induce dedifferentiation to a more duct-like cell. In response to 
inflammation this process is reversible but in the presence of KrasG12D it is irreversible 
and can initiate pancreatic cancer precursor lesion formation. Figure is based on 
Storz, 2017. 
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1.3.2 RAS/MAPK Signalling in Pancreatic Cancer 
 
 RAS/MAPK signalling is integral to all parts of PDAC development. 
Mutational activation of KRAS is found in around 95% of PDAC tumours (Biankin 
et al., 2012), can drive disease in mouse models (Hingorani et al., 2003) and 
KrasG12D expression is required for the maintenance of precancerous lesions 
(Collins et al., 2014). This demonstrates that oncogenic Kras expression is critical 
for the initiation, growth and maintenance of PDAC. 
 KRAS is a member of the Ras family of small GTPases which includes: 
HRAS, NRAS and KRAS and together constitute the most frequently mutated 
oncogene family in human cancer (Prior et al., 2012). However, the mutation of 
family members is associated with different cancers; for example, HRAS is 
frequently mutated in melanoma and bladder whereas KRAS mutations are 
found in ovary, lung, colon and pancreas. Furthermore, the mutation frequency 
of KRAS can vary between cancer types. In PDAC, KRASG12D mutations are 
dominant whereas a relatively high frequency of G13 mutations are found in 
colorectal cancer (Hobbs et al., 2016). This suggests different Ras isoforms and 
mutations are important for different forms of cancer. 
 The RAS family of proteins have been involved in cell differentiation, 
proliferation, migration and apoptosis (Cox and Der, 2010). RAS proteins 
become active when bound to guanine triphosphate (GTP) and inactive when 
bound to guanine diphosphate (GDP). RAS proteins have an intrinsic GTP-GDP 
cycling ability which is regulated by guanine nucleotide exchange factors (GEFs) 
and GTPase activating proteins (GAPs), that stimulate nucleotide exchange and 
the intrinsic GTP hydrolysis activity of RAS respectively. In the active, RAS-GTP 
bound form it interacts with a spectrum of downstream effectors to regulate a 
wide range of signalling networks. Mutations to residues G12 and G13 lead to 
constitutive activation of KRAS, holding it in the KRAS-GTP form promoting 
persistent signalling to downstream effectors. Downstream of KRAS are a 
diverse range of signalling pathways. In PDAC, the KRAS signalling pathways 
activated in PDAC are: Raf/Mek/Erk, PI3K/Pdk1/Akt and Ral GEF pathway 
(Collisson et al., 2012; Eser et al., 2013; Feldmann et al., 2010; Lim et al., 2005). 
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 In summary, KrasG12D mutations lock KRAS in the active GTP-bound form 
which is required for the initiation and development of PDAC. Other RAS isoforms 
can be mutated but are not as important in PDAC.  
 
1.3.4 Models of Pancreatic Ductal Adenocarcinoma 
 
 Our understanding of how KRAS signalling contributes to the progression 
and development of PDAC has largely come from mouse models. However, initial 
studies of Kras mutational activation in murine models were unsuccessful. 
Expression of mutant Kras under acinar and ductal promoters resulted in ductal 
lesions and mixed acinar and ductal carcinomas (Grippo et al., 2003) or 
periductal inflammation (Brembeck et al., 2003), but not PDAC. This could have 
been a result of differences in Kras output between the endogenous and lineage 
specific promoters. The development of the Cre-inducible conditional allele 
targeted to the endogenous Kras locus allowed temporal and spatial control 
using the endogenous promoter (Hingorani et al., 2003; Tuveson et al., 2004).  
 Cre recombinase is an enzyme that recognises loxP sites on DNA and 
can excise the segment between them (Hoess et al., 1984). Artificial integration 
into the genome allows targeting of specific DNA sequences to inactivate and 
activate genes of interest. Activation is typically achieved with a loxP-STOP-loxP 
cassette at the start of a gene; Cre activation then removes a stop codon and 
permits gene expression. Control of Cre activation can be provided by using 
different cell type specific promoters to drive Cre expression. The first models to 
accurately recapitulate PDAC used Cre-recombinase under the control of 
promoters of pancreatic progenitor genes such as pancreatic duodenal 
homeobox 1 (Pdx1) and Ptf1a (also known as p48) which target KrasG12D to 
almost all cells in the developing pancreas (Hingorani et al., 2003). These early 
studies using Cre-LoxP system demonstrated that physiological levels of 
KRASG12D induced lesions that recapitulate the full spectrum of human PanINs. 
Moreover, animals developed invasive and metastatic PDAC at a low frequency 
over 1 year (Hingorani et al., 2003). However, even in these models whereby 
KrasG12D is expressed in almost every cell in the pancreas during development, 
only a small number of lesions formed with most of the tissue histologically 
normal. This suggests other factors are involved in lesion formation. 
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 These models were then expanded to investigate the contribution of 
different cell types in PDAC. It has been demonstrated that expression of 
KrasG12D in adult mature acinar cells results in spontaneous PanIN lesion 
formation (Habbe et al., 2008). However, the ductal exocrine compartment 
appears more refractory to tumourigenesis with expression of KrasG12D alone 
insufficient to drive tumourigeneis. Recent work has demonstrated that two 
mutant p53R172H alleles in addition to oncogenic Kras is required to initiate PDAC 
from the ductal compartment in adult mice (Bailey et al., 2016). Moreover, it 
appears that PDAC originating from ductal cells progresses to PDAC via tubular 
lesions distinct from PanIN lesions (Ferreira et al., 2017). Therefore, both ductal 
and acinar cells can be a cell of origin for PDAC although duct-derived PDAC 
requires additional mutations and displays distinct pathophysiology. 
 The original KrasG12D-driven models have also been combined with 
mutations and loss-of-function alleles for tumour suppressors commonly mutated 
in PDAC. It is important to note that in these current models, simultaneous 
activation of KrasG12D and loss of tumour suppressor occurs, in contrast to human 
tumour progression where aberrations accumulate over time. Loss of tumour 
suppressors in combination with oncogenic Kras expression accelerates disease 
and can alter the type of precursor lesion that develops, metastatic behaviour 
and the differentiation state of the malignant disease (Morris et al., 2010a). This 
illustrates the plasticity of the pancreas, with the same pancreatic cells 
developing a range of distinct phenotypes based on a few mutations. Studies of 
murine models has also indicated that mutational ‘inactivation’ and complete loss 
of protein can have different functions. Mice expressing mutant p53R127H can 
promote the metastasis of PDAC, in contrast to genetic loss of p53 which does 
not (Morton et al., 2010). This model, Pdx1-Cre; KrasLSLG12D/+;p53R172H (KPC) has 
become  one of the most widely used models of PDAC for several reasons. They 
develop a spectrum of premalignant lesions that progress to PDAC with 100% 
penetrance. Tumours accurately recapitulate the extensive stroma and 
moderately differentiated ductal morphology observed in human patients. The 
KPC model also develop co-morbidities such as cachexia and jaundice and 
develop lung and liver metastases, the most commonly observed sites in humans 
(Gopinathan et al., 2015). 
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 Other murine models have used the tamoxifen inducible Cre (CreERT). In 
this model, the Cre enzyme is fused with a modified oestrogen receptor (ERT) 
that prevents translocation of the Cre protein into the nucleus (Feil et al., 1996). 
This results in the CreERT construct only translocating to the nucleus upon binding 
of tamoxifen which provides temporal control of recombination. This also 
provides spatial control as tamoxifen dose can be titrated to lower the number of 
cells in which recombination takes place. Recently, this model has been used to 
study early pancreatic cancer in the adult and shows differential changes based 
on whether recombination occurs on a global or much lower level (Krah et al., 
2015). Loss of the acinar determinant Ptf1a in around a quarter of acinar cells 
resulted in no histological change after 6 weeks, but deletion in >65% of cells 
drove rapid dedifferentiation (Krah et al., 2015). This suggests the interaction of 
normal and transformed cells impacts disease initiation and proposes that 
heterotypic interactions may be important in the initiation of PDAC. 
 
1.4 Cell Competition 
 
 
 The heterotypic interaction of two different cell populations can have a 
major impact on the fate of aberrant cells and tumourigenesis. It has been 
demonstrated that normal cells can remove aberrant or defective cells through a 
process known as cell competition. Cell competition is a cell fitness-sensing 
mechanism that compares the relative fitness of a cell with its neighbour and is 
essential for proper development of embryos and tissue homeostasis in adults 
(Bowling et al., 2018; Morata and Ripoll, 1975; Moreno et al., 2002). Through 
competition and the sensing of relative fitness, those cells deemed less fit than 
their neighbours are eliminated (i.e., become “losers”), with the fitter population 
(“winners”) undergoing compensatory proliferation (Figure 1.4). Importantly, loser 
cells lost through this mechanism are viable in different contexts. Cell competition 
was first described in Drosophila melanogaster imaginal wing discs by Morata 
and Ripoll (1975). Analysis of cells carry a heterozygous mutation in Minute (a 
ribosomal protein) found that heterozygous animals are viable and display a 
developmental delay due to slower proliferation. However, analysis of mosaic 
flies found that in heterozygous animals, Minute+/- cells undergo apoptosis when 
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surrounded by normal, wild-type cells (Figure 1.4). This first demonstrated that 
tissues sense differential growth rates within a tissue and eliminate the slower-
growing population. This early work also established a number of rules governing 
cell competition. Cell competition was found to be regionally modulated and 
sensitive to tissue type. For example, Minute hemizygous clones are more 
strongly outcompeted in the centre of the wing disc compartment, than at the 
periphery (Simpson, 1979). The proximity of winners and loser cells is important 
for cell competition but are not transmitted across compartment boundaries, 
indicating not only local but lineage specific cell interactions are essential 
(Simpson and Morata, 1981). Furthermore, cell competition can have a number 
of different effects on the loser cell population. Although classically associated 
with inducing apoptosis in loser cell populations (Moreno et al., 2002) loser cells 
can also be induced to undergo senescence  (Bondar & Medzhitov, 2010), 
differentiation (Shiozawa et al., 2011) or extrusion (Hogan et al., 2009). 
 Evidence that cell competition is conserved in mammals was 
demonstrated using mouse cells carrying a heterozygous mutation in ribosomal 
protein L24 (Oliver et al., 2004). In chimera animals, mutant cells are eliminated 
by wild-type neighbours whereas they survive in a heterozygous mutant animal. 
The mutant cells displayed a growth disadvantage, but could generate viable 
mice in isolation. Evidence for cell competition in mammals also arises from a rat 
liver regeneration model (Oertel et al., 2006). Adult hepatocytes were found to 
be replaced by transplanted foetal hepatocytes over time, with apoptosis of adult 
hepatocytes at the border with foetal repopulating hepatocytes. Recently, the 
importance of cell competition in murine embryo has been highlighted with 
around 35% of cells eliminated via p53 mediated competition in normal 
development (Bowling et al., 2018). Mosaic activation of Myc in vivo has also 
been shown to induce apoptosis-dependent cell competition in several tissues 
and organs in developing mice (Clavería et al., 2013; Villa del Campo et al., 
2014). The investigation of Myc in cell competition has identified a number of 
concepts of cell competition, for example, that relative-fitness levels are 
important rather than absolute fitness values. This was first demonstrated in 
Drosophila where cells overexpressing dMyc, the homolog of the mammalian 
proto-oncogene c-Myc induce the death of surrounding, normal growing, wild-
type cells (De La Cova et al., 2004; Moreno and Basler, 2004). Wild-type cells 
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confronted with fitness-enhanced cell overexpressing non-tumourigeneic levels 
of Myc become losers and are eliminated (Figure 1.4) from the wing disc 
epithelium, a phenomenon known as supercompetition. 
 So far, cell competition appears to be a general feature of metazoan 
tissues that is important for expanding or eliminating cell lineage variants. 
Although cell competition drives changes in cellular properties, total tissue size 
does not alter suggesting homeostasis is preserved. With mutations predicted to 
occur in every cell division and the exposure to environmental factors also 
inducing DNA damage, adult tissues can be considered a patchwork of mutant 
clones. Indeed, sun-exposed skin is a patchwork of mutated cells with 18-32% of 
normal skin cells containing a carcinoma driver mutation (Martincorena et al., 
2015). Therefore, cell-competitive interactions could play a lifelong role in 
homeostasis of tissues. 
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Figure 1.5: Types of cell competition. Cells that are viable in homotypic 
environments but are less fit (e.g. Minute+/-) are eliminated via apoptosis when 
surrounded by fitter neighbours. In supercompetition, more fit cells (e.g. cMyc 
overexpressing cells) induce apoptosis in the surrounding less fit, wild-type 
neighbours. 
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1.4.1 Triggers of Cell competition. 
 
 A defining feature of cell competition is the elimination of aberrant cells 
only when confronted with more-fit cells. Three broad categories of changes to 
cells are known to trigger cell competition: those leading to metabolic changes, 
those causing sharp signalling differences and those disrupting apical-basal 
polarity (summarised in Table 1.1) 
 In many studies of cell competition, the two competing populations display 
different growth rates, for example, Minute lose clones grow slower than wild-
type counterparts (Morata and Ripoll, 1975). However, it is now clear that 
differences in growth rate alone are not sufficient to induce loser cell elimination 
by cell competition. Overexpression of cell-cycle regulators such as cyclin-D and 
cyclin-dependent kinase 4 (Cdk4), are not sufficient for cells to acquire a winner 
status and eliminate slower-growing wild-type cells (De La Cova et al., 2004). 
Conversely, decreasing proliferation of cells in a mosaic fashion via insulin 
signalling also does not induce cell competition in the slower growing cells (Böhni 
et al., 1999; Verdu et al., 1999). Furthermore, cell competition can be induced in 
post-mitotic cells in Drosophila follicular epithelium leading to apoptosis of losers 
and hypertrophy of winners (Tamori and Deng, 2013). 
 A number of mutations that alter proliferation and cause cell competition 
alter protein synthesis. The Minute and Bst mutations disrupt ribosomal proteins 
and MYC is known to regulate protein synthesis so alterations to this process 
may be the underlying trigger (Dang, 2012; Eilers and Eisenman, 2008; Meyer 
and Penn, 2008). In addition to this, metabolic pathways that impact cell 
proliferation may trigger cell competition. For example, MYC can activate 
glycolysis and regulate metabolism during cell competition (De La Cova et al., 
2014). Difference in energy metabolism have also been shown to be required for 
elimination of slow-growing cells in immortalised cell models (Penzo-Méndez et 
al., 2015). Therefore, proliferation may only be a readout of the different 
properties of winner and loser cells.  
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1.4.1.1 Signalling Pathways that trigger Cell Competition 
 
 The second set of mutations that induce cell competition affect signalling 
pathways. Sharp differences in bone morphogenetic protein (BMP)/Dpp (Moreno 
et al., 2002; Sancho et al., 2013), Wnt/Wg (Vincent et al., 2011), JAK-STAT 
(Rodrigues et al., 2012), Hippo signalling (Mamada et al., 2015; Tyler et al., 
2007), Notch signalling (Alcolea and Jones, 2015) and p53 mutations (Watanabe 
et al., 2018) have all been shown to induce cell competition and are summarised 
in Table 1.1. 
 The first signalling pathway found to regulate cell competition was the 
BMP/Dpp pathway. Minute+/- mutant clones in Drosophila have lower levels of 
Dpp signalling which causes apoptosis (Moreno et al., 2002). In mammals, 
pluripotent cells with decreased BMP signalling are also eliminated via an 
apoptosis-dependent mechanism (Sancho et al., 2013). 
 Differences in both WNT/Wg and JAK-STAT signalling between cells can 
also induce cell competition. Work in Drosophila models has demonstrated that 
cells with low WNT/Wg signalling levels are eliminated when surrounded by 
normal neighbours. Conversely, cells with higher levels of Wnt/Wg signalling via 
Axin or APC mutations, behave as supercompetitors and eliminate surrounding 
wild-type cells (Suijkerbuijk et al., 2016; Vincent et al., 2011). Similarly, in JAK-
STAT signalling, wild-type cells eliminate JAK-STAT signalling deficient cells with 
sustained activation of this pathway producing supercompetitors (Rodrigues et 
al., 2012).  
 Another pathway that can induce cell competition is the Salvador-Warts-
Hippo signalling pathway. In mouse cell cultures, activation of the Hippo 
signalling pathway in fibroblasts leads to elimination by normal neighbours 
(Mamada et al., 2015). Furthermore, inhibition of the Hippo pathway by Yorkie or 
Tead4 overexpression leads to cells becoming supercompetitors and elimination 
of wild-type cells (Mamada et al., 2015; Neto-Silva et al., 2010; Tyler et al., 2007; 
Ziosi et al., 2010). 
 Sharp signalling differences can also alter differentiation balance within an 
epithelium (Alcolea and Jones, 2015). Inactivation of Notch in single murine 
oesophageal epithelial progenitor cells results in these cells producing more 
progenitor daughters (Alcolea et al., 2014). Moreover, mutant cells promote the 
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differentiation of neighbouring wild type cells and hence the elimination of normal 
cells from the tissue. 
 Finally, it has recently been demonstrated that in MDCK cells and 
intestinal organoids expressing mosaic expression of mutant p53 results in 
elimination of transformed cells (Watanabe et al., 2018). Although p53 is 
generally considered a sensing mechanism for cell competition, with this role 
discussed later, cells expressing mutant p53R273H undergo necroptosis when 
surrounded by normal epithelial cells.   
  
1.4.1.2 Polarity genes and Disruption of Epithelial Integrity in Cell Competition 
 
 Mutation of several different proteins involved in maintenance of apical-
basal polarity are also known to induce cell competition. In Drosophila, mutation 
to Scribble, Lethal giant larvae (Lgl), or Discs Large (Dlg) in all cells leads to 
neoplastic overgrowth and tumours. However, mutation of these genes in a 
mosaic fashion in Drosophila or MDCK cells in vitro leads to apoptosis of mutant 
cells by normal neighbours (Agrawal et al., 1995; Brumby and Richardson, 2003; 
Chen et al., 2012; Igaki et al., 2006; Norman et al., 2012; Tamori et al., 2010; 
Woods and Bryant, 1991). This suggests that cell competition does not just 
function to remove aberrant cells but also removes oncogenic cells. Indeed, 
overexpression of dMyc in Lgl mutant clones promotes retention of transformed 
cells and promotes neoplastic outgrowth (Froldi et al., 2010; Menendez et al., 
2010). Further indication that cell competition measures relative fitness, not 
absolute fitness levels, is that polarity deficient cells are not eliminated when 
surrounded by Minute+/- mutant cells (Froldi et al., 2010) 
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Factor/Pathway Role in Cell Competition Difference Reference 
Minute Heterozygous mutants are eliminated Growth (Morata and Ripoli, 1975) 
Myc High expressing cells are supercompetitors Growth 
(Claveria et al., 2013; de la 
Cova et al., 2004) 
BMPs Low levels associated with loser status Signalling 
(Moreno et al., 2002; Sancho et 
al., 2013,) 
Hippo 
Activation associated with loser 
cells whilst nuclear YAP 
associated with supercompetitor 
status 
Signalling (Neto-Silva et al., 2010; Ziosi et al., 2010) 
JAK/STAT 
Low levels associated with loser 
status and high levels with 
supercompetitors 
Signalling (Rodrigues et al., 2012) 
Notch 
Notch mutant cells promote 
differentiation and loss of wild 
type neighbours 
Signalling (Watanabe et al., 2018) 
p53 
p53 mutant cells undergo 
necroptosis and are basally 
extruded 
Signalling (Alcolea et al., 2014) 
Wingleess 
(Wg) 
Low levels associated with loser 
status and high levels with 
supercompetitors 
Signalling (Vincent et al., 2011) 
Scribble Scribble mutant cells are eliminated by normal neighbours Polarity 
(Brumby and Richardson, 2003; 
Igaki et al., 2006; Norman et al., 
2012) 
Discs large 
(Dlg) 
Dlg mutant cells are eliminated 
by normal neighbours Polarity (Igaki et al., 2006) 
Lethal giant 
larvae (Lgl) 
Lgl mutant cells are eliminated by 
normal neighbours Polarity 
(Agrawal et al., 1995; Tamori et 
al., 2010) 
Table 1.1: Summary of cell competition triggering signals  
 
1.4.2 Mechanisms of Sensing Cell Competition. 
 
  A core concept of cell competition is how cells sense the relative fitness 
levels of surrounding neighbours. Three main theories have been put forward to 
explain the context-dependent elimination of less-fit cells: 1) competition for 
growth factors/ nutrients, 2) direct cell fitness comparison and 3) mechanical 
sensing. 
 
1.4.2.1 Competition for ligands 
 
 An initial model to describe cell competition is that cells compete for a 
limiting factor necessary for survival. For example, neurons competing for a 
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limited pool of extracellular nutrients or growth factors required for viability (Raff, 
1992). This is supported by the fact that damage to growth or survival factor 
pathways leads to cell competition (Moreno et al., 2002; Senoo-Matsuda and 
Johnston, 2007). However, more recent studies suggest this model is too 
simplistic and does not occur in most competitive situations. Mouse pluripotent 
cells with defective BMP signalling are removed when surrounded by normal 
neighbours, however excess of BMP ligands cannot prevent this process 
(Sancho et al., 2013). If BMP were a limiting factor then the level of competition 
could be modulated by BMP levels, however, varying BMPs in co-culture systems 
does not alter cell competition intensity (Sancho et al., 2013). Furthermore, 
different types of cell competition take place in mammalian culture conditions in 
which growth factors are provided in excess (Hogan et al., 2009; Mamada et al., 
2015; Norman et al., 2012; Tamori et al., 2010). Therefore, it is likely other 
pathways are more relevant in competitive interactions. 
 
1.4.2.2 Direct-Sensing of Fitness 
 
 Another proposed model of cell competition is that fitness levels are 
communicated directly between cells. In this mechanism, the molecules exposed 
on the surface of cells reports the fitness status of a cell. Evidence for this 
mechanism arose with the discovery of Flower genes which encode a 
transmembrane calcium channel ubiquitously expressed in Drosophila (Rhiner et 
al., 2010). It has been demonstrated that less fit cells upregulate specific Flower 
isoforms that promote apoptosis, only when surrounded by cells expressing the 
ubiquitous Flower isoform. The isoforms associated with decreased fitness, 
termed Flower-lose isoforms, have been detected in Drosophila cell competition 
models induced by Minute, Myc and Scribble (Rhiner et al., 2010). Moreover, the 
expression of Flower-lose isoforms is sufficient to induce cell competition when 
surrounded by cells expressing the ubiquitous isoform (Levayer et al., 2015; 
Rhiner et al., 2010). Although it is not yet clear how differences in Flower isoform 
expression are established and the relevance to mammals. 
 A mechanism for the recognition of less-fit cells has recently been 
proposed that is similar to the detection of pathogens. The innate immune system 
can recognise both non-self, such as microbial infection, and altered-self, such 
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as cancer cells. Therefore, this could provide a potential mechanism to 
distinguish fitness levels between cells. In support of this, during cell competition 
the Toll and Immune Deficiency signalling pathways are rewired to drive loser 
cell elimination. For example, in dMyc overexpressing or Minute+/- mutant cells, 
the elimination of loser cells requires Toll-related receptors (TRRs)(Meyer et al., 
2014). However, it is not precisely understood how different fitness levels in cells 
results in TRR activation. Therefore, although differences in signalling proteins 
presented by less-fit loser cells appear to be important for establishing winners 
and losers, how decreased fitness leads to alterations in these surface markers 
is unclear. 
 
1.4.2.3 Mechanical Cell Competition 
 
 A final model of sensing fitness has been proposed based on mechanical 
stress. This was first proposed based on mathematical modelling of populations 
of cells with non-uniform proliferation rates (Shraiman, 2005). Faster-growing 
cells will compress the slower-growing surrounding cells and once the level of 
mechanical stress is sufficient it will drive apoptosis, relieving the overall tissue 
pressure. Evidence for this model comes from developing Drosophila tissue 
where cell crowding leads to delamination or forcing out of cells (Marinari et al., 
2012). 
 More recently, p53 levels have been identified as important in mechanical 
cell competition. It was found that Scribble knockdown Madin-Darby Canine 
Kidney (MDCK) cells in vitro have a basal level of p53 activation which makes 
them hypersensitive to mechanical stress (Wagstaff et al., 2016). When these 
mutant cells were surrounded by normal neighbours they become compacted 
and eliminated. Upon compression by normal neighbours, Scribble knockdown 
cells activate ROCK and p38 which further increased p53 and led to apoptosis. 
Indeed, p53 appears to be a general mechanism for fitness sensing, separate to 
it’s classical DNA-damage response. Cells with  stress-induced p53 activity are 
outcompeted by fitter cells in the mouse haematopoeitc system (Bondar and 
Medzhitov, 2010). Moreover, elevated p53 expression labels defective cells for 
competitive elimination in murine development (Bowling et al., 2018). 
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 Tension generated at the interface between winner and loser cells can 
also control mechanical competition. Interface contractility is generated between 
wild-type cells and cells expressing transcription factors for different fates 
(Bielmeier et al., 2016). Actomyosin accumulates at the boundary between 
normal and aberrantly-specific cells with contractility in single aberrant cells 
causing apoptosis. However, in larger clusters of mis-specified cells the 
contractile forces induced cyst formation. 
Furthermore, in dMyc-induced cell competition in Drosophila the probability of 
elimination of wild-type cells correlates with surface area in contact with mutant 
cells (Levayer et al., 2015). With tension differences between mutant and normal 
cells promoting intercalation, normal cell elimination and the subsequent invasion 
of tissue by oncogenic cells. 
  
 
1.4.3 Cell competition in Cancer 
 
 Newly arisen, pre-cancerous cells are produced in normal epithelial 
sheets and must overcome the barriers that act to maintain homeostasis in order 
to form a tumour. It therefore follows that the interaction of normal and mutant 
cells can lead to cell competition.  
 A number of observations support a tumour-suppressive role for cell 
competition. For example, polarity or Rab5 knockdown cells produce neoplastic 
lesions in mutant animals but are eliminated by surrounding wild-type cells via 
cell competition (Agrawal et al., 1995; Ballesteros-Arias et al., 2014; Brumby and 
Richardson, 2003; Chen et al., 2012; Gateff, 1978; Igaki et al., 2006; Norman et 
al., 2012; Tamori et al., 2010). Furthermore, in the mouse thymus, bone-marrow-
derived progenitors consistently replace T-lymphocyte precursors. A cell-
competition-type mechanism is thought to drive the elimination of older bone 
marrow progenitors by younger cells due to a decreasing responsiveness to 
interleukin-7 over time (Martins et al., 2014). If this cell competition is inhibited 
and older cells are no longer replaced then T cell acute lymphoblastic leukaemia 
arises. 
 In addition to the tumour-suppressive role of cell competition, a number of 
studies have also demonstrated a tumour-promoting role at multiple stages of 
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tumourigenesis. The overexpression of dMyc provided the first evidence of cell 
competition promoting tumourigenesis. With dMyc overexpression sufficient to 
transform mutant cells into supercompetitors and eliminate surrounding wild-type 
cells (De la Cova et al., 2004). The oncogenic role of MYC is well characterised 
and this supercompetitor role led to the suggestion that elimination of neighbours 
allows expansion of early-stage tumours (Moreno, 2008). However, the 
elimination of wild-type cells by dMyc overexpressing winner cells does not give 
rise to tumours and is phenotypically silent in both mice and Drosophila (Clavería 
et al., 2013; De La Cova et al., 2004; Moreno and Basler, 2004). This led to the 
suggestion that cell competition is limited to aiding the expansion of pre-
cancerous lesions that require a second oncogenic hit for tumour formation. The 
replacement of normal cells by a cancer-primed cell population that is 
morphologically normal is termed field cancerisation (Braakhuis et al., 2003; 
Slaghter et al., 1953). It has been demonstrated that competitive interactions can 
drive clonal expansion of a mutant cell population (Alcolea et al., 2014). 
Inactivation of Notch in single oesophageal epithelial progenitor cells promotes 
the differentiation and hence loss from the tissue of neighbouring wild type cells. 
Moreover, mutant cell division produces more progenitor cells and less 
differentiating cells leading to clonal expansion and a field change (Alcolea et al., 
2014). 
 However, several studies in Drosophila have demonstrated that 
elimination of wild-type cells by mutant cells can also promote tumour 
progression. In the Drosophila intestine APC -/- mutant cells kill surrounding 
normal cells and form adenomas (Suijkerbuijk et al., 2016). Importantly, 
preventing cell competition, by inhibition of apoptosis, restores tissue 
homeostasis and contains adenoma expansion. This demonstrates a 
requirement for cell competition to drive expansion of mutant cells. Furthermore, 
in the Drosophila wing disc, once clusters of less-fit cells reach a certain size cell 
competition also promotes tumourigenesis. Wild-type cells eliminate Rab5 
knockdown cells, however, once clusters reach about 400 cells in size the 
apoptosis in mutant cells at the boundary of normal:mutant cells is not sufficient 
to remove the cluster. The mutant cells further away from wild-type cells survive 
and proliferate. Moreover, the apoptosis of mutant cells at the boundary promotes 
tumour growth of cells further from the border (Ballesteros-Arias et al., 2014). 
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 Together, this suggests cell competition can act as both a tumour-
suppressive and tumour-promoting mechanism depending on context and stage 
of tumour formation. 
 
1.4.4 Ras and Cell Competition 
 
The three Ras genes are the most commonly mutated oncogenes in cancer with 
mutations found in around 16% of all human tumours (Prior et al., 2012). It has 
also been found to be involved in cell competition. Cells deficient in 
Ras/Raf/MAPK signalling can be outcompeted by wild-type neighbours (Prober 
and Edgar, 2000). However, expression of constitutively active Ras turns cells 
into supercompetitors with apoptosis in surrounding wild-type cells (Karim and 
Rubin, 1998). 
 Use of mammalian MDCK cells has demonstrated a role for cell 
competition between mammalian cells expressing RasV12, referred to as RasV12 
cells, and normal neighbours in vitro. When RasV12 cells are surrounded by 
normal neighbours, the transformed cells undergo two independent phenomenon 
in a non-cell autonomous manner. Mutant cells are either apically extruded from 
the monolayer, or form dynamic basal protrusions and invade the basal matrix 
(Hogan et al., 2009). When RasV12 cells are plated alone no cell extrusion or 
basal invasion occurs.  Basal invasion occurs in mutant cells that avoid extrusion 
at protracted time points. Cdc42 and ROCK activity are required in RasV12 cells 
and E-cadherin-based cell-cell adhesions in normal cells were required for 
efficient extrusion. It was also found that extrusion is independent of apoptosis 
suggesting a different mechanism to the homeostatic elimination of apoptotic 
cells that occurs via sphingosine-1-phsophate (S1P) (Gu et al., 2011). It has 
since been demonstrated that Src-transformed, ErbB2-transformed cells, and 
cells expressing constitutively active YAP are also apically extruded in vitro 
(Chiba et al., 2016; Kajita et al., 2010; Leung and Brugge, 2012; Wu et al., 2015).  
 Recent work has begun understanding the molecular mechanisms of how 
normal and RasV12-transformed cells interact and changes that occur at the 
interface (Figure 1.6). In normal cells neighbouring Ras-transformed cells, the 
cytoskeletal protein filamin accumulates (Kajita et al., 2014). Filamin recruits 
vimentin at the basal side of cell-cell contact sites to generate contractile force 
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thought to squeeze transformed cells out apically. This suggests normal epithelial 
cells sense that neighbouring cells are aberrant and actively eliminate them from 
the epithelium.  
 In the RasV12-transformed cells surrounded by normal cells a variety of 
molecular changes have also been characterised. When Ras-transformed cells 
surrounded by normal neighbours, the actin-binding protein Epithelial Protein 
Lost In Neoplasm (EPLIN) is accumulated (Ohoka et al., 2015). EPLIN does not 
accumulate in RasV12 cells cultured alone. In co-cultures, EPLIN activates protein 
kinase A (PKA), myosin-II and induces enrichment of caveolae-containing 
microdomains. This facilitates apical extrusion of mutant cells surrounded by 
normal neighbours. In RasV12 cells surrounded by normal neighbours, Rab5 also 
accumulates and endocytosis is enhanced (Saitoh et al., 2017). This disrupts E-
cadherin-based cell-cell adhesions and promotes mutant cell extrusion. 
 Physical forces are also important for the extrusion of RasV12-cells 
surrounded by normal cells and therefore this could be considered a form of 
mechanical cell competition. The activity of myosin-II is increased in RasV12 cells 
and transformed cells become round and tall with the enhanced tensile force 
(Hogan et al., 2009; Kajita et al., 2014). Filamin in the normal cells can crosslink 
actin and act as a mechanotransducer/sensor (Ehrlicher et al., 2011). 
Redistribution of N-WASP is also observed during apical extrusion of Ras-
transformed cells (Wu et al., 2014). At the interface between normal and RasV12 
cells N-WASP is reduced at the apical junctions and increased at the lateral 
membrane; increasing lateral tension and promoting extrusion. 
 More recently, apical cell extrusion has been investigated in vivo using 
murine models. Expression of RasV12 in a mosaic fashion in the crypt epithelia in 
combination with in vivo time lapse imaging observed dynamic apical extrusion 
of mutant cells (Kon et al., 2017). In this study, organoid models of the intestinal 
epithelium were also generated and recapitulated apical extrusion. In organoids 
EPLIN accumulates in RasV12 cells surrounded by normal neighbours with 
pyruvate dehydrogenase kinase 4 (PDK4) – mediated metabolic changes in 
mutant cells also promoting the extrusion of RasV12 cells (Kon et al., 2017). 
Evidence for the extrusion of RasV12-transformed cells has also been observed 
from the pancreatic ductal and lung epithelium using CK19-driven Cre 
recombinase (Sasaki et al., 2018). However, <1% of pancreatic cancer patients 
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have Hras mutations (Hobbs et al., 2016; Prior et al., 2012) and the cell of origin 
in pancreatic cancer is still unclear (Yamaguchi et al., 2017), so further work is 
required to establish the role of cell competition in pancreatic cancer. 
 It is also unclear as to whether extrusion of RasV12 mutant cells is tumour-
suppressive or tumour-promoting. Apical extrusion of epithelial cells in the body 
will typically result in mutant cells in a lumen, for example the intestinal lumen. 
This will not only remove the cells from the supporting extracellular matrix, 
promoting programmed cell death via anoikis (Frisch and Francis, 1994), but will 
also subject the extruded cell to harsh physical conditions (e.g., stool, urine, 
digestive fluids). Thus, apical extrusion may be considered as cancer-
preventative. However, extrusion can also allow sporadic mutant cells to escape 
the suppressive epithelium and proliferate (Leung and Brugge, 2012), or colonise 
other sites within the pancreas (Makohon-Moore et al., 2018). With KrasV12 
associated with anoikis resistance (Zhang et al., 2017), it is conceivable that 
extrusion allows Ras-transformed cells to evade the suppressive 
microenvironment and proliferate outside the native niche. The interaction of 
Ras-transformed and Ras-wild type cells may also be maintained at later stages 
of tumourigenesis. As spatial analysis of KrasG12D mutant cells using RNA in situ 
hybridisation has demonstrated that mutant cells intimately mix with Kras wild-
type cells even within tumours (Baker et al., 2017), these interactions may be 
relevant to multiple stages of tumourigenesis. 
 
1.4.4.1 Extrusion in homeostasis 
 
 Although extrusion of oncogenic cells can occur from epithelial sheets 
extrusion is also cellular process that occurs within non-transformed epithelial to 
maintain homeostasis. To maintain homeostasis as a tight barrier an epithelium 
requires a fine balance of growth and apoptosis which occurs via several 
mechanisms. One classical mechanism for this is contact inhibition; with high cell 
density inhibiting cell proliferation (Eagle and Levine, 1967; Stoker and Rubin, 
1967). Another homeostatic mechanism is the elimination of apoptotic cells. In 
this process, apoptotic cells are identified by neighbouring cells and pushed out 
of the epithelium by actomyosin-mediated contractile forces (Gu et al., 2011; 
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Rosenblatt et al., 2001). It has also been demonstrated that overcrowding 
induces extrusion of live cells (Eisenhoffer et al., 2012; Marinari et al., 2012). 
 To remove dying cells from an epithelium extrusion occurs via a distinct 
extrusion mechanism. Sphingosine 1 phosphate (S1P) from apoptotic MDCK 
cells interacts with the G-protein-coupled receptor Sphingosine 1 Phosphate 
receptor 2 (S1P2) which activates Rho mediated contraction (Gu et al., 2011). 
This leads to the formation of a basal actomyosin ring at the base of surrounding 
cells to squeeze the cell out and draw together neighbouring cells to prevent gaps 
in the epithelial barrier. Overcrowding has also been shown to lead to extrusion 
via S1P and myosin contraction, however extrusion from overcrowding also 
requires the stretch-activated channel Piezo1 (Eisenhoffer et al., 2012). Other 
work investigating crowding-induced extrusion of live cells in Drosophila found 
that cells progressively lose junctions with the surrounding cells (Marinari et al., 
2012). This is followed by loss of apical area, recruitment of a contractile myosin 
II ring in neighbouring cells and extrusion. Modulating cell growth and density 
altered extrusion, suggesting overcrowding induced mechanical forces triggers 
extrusion in crowded regions. 
Recently, computer simulations of the epithelium have found similarities between 
molecules in liquid crystals, with cells forming a dense and polarised monolayer 
(Kawaguchi et al., 2017; Saw et al., 2017). Epithelia cells can spontaneously 
orientate and align towards singular points, known as topological defects. The 
head of these coordinated flow of cells generates compressive stress that 
promotes extrusion. Although blocking crowding induced extrusion can cause 
atypical cellular accumulation in zebrafish (Gu et al., 2015), the organism-wide 
consequences of inhibiting this extrusion appear relatively mild.  
 Cell extrusion can also determine the fate of a cell in development. For 
example, in lung development random cell subpopulations of bronchial epithelia 
are extruded and undergo epithelial-to-mesenchymal transition (EMT)-like 
migration before colonising lung branch points as committed neuroendocrine 
progenitors (Kuo and Krasnow, 2015). Furthermore, extrusion of embryonic 
neural crest cells (NCCs) from the dorsal neural epithelia is key in development 
of craniofacial structures (Le Douarin and Kalcheim, 1999). Extruded cells 
undergo EMT and migrate to multiple destinations to differentiate into neurons 
and glia of the peripheral nervous system (Berndt et al., 2008; Thiery et al., 2009). 
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Thus, cell extrusion also allows the initiation of migration and subsequent 
differentiation during development. In addition to the active elimination of 
aberrant cells extrusion occurs in epithelial tissues to control tissue dynamics and 
aid the movement of cells in development. 
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Figure 1.6: Mechanism of extrusion of RasV12 cells. In Ras-transformed 
cells (green) and the surrounding normal neighbours (yellow) various 
signalling pathways are modulated leading to extrusion of mutant cells.   
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1.4.7 EphA2-dependent elimination of RasV12 cells. 
  
 Although the trigger for extrusion of non-transformed cells in apoptosis 
and overcrowding has been elucidated, how oncogene-transformed cells are 
detected and eliminated is less clear. To investigate the signals underlying 
detection of RasV12 cell extrusion we have previously used a cell confrontation 
assay to amplify the boundary between Ras-transformed and normal MDCK 
epithelial cells in vitro (Porazinski et al., 2016). EphA2 is elevated in RasV12 cells 
at the mRNA and protein level (Macrae et al., 2005) and allows detection of 
mutant cells by the surrounding normal epithelia. The interaction of normal and 
RasV12 cells then induces ephrin-A-EphA2 signals which drives repulsion and is 
accompanied by EphA2 dependent increased contractility of mutant cells. 
Drosophila Eph receptor (dEph) was also detected in segregating clones of 
RasV12 cells and is functionally required for segregation of RasV12 cells from wild-
type cells in Drosophila wing imaginal discs. Therefore, Ras-transformed cells 
arising in normal epithelial sheets generates ectopic EphA2 boundaries causing 
segregation and extrusion of mutant cells. Furthermore, we have demonstrated 
that normal epithelial cells can trigger EphA2-dependent RasV12 repulsion at the 
level of the single cell (Hill and Hogan, 2017). Dropping low numbers of normal 
cells onto confluent monolayers of RasV12-transformed cells demonstrated that 
even small clusters of normal cells can drive repulsion and enhanced contractility 
of Ras-transformed cells. Expression of a dominant-negative EphA2, which lacks 
a functional intracellular domain, was also sufficient to inhibit Src-transformed 
cell extrusion (Porazinski et al., 2016).  
 
 
1.7 Eph-Ephrin Signalling 
  
 EphA2 is a member of the Eph receptor tyrosine kinase (RTK) family. Eph 
(from ‘erythropoietin-producing hepatocellular carcinoma cell line’) receptors 
were first identified in 1987 and are divided into two subfamilies (Hirai et al., 
1987). The type A Eph receptors (EphA1-EphA2 and EphA10) bind and activate 
five type A ephrins (ephrin-A1-ephrinA5) and the type B Eph receptors (EphB1-
EphB4 and EphB6), bind and activate three type B ephrins (ephrin-B1-B3). A 
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degree of promiscuity exists between and within subfamilies, for example, EphB2 
can bind ephrin-A5 and EphA3 binds ephrin-A3, -A4 and –A5 (Noberini et al., 
2012). 
 Both Eph receptors and ephrin ligands are membrane tethered, thus 
signalling occurs from direct cell-cell contact (Davis et al., 1994). Forward Eph-
ephrin signalling in the receptor expressing cell consists of Eph-receptor 
interaction with ephrin ligand on a neighbouring cell and leads to activation of the 
Eph receptor kinase domain and often leads to cell repulsion (Figure 1.7). 
Following ligand interaction, Eph receptors cluster together and become 
phosphorylated at key tyrosine residues (Kania and Klein, 2016). However, it has 
also been established that reverse signalling can occur through ephrin ligands 
and this can elicit either cell repulsion or adhesion (Cowan and Henkemeyer, 
2001; Jørgensen et al., 2009; Palmer et al., 2002; Xu and Henkemeyer, 2009). 
This generates a large amount of signalling complexity which is further 
complicated by how both Eph receptors and ephrins cluster, impacting signalling. 
Both Ephs and ephrins need to be clustered to trigger efficient activation (Davis 
et al., 1994), with activation driving receptor and ligand tetramers to form, 
producing large signalling arrays. The size of an array correlates with the degree 
of cellular response (Smith et al., 2004). Another layer of complexity in signalling 
is generated by the finding that Eph receptors can interact in cis with ephrins on 
the same cell membrane (Hornberger et al., 1999; Yin et al., 2004). This has 
been demonstrated to inhibit forward signalling through the Eph receptor (Yin et 
al., 2004). Also, Eph receptors can signal in a ligand-independent manner when 
overexpressed, such as in tumourigenic cells. For example, EphA2 can be 
activated by growth factors in serum via AKT phosphorylation of EphA2 serine 
897, leading to increased cell migration and invasion (Miao et al., 2009). 
Recently, it has also been identified that extracellular vesicles (exosomes) can 
contain Eph receptors and can lead to Eph-ephrin signalling without direct cell 
contact (Gong et al., 2016). 
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Figure 1.7: Principles of Eph signalling. Interaction of membrane bound Eph 
receptor and ligand can lead to signalling in both cells. Eph receptors can also be 
activated independently of ligand. The interaction of receptor and ligand, in cis, on the 
same membrane can inhibit classical downstream signalling. 
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1.7.2 Functions of Eph-Ephrin Signalling 
 
 Due to the complexity of Eph-ephrin signalling, the intracellular signalling 
pathways downstream of individual Ephs are yet to be fully elucidated. What is 
known is that Eph-ephrin signalling plays a key role in tissue organisation both in 
development and adult homeostasis and can regulate adhesion, repulsion and 
influence cell migration. 
 In the developing embryo, Eph-ephrin interactions ensure correct 
migration and cellular positioning. The combination of repulsion and attraction 
generated by Eph-ephrin signalling allows delicate balance to control neuronal 
growth cone migration (Wang and Anderson, 1997). The formation of different 
compartments with sharp borders is essential for development in vertebrates 
(Bronner-Fraser, 1999; Langenberg and Brand, 2005) with Eph-ephrin signalling 
critical to this process (Cayuso et al., 2015). For example, in the brain Eph 
receptors and ephrin ligands are expressed in complementary patterns. 
Signalling leads to cellular repulsion to inhibit cell intermingling which is vital for 
correct brain development (Twigg et al., 2004). During early development, 
segregation from a homologous population of cells into distinct cell types is the 
basis for different tissue and organ formation. Somatogenesis has been used to 
model segregation and boundary formation and how this is associated with 
dynamic morphological changes such as mesenchymal-to-epithelial transitions. 
Eph-ephrin signalling has been found to underly the formation of this 
morphological boundary and cell epithelialisation in early development (Barrios 
et al., 2003; Watanabe et al., 2009). In the developing pancreas, defective Eph 
signalling causes disorganised epithelia with a loss of cell-cell contacts leading 
to branching defects (Villasenor et al., 2010). 
 Eph receptors also play key roles in tissue maintenance and cell sorting 
in adult tissues. In the small intestine Eph-ephrin signalling regulates correct cell 
compartmentalisation (Batlle et al., 2002). At the base of each crypt stem cells 
proliferate and differentiate to produce the distinct cell lineages required, with 
progenitors migrating up the villus passively. EphB receptors are Wnt signalling 
target genes and highly expressed at the base of the crypt whereas ephrin-B 
ligands are found in differentiated cells further up the villus.The repulsive force 
generated by EphB-ephrinB interactions restricts the mixing of differentiated and 
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proliferating cells. Another intestinal cell lineage, Paneth cells, retain elevated 
EphB levels after differentiation which inhibits travelling up the villus, with these 
cells held at the base of the crypt.  
 Eph-ephrin signalling can control sorting at both the level of cells and 
tissues due to the variety of effects they can have on cell adhesion, repulsion and 
migration. For example, forward signalling through EphA2 can lower integrin 
function to reduce cell migration and integrin-mediated adhesion (Miao et al., 
2000). Conversely, EphB1-ephrinB1 signalling can increase adhesion via a1b5 
integrin activation (Huynh-Do et al., 1999). Indication that adhesion is dictated by 
the combination of Eph and ephrins expressed and present at the surface. 
 At the molecular level, to regulate repulsive and attractive forces upon cell-
cell contact, Eph-ephrin signalling can modulate Rho family GTPases (Noren and 
Pasquale, 2004). The Rho GTPase family controls cell movement by regulating 
the formation of actin structures required for cell migration. With Eph-ephrin 
signalling known to both promote and inhibit the activation of three key members 
of this family: Rac1, Cdc42 and RhoA (Pasquale, 2010; Pasquale et al., 2008). 
To alter these small GTPases, Eph receptors and ephrins act via GTPase-
activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). 
With regulation of GAPs and GEFs allowing both activation and inhibition of Rho 
GTPases by Eph receptors to control repulsion. For example, stimulation of 
neural cells with ephrinA5 leads to growth cone collapse via activation of Rho 
causing cell retraction (Wahl et al., 2000). Cell repulsion also requires the 
adhesive properties of Eph-ephrin binding are overcome, either by cleavage of 
ligand from the membrane (Hattori et al., 2000) or endocytosis (Marston et al., 
2003; Zimmer et al., 2003). Although it is worth noting that control of Rho 
GTPases can regulate other functions. For example, EphA2 forward signalling 
can promote epithelial characteristics by inhibiting RhoA (Wakayama et al., 
2011), and enhance endothelial angiogenic responses via Rac1 (Hunter et al., 
2006). It has also been reported that upon Eph-ephrin interaction, cleavage and 
shedding of E-cadherin at the interface occurs establishing differential adhesion 
that contributes to cell segregation (Solanas et al., 2011). 
 In contrast to the function of other RTKs, Eph receptors do not generally 
regulate cell growth through the Ras pathway and frequently inhibit Ras 
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signalling. Stimulation of EphA receptors with ephrin-A1 has been demonstrated 
to inhibit the Ras/MAPK pathway and inhibit cell proliferation in prostatic epithelial 
cells and endothelial cells (Miao et al., 2001). Furthermore, EphA2 is a direct 
transcriptional target of the Ras/MAPK pathway with EphA2-ephrin-A1 forward 
signalling negatively regulating activation of Ras (Macrae et al., 2005). Therefore, 
EphA2 can be considered to act in a negative feedback loop with Ras/MAPK 
signalling in some contexts. 
 Eph-ephrin signalling has also been implicated in contact inhibition of 
locomotion (CIL). This is the process by which cells collide and stop migrating 
before repolarising and migrating in a different direction (Abercrombie and 
Heaysman, 1954). In prostate cancer cells, the balance between repulsive EphA 
and attractive EphB signalling was found to alter CIL (Astin et al., 2010). EphA2 
and EphA4 act together to coordinate CIL, whereas EphB3 and EphB4 
upregulation leads to inhibition of CIL and increased invasion. 
 
1.7.3 EphA2 in cancer 
 
 With the variety of effects Eph-ephrin signalling can have on a cell, it is 
not surprising that changes to Eph receptors are implicated in tumourigenesis. 
EphA2 receptor is important for detection and extrusion of Ras-transformed cells 
and so will be primarily discussed. EphA2 is upregulated in an array of different 
cancers including: breast, glioblastoma, prostate, melanoma and ovarian with 
elevated levels associated with advanced disease and poor prognosis (Andres 
et al., 1994; D’Amico et al., 2001; Duxbury et al., 2004; Kataoka et al., 2004; 
Landen et al., 2006; Walker-Daniels et al., 1999; Zelinski et al., 2001). However, 
the mechanisms by which EphA2 signalling promotes tumourigenesis are 
complex and are not well characterised with evidence for both a tumour 
suppressive and tumour promoting role, suggesting context-dependent 
functions. When stimulated by ephrin ligands EphA2 appears to have a tumour 
suppressive function. Upon ligand binding, EphA2 becomes autophosphorylated 
at cytoplasmic tyrosine residues, and recruits p120Ras-GAP to downregulated 
Ras-GTP (Dail et al., 2006; Miao et al., 2001). Autophosphorylation of EphA2 
also supressing activated Akt (Miao et al., 2009). Using a shRNA screen for 
tumour suppresses in vivo in a KrasG12D-drive murine lung adenocarcinoma 
 41 
model identified EphA2 as a key tumour suppressor (Yeddula et al., 2015). Loss 
of EphA2 was found to promote cell proliferation via activation of the Ras/MAPK 
and hedgehog pathway and drive tumourigenesis. But when overexpressed 
EphA2 can become activated in a ligand-independent manner and promoter 
tumourigenesis. For example, in the absence of ligand, tyrosine residues on the 
receptor are not phosphorylated allowing Akt signalling. Activated Akt can then 
phosphorylate EphA2 at cytoplasmic serine residues  which promotes a 
migratory phenotype in part via Rho GTPases (Hiramoto-Yamaki et al., 2010; 
Miao et al., 2009). Moreover, expression of EphA2 alone in mammary MCF10A 
cells is sufficient to confer tumourigenicity in mice (Zelinski et al., 2001).  
 In addition to a role in tumour growth EphA2 has also been implicated in 
tumour metastasis. Overexpression of EphA2 is strongly associated with 
increased metastatic burden in colorectal cancer (Saito et al., 2004). However, 
in pancreatic ductal adenocarcinoma (PDAC) EphA2 levels is decreased in 
metastatic tumours compared to non-metastatic tumours (Mudali et al., 2006). 
This suggests EphA2 could promote a mesenchymal phenotype and so must be 
downregulated during mesenchymal-epithelial transition (MET).  In PDAC, 
genetic disruption of EphA2 has also been shown to reduce invasion and 
metastasis in vivo (Gundry et al., 2017). We have also previously identified that 
EphA2 drives the extrusion of Ras-transformed cells using in vitro models of early 
disease (Porazinski et al., 2016). What effect this may have on tumour growth or 
spread is unclear and requires further investigation. Thus, Eph-ephrin signalling 
is a cell-cell contact dependent, multi-layered and complex signalling pathway 
that precisely controls organisation at both the cell and tissue level. It allows cells 
to sense their immediate surroundings and react appropriately, for example by 
repulsion of a neighbouring cell. Aberrant expression of EphA2 is implicated in 
cancer, particularly Ras-drive carcinomas, and can both promote and suppress 
tumourigenesis. 
 In summary, epithelial tissues have several mechanisms to maintain 
homeostasis with competitive interactions between normal and aberrant cells 
driving the elimination of single less fit cells surrounded by normal neighbours. 
These competitive interactions can also drive the extrusion of mutant cells with 
Ras-transformed cells eliminated via a process that requires EphA2. KrasG12D 
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mutations drive the initiation of PDAC yet is unclear how pancreatic tissues 
homeostasis is restored following the emergence of mutant cells. 
 
 
1.8 Aims and Objectives 
 
 KrasG12D transformed cells initiate pancreatic cancer and these 
transformed cells emerge within normal epithelial sheets. We know from cell 
competition studies that the interaction of mutant cells with normal neighbours 
can have both negative and positive effects on the transformed cell. Furthermore, 
it has been demonstrated that EphA2 signalling drives the segregation and 
elimination of Ras-mutant cells. The principal aim of this study was to investigate 
whether these interactions occur at the earliest stages of pancreatic cancer; 
when KrasG12D cells arise within a normal pancreatic epithelium and what effect 
this may have on the fate of transformed cells. Specifically, the objectives were: 
 Establish in vivo mouse models to investigate the fate of KrasG12D cells 
surrounded by normal neighbours over time within the context of a tissue. The 
requirement of EphA2 for these interactions will also be assessed. 
 Second, an in vitro model of primary pancreatic cell culture will be 
developed to investigate heterotypic interactions between normal and 
transformed cells. This will allow further elucidation of KrasG12D and normal cell 
interactions at the level of the single cell over time to decipher the underlying 
mechanism. Furthermore, the downstream signalling mechanisms underlying 
normal:mutant cell interactions and fate of transformed cells will be examined. 
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Chapter 2: Materials and Methods 
 
2.1 Experimental Animals 
 
2.1.1 Animal Husbandry 
 
	 All experiments in this thesis were performed in murine models (mus 
musculus) or with tissues and cell cultures derived from mouse tissue. All animals 
were maintained on an outbred background and housed in a specified pathogen-
free (SPF) facility in accordance with institutional animal care guidelines and UK 
Home Office regulations, under valid personal and project licenses. Animals were 
given access to Standard diet (Special Diet Service UK, expanded diet) and fresh 
water ad libitum and maintained on a 12:12 hour light-dark schedule.   
 Once mice had reached 6 weeks of age or older they were bred in trios of 
one male and two females or duos of one male and one female as required. At 
approximately 4 weeks of age, pups were weaned and separated based on sex. 
At point of weaning ear biopsies were also taken for identification and genotyping. 
 
2.2 Genetic Mouse Models 
 
 To investigate mosaic KrasG12D induction in the pancreas requires both 
temporal and spatial control of recombination (Figure 2.1). To this end a Pdx1-
CreERT transgene was utilised to drive expression of a tamoxifen inducible form 
of Cre recombinase/oestrogen receptor fusion protein in the endocrine, exocrine 
and duct tissue of the pancreas. The expression of a mutant KRAS protein was 
achieved by employing a model whereby the Kras2 locus was targeted with a 
cassette containing the oncogenic form of the KRAS2 protein with the glycine at 
position 12 substituted with an aspartic acid. A loxP flanked stop codon was 
included upstream of the sequence so mutant transcript was only expressed after 
Cre-mediated recombination. To mark cells where recombination had occurred 
an inverted sequence coding for tandem-dimer red fluorescent protein (tdRFP) 
was inserted in intron 1 of the Rosa26 locus (Luche et al., 2007). Inverted loxP 
sites are arranged around these sequences so that two cre-mediated events 
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were required for expression; both excision of the stop codon and inversion of 
the tdRFP sequence. To investigate the role of EphA2 a transgenic model was 
also used whereby EphA2 was disrupted. A vector was used to disrupt the EphA2 
gene within the extracellular domain resulting in the gene to encode an expected 
non-function truncated protein (Brantley-Sieders, 2004). Previously, 
characterisation of N-terminal and C-terminal EphA2 expression demonstrated 
that neither the full length nor a truncated form of EphA2 is present in these mice 
and thus can be considered a EphA2 null mouse (Amato et al., 2016). A summary 
of the animal models and abbreviations used in this thesis is presented in Table 
2.1. 
 
 
 
Abbreviation Genotype 
KC Pdx1-CreERT; Rosa26tdRFP; LSL-KrasG12D 
Control Pdx1-CreERT; Rosa26tdRFP 
KC-Eph Pdx1-CreERT; Rosa26tdRFP; LSL-KrasG12D; EphA2 
RFP-Eph Pdx1-CreERT; Rosa26tdRFP; EphA2 
 
Table 2.1 Glossary of Animal models 
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Figure 2.1: Genetic model of KrasG12D expression in the pancreas. Cre 
recombinase activity in pancreatic cells results in excision of a stop codon and 
expression of KrasG12D from the endogenous locus and RFP from the Rosa26 
promoter. 
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2.3 Experimental Procedures 
 
All experiments involving animals were conducted according to the UK 
Home Office regulations under valid personal and project licenses and in 
accordance with the Animal [Scientific Procedures] Act 1986. Experimental 
procedures were carried out in designated procedure rooms. 
  
2.3.1 Identification of Experimental Cohorts 
 
2.3.1.1 Ear Biopsy for identification and genotyping 
 
 For identification purposes ear biopsies were taken at weaning using a 2 
mm ear punch (Harvard apparatus). DNA extraction from these biopsies was 
then used for genotyping. Biopsies were also taken from experimental cohorts at 
time of death to confirm genotype. 
 
2.3.1.3    DNA extraction 
 
 Ear biopsies were collected and stored at -20°C until processing. Samples 
were then digested in 250 μL cell lysis buffer (VWR) containing 0.4 mg/mL 
proteinase K (Sigma) overnight at 42°C with agitation. The following day, 
samples were cooled to room temperature and 100 μL of protein precipitation 
solution (VWR) was added. The samples were then briefly mixed by inversion 
and insoluble debris and protein were pelleted by centrifugation at 16,000 G for 
10 minutes at room temperature. The DNA was precipitated by adding the 
supernatant to 250 μL of isopropanol (ThermoFisher Scientific) in a DNase free 
eppendorf. The solution was mixed by inversion and DNA was pelleted by 
centrifugation at 16,000 G for 15 minutes. The supernatant was discarded and 
the pellet was washed with 70% ethanol. The DNA was pelleted by centrifugation 
at 16,000 G for 10 minutes and supernatant discarded. The pellet was air dried 
for 30 minutes at room temperature and resuspended in 250 μL of DNase/Rnase 
free water (Ambion). DNA was then stored at 4°C or at -20°C for long-term 
storage. 
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2.3.1.4 PCR Protocol 
 
 PCR was carried out in tube strips (0.2 mL thin walled, Alpha 
Laboratories). To each tube 3 μL of gDNA extracted from ear biopsies 47 µL of 
PCR mix (Table 2.2) was added. Primer sequences can be found in Table 2.3. 
The reaction was then run in a GS4 thermocycler (G storm) with the cycling times 
found in Table 2.2. 
 
2.3.1.5 Gel electrophoresis of PCR products 
 
 Agarose gels were made by dissolving agarose (Bioline) 2% (w/v) in Tris-
acetate-EDTA (TAE) buffer (National Diagnostic) and heating in a microwave at 
full power for 3 minutes and 10 seconds with agitation at regular intervals. After 
cooling slightly, 5 μL Safeview (NBS biologicals) was added per 100 mL. This 
was mixed gently to avoid bubbles and the gel was then cast into moulds with 
combs. Once set, the combs were removed and the gel placed into an 
electrophoresis tank and covered with 1x TAE. Following this 10 μL of each PCR 
sample was added to individual wells and run alongside a 100 bp ladder (PCR 
Biosystems). The samples were run at 120 V for approximately 30 minutes and 
then visualised using a GelDoc UV Transilluminator (Bio-Rad) and images taken 
with the GelDoc software (Bio-Rad). Genotypes were then established based on 
PCR product sizes in Table 2.3.  
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PCR Mix Pdx1-Cre KrasG12D EphA2tm1Jrui Rosa26tdRFP 
Template DNA 3 µL 3 µL 3 µL 3 µL 
Distilled Water 21.8 µL 21.7 µL 21.7 µL 21.7 µL 
2x Hot Start Taq Mix 
Red (PCR 
Biosystems) 25 µL 25 µL 25 µL 25 µL 
Primer 1 (100 mM) 0.1 µL 0.1 µL 0.1 µL 0.1 µL 
Primer 2 (100 mM) 0.1 µL 0.1 µL 0.1 µL 0.1 µL 
Primer 3 (100 mM) N/A 0.1 µL 0.1 µL 0.1 µL 
PCR Cycling 
conditions         
Initial Denaturation 3 min; 94°C 3 min; 94°C 3 min; 94°C 3 min; 94°C 
Cycle number 35 35 35 35 
Step 1: Denaturation 
(Time; Temp) 30 sec;94 °C 30 sec;94 °C 30 sec;94 °C 
30 sec;94 
°C 
Step 2: Annealing 
(Time; Temp) 30 sec; 55°C 30 sec;68 °C 30 sec; 60°C 
30 sec; 
56°C 
Step 3: Extension 
(Time; Temp) 1min; 72°C 1min; 72°C 1min; 72°C 1min; 72°C 
Final 5min; 72°C 5min; 72°C 5min; 72°C 5min; 72°C 
  Hold at 4°C Hold at 4°C Hold at 4°C Hold at 4°C 
Table 2.2 Genotyping PCR reaction conditions 
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Gene Forward primer (5' - 3') Reverse primer (5' - 3') Product Size 
Pdx1-Cre CTG GAC TAC ATC TTG AGT 
TGC 
GGT GTA CGG TCA 
GTA AAT TTG 650 bp 
KrasG12D 
WT Forward: TGT CTT TCC 
CCA GCA CAG T CTG CAT AGT ACG CTA 
TAC CCT GT 
WT = 250bp 
Mut Forward: GCA GGT CGA 
GGG ACC TAA TA Mutant=100bp 
EphA2tm1Jrui TGT CAC TTG CGA ACA GTG CT 
WT: CGC TAT CAC ACT 
CAG CAG GA   WT=414 bp 
Mutant: GTG GAG AGG 
CTT TTT GCT TC Mutant=280bp 
Rosa26tdRFP AAG ACC GCG AAG AGT TTG TCC 
Mutant: GTG GAG AGG 
CTT TTT GCT TC WT = 209 bp 
WT: TAA GCC TGC CCA 
GAA GAC TCC Mutant = 310 bp 
Table 2.3 Primer sequences used for genotyping and product sizes. KrasG12D, 
EphA2 and RFP genotyping also includes primer for wild-type (WT) and mutant 
alleles. 
 
2.4 Experimental Cohorts induction 
 
 After PCR was used to identify the genotype of mice they were randomly 
placed into control and experimental cohorts at 42 – 56 days of age. Cre-
recombinase translocation to the nucleus and hence recombination was induced 
by intraperitoneal injection (IP) of tamoxifen. Stocks of 10 mg/mL tamoxifen 
(Sigma) were generated by dissolving tamoxifen in corn oil (Sigma) overnight at 
37°C with agitation. This was then diluted 1:1000 to produce 10 μg/mL of 
tamoxifen. Animals were then administered 100 μL of 10 μg/mL in a single 
injection to produce a 1 μg dose respectively. For high dose tamoxifen was 
dissolved in corn oil at 20 mg/mL and dissolved in the same manner as before. 
Mice were then injected with 9 mg/40 g of body weight every other day for 3 
injections over 5 days. 
 
2.5 Tissue sample preparation 
 To avoid degradation of RNA and protein, all tissues were dissected 
immediately after animal sacrifice. 
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2.5.1 Dissection of mice 
 
 Mice were culled following a schedule 1 approved method of culling (e.g. 
cervical dislocation) and dissected upon confirmation of death by permanent 
cessation of circulation. The abdomen was sprayed with 70% ethanol and a V-
shaped incision from the genital area up to the diaphragm. The gut and colon can 
then be pulled outside the abdominal cavity, revealing the pancreas next to the 
spleen and stomach, allowing excision of the pancreas. 
 
2.5.2 Fixation of tissue 
 
 Once removed the pancreas was cut transversely into 3 segments. The 
segment corresponding to the tail was placed in optimal cutting temperature 
(OCT) compound (Agar Scientific) and orientation recorded before being rapidly 
frozen in dry ice. Samples were stored at -80°C until processing for 
cryosectioning and RFP analysis. The middle section was fixed in ice cold 2% 
paraformaldehyde (ThermoFisher scientific) and then stored at 4°C for 24 hours 
before embedding for 3D immunofluorescence tomography. The final segment 
was fixed in ice cold 10% neutral buffered formalin (Sigma) for 24 hours at 4°C. 
Samples were then stored in 70% ethanol in distilled H2O for 4°C until processing 
for immunohistochemistry. 
 
2.6 Tissue Analysis 
 
2.6.1 Sectioning of frozen tissue 
 
 Following tissue sample preparation pancreas frozen in OCT was cut on 
a Leica CM1860 UV cryostat. Each block of OCT was brought up to -20oC and 
then 10 µm sections were cut from the tail and placed on glass slides. Slides 
were then placed in 50 mL falcon (Sigma) and stored at -80°C until imaging. For 
RFP area and cluster analysis 5 sections were collected with each slice 
separated by at least 50 µm. 
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2.6.2 Tile-scan frozen tissue 
 
 After sections were generated they were imaged on a LSM 710 confocal 
microscope (Zeiss). Each slide was rapidly thawed before the whole tissue area 
was imaged using tile-scans for RFP and brightfield. 
 
2.6.3 Laser Capture Microdissection (LCM) 
 
 Frozen tissue sections were also used for laser capture microdissection 
of RFP positive and RFP negative tissue. Each slide was rapidly thawed and 
regions of interest (ROI) were marked manually on a PALM Microbeam Laser 
Micro-dissector (Zeiss). ROI were then catapulted into the cap of a 0.2 mL 
Eppendorf containing 15 µL Buffer ATL (Qiagen) and stored at -80°C.  
 
2.6.3.1 Genomic DNA isolation from Laser Capture Micro-dissected Tissue 
 
 Once all microdissected tissue samples had been collected gDNA was 
then extracted using a MinElute DNA purification kit (Qiagen) which provided all 
reagents unless stated. Firstly, 10 µL of proteinase K was added to the sample 
before pulse-vortexing for 15 seconds. Samples were then incubated at 56°C for 
1 hour before adding 25 µL of Buffer ATL. To this 50 µl of Buffer AL and 50 µL of 
ethanol were added before thoroughly mixing and incubating at room 
temperature for 5 minutes. This was then passed through a QIAmp MinElute 
column by centrifuging at 6000 g for 1 minute. The column was then washed with 
500 µL Buffer AW1 and then 500 µL of Buffer AW2 by centrifuging as before. The 
column was then dried by centrifuging at 20,000 g for 3 minutes before elution of 
the DNA using DNase/Rnase free water. 
 
2.6.3.2 PCR for recombined KrasG12D allele 
 
To test for recombination at the KrasG12D locus a PCR reaction was carried out 
that would differentiate between: the wild-type Kras allele, the LSL-KrasG12D allele 
and the KrasG12D allele where Cre recombinase has excised the stop codon. To 
3 µL of DNA was added 47 µL of PCR as described in Table 2.1 with the following 
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3 primers: 5’GTC TTT CCC CAG CAC AGT GC 3’, 5’CTC TTG CCT ACG CCA 
CCA GCT 3’, 5’ AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC 3’. Cycling 
conditions were the same as EphA2 genotyping from Table 2.1 with a product 
size of 500 bp for the non-recombined KrasG12D allele, 622 bp for the wild-type 
allele and 650 bp for the recombined KrasG12D allele where Cre has excised the 
LoxP-Stop-LoxP cassette. 
   
2.6.4 Immunohistochemistry (IHC) 
 
5 µm formalin-fixed paraffin-embedded (FFPE) sections were produced by Derek 
Scarborough in the Histology Core Service, School of Biosciences, Cardiff 
University, before staining was carried out. IHC and quantification of staining was 
carried out by Dr Andreas Zaragkoulias, a Postdoctoral research associate within 
the lab. Sections were deparaffinised and rehydrated by passage through Xylene 
down a decreasing gradient of ethanol washes: 100%, 95% and 75% each for 5 
minutes. Antigen retrieval was then carried out using citrate buffer (2.94 g Sodium 
citrate tribasic dehydrate (Sigma) in 1 L dH2O, pH 6). Citrate buffer was heated 
in a pressure cooker for 5 minutes at 1000W before immersing slides and heating 
for a further 10 minutes before leaving the slides to cool at room temperature. 
Endogenous peroxidase was blocked by incubation in 3% hydrogen peroxide 
(Sigma) in distilled H2O (dH2O). Sections were then blocked in 5% normal goat 
serum (NGS) in tris-buffered saline (TBS) for 30 minutes at room temperature 
before incubation in primary antibody (anti-Ki67 1:100 (Abcam), anti-Cleaved 
Caspase 3 1:100 (Cell signalling)) overnight at 4°C in a humidity chamber. Slides 
were then washed for 3 x 5 minutes in TBS before incubation in secondary 
antibody. A biotinylated goat anti-rabbit (DAKO) secondary was used at 1:200 for 
30 minutes at room temperature before washing in 3 x TBS for 5 minutes each 
again. A Vectastain ABC kit (Vector labs) was used for binding of HRP to the 
antibody complex and carried out according to manufacterer’s protocol. Staining 
was visualised using 3,3’-diaminobenzidine tetrehydrochloride (DAB) (DAKO) 
before dehydration and mounting of slides. Whole tissue sections were imaged 
using a Zeiss Axioscan Z1 before counting of positive nuclei and measurement 
of tissue area was carried out in Zeiss blue software. 
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2.7 Primary cell isolation – Acinar epithelia 
 
2.7.1 3D Acinar Culture 
 
Mice were culled and pancreas removed as previously described (Section 
2.5.1) and then rinsed in 1 x Hank’s Balanced Salt Solution (HBSS, 
ThermoFisher scientific). The pancreas was then sliced into small 1 to 3 mm3 
pieces by mechanical dissociation using Noyes scissors and centrifuged at 450 
g for 2 minutes at 4°C. The supernatant was aspirated and discarded to remove 
cell fragments and blood cells. Then 10 mL of collagenase IA solution (HBSS 1x 
containing 10 mM HEPES (ThermoFisher), 200 U/mL of collagenase IA (Sigma), 
and 0.25 mg/mL trypsin inhibitor (Sigma)) was added. This was incubated for 20-
30 minutes at 37°C. During this time (every 5 minutes) mechanical dissociation 
by pipetting back-and-forth in pipettes of decreasing size (25, 10, and 5 mL 
serological pipettes). To stop the enzymatic reaction 10 mL of cold buffered 
washing solution (HBSS 1x containing 5% Foetal Bovine Serum (FBS) and 10 
mM HEPES (ThermoFisher scientific)). This was then spun at 450 g for 2 minutes 
at 4°C and the supernatant removed and discarded. The pellet was then washed 
a further 3 times in 10 mL of buffered wash solution each time and centrifuged at 
450 g for 3 minutes and 4°C to allow aspiration of the wash. 
 The cellular pellet was then resuspended in 7 mL of acinar culture media 
(Table 2.4). This mixture was then allowed to pass through a 100 μm filter to 
remove non-digested fragments but allow pancreatic acinar structures (10-15 
cells) to pass through. This solution was then added dropwise to HBSS 
containing 30% FBS and acinar cells were pelleted (450 g, 2 minutes at 4°C). 
Acinar cells were then resuspended in 12 mL of acinar culture media. The acini 
were then left overnight to eliminate contaminant cells and cellular remnants that 
have adhered overnight. 
 After leaving in suspension overnight the acini were transferred and 
seeded on collagen matrix scaffolds. For this, 300 μL of type I Rat tail collagen 
solution (Corning, 2.31 mg/mL in 17mM NaOH) was used to coat the glass of 35 
mm glass bottom well plates (MatTek). To each well, 300 µL of collagen was 
 54 
added to cover the glass insert and then 200 µL removed to produce a thin coat. 
This was dried for around 1 hour at 37°C. The acini suspension was mixed at 1:1 
ratio with 2.7 mg/mL type I Rat tail collagen with 17 mM NaOH and plated on top 
of collagen coating.  
 
Reagent Concentration Supplier 
Waymouth's media with 2.5% 
FBS   
ThermoFisher 
scientific 
Penicillin/Streptomycin 1x 
ThermoFisher 
scientific 
Serum Trypsin Inhibitor 250 ng/mL Sigma 
recombinant epidermal growth 
factor 25 ng/mL 
ThermoFisher 
scientific 
Dexamethasone 1 µg/mL Sigma 
Table 2.4 Acinar epithelial media composition 
 
2.8 Primary cell isolation – Ductal epithelia 
 
2.8.1 2D Ductal culture 
 
Collagen plates were first prepared to culture primary pancreatic epithelia. 
The collagen mix was generated consisting of PBS (1x) with phenol red and 
NaOH (17 mM). Collagen was used at 2.31 mg/mL and diluted in filter sterilised 
water. Following this, 2 mL of collagen was plated in each well of a 6-well plate 
(Greiner) and incubated for at least one hour at 37°C. 
Next, the cells were harvested and isolated. Mice were culled and the 
pancreas was then carefully removed as previously described (Section 2.5.1) 
and rinsed in G solution (HBSS (ThermoFisher scientific), 1x 
penicillin/streptomycin (P/S, ThermoFisher scientific), 1x Fungizone 
(ThermoFisher scientific) and 5 mM D-glucose (Sigma)). Mechanical cutting of 
the tissue was then carried out to produce fragments around 1 mm2 and this was 
digested using 25 mL of 1 mg/mL collagenase at 37°C with stirring for 15 – 20 
minutes. Once digested, 20 mL of G solution was used to transfer the digested 
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tissue through a 40 µm nylon strainer. Flow through was discarded and the 
strainer was washed to collect the remaining tissue. This tissue was then washed 
with G solution and spun down at 200 g for 3 minutes using half deceleration. 
The supernatant was discarded and the pellet was washed twice more using G 
solution. The cells were then digested using trypsin at room temperature for 5 
minutes and this reaction was then stopped by adding soybean trypsin inhibitor 
(Sigma) to a final concentration of 0.6 mg/mL. Following this the cells were 
washed with DMEM six times to completely remove any trace of collagenase, 
spinning down at 200 g for 3 minutes with half deceleration after each wash to 
pellet cells. Finally, the pellet was resuspended in 12 mL PDEC media (Table 
2.5) and plated onto 6-well plates. Cells were cultured at 37°C and 5 % CO2 and 
passaged once they have reached high confluency. 
 
Reagent Concentration Supplier 
DMEM/F12 + 15 mM HEPES, 3.2 mg/mL 
glucose   ThermoFisher scientific 
Nu-Serum IV culture supplement 5% 
Collaborative 
biomedical products 
Penicillin/Streptomyocin 1x ThermoFisher scientific 
D-Glucose 5 mg/mL Sigma 
Nicotinamide 1.22mg/mL Sigma 
Soybean Trypsin Inhibitor type I 0.1 mg/mL Sigma 
ITS+ Cell culture supplement 5 mL/L BD Biosciences 
Bovine pituitary extract 25 µg/mL BD Biosciences 
EGF 20 ng/mL BD Biosciences 
Dexamethasone 1 uM Sigma 
Cholera toxin 100 ng/mL Sigma 
3,3,5-tri-iodo-L-thyronine 5 nM Sigma 
Table 2.5: Ductal epithelia media composition 
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2.8.2 Passaging Pancreatic Ductal Epithelial Cells 
 
Upon reaching or nearing confluency, cells were passaged by splitting at 
no more than 1:4 ratios. Firstly, new collagen coated plates were generated as 
previously described (Section 2.8.1). Following this the cell-collagen mix was 
removed from the well plates and incubated in 5 mg/mL collagenase V (Sigma) 
for 20 minutes at 37°C. The mix was then spun at 200 g for 3 minutes with half 
deceleration and supernatant discarded. The pellet was then digested in trypsin 
for 5 minutes at 37°C and digestion stopped by adding soybean trypsin inhibitor 
to a final concentration of 0.6 mg/mL. Next the suspension was washed using 
DMEM (Gibco) and pelleted by centrifugation at 200 g for 5 minutes with half 
deceleration. The pellet was washed a further 6 times washing in the same 
manner before resuspension in PDEC media and plating onto collagen coated 
plates. Pancreatic ductal epithelial cells were used after the first or second 
passage to ensure reproducible results   
 
2.9 Tumour Derived Cell lines 
 
2.9.1 Cell culture 
 
 Primary murine pancreatic tumour-derived epithelial cells lines KR, KP 
and KRE were a gift from Dr Jennifer P. Morton (Beatson Institute, Glasgow). All 
cells were maintained in DMEM including GlutaMAX and D-Glucose 
supplemented with 10% FBS (ThermoFisher). Cells were incubated at 37°C and 
5% CO2 in 10 cm cell culture plates (Greiner) with media changed every 2-3 days 
and passaged when confluent. 
 When cells became 80-90% confluent they were split at a ratio between 
1:6-1:10. To remove cells, media was aspirated and cells washed with warm PBS 
(ThermoFisher) and then 1 mL of 0.25% trypsin/EDTA (Invitrogen) was added 
and incubated at 37°C for 5 minutes. Once cells had detached 5 mL of normal 
growth media was added to inactivate trypsin activity before splitting at 
appropriate ratios (KR 1:6, KP 1:10, KRE 1:10). 
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2.9.2 Long term Storage of cell lines 
 
 Low passage cell lines were frozen and cryo-stored in liquid nitrogen. Cells 
were detached from culture as described previously before resuspending in 
growth media containing 10% dimethyl sulfoxide (DMSO; Sigma) and aliquoted 
at >1x106 cells/mL in cryotubes (Nunc). Cells were then frozen at -80°C in a cryo-
freezing vessel containing isopropanol (ThermoFisher) for 24 hours before 
transferring to liquid nitrogen. 
 To raise cells from long term storage, cells were rapidly defrosted in a 
water bath at 37°C for 2 minutes. Cells were then plated in complete growth 
media and once attached to the surface (~1 hour) media was changed to remove 
any trace of DMSO. 
   
 
2.9 Cell Interaction experiments 
 
2.9.1 Cell-cell mixing 
 
To investigate direct cell-cell interactions cells were pre-mixed before 
plating to generate heterotypic cell-cell interactions. To distinguish between cell 
populations, it was necessary to use a cell tracker dye to label one population. 
This was achieved using CellTracker Orange CMRA Dye (ThermoFisher 
scientific) which is soluble; once taken up by cells it becomes cell-impermeable. 
Cells were washed twice with PBS and then incubated in serum-free DMEM with 
4 µM CellTracker for one hour at 37°C and 5% CO2. Once labelled, cells were 
washed twice more with PBS and split as described previously. Cells were then 
mixed with 2.5x106 primary ductal cells mixed with 5x104 labelled tumour-derived 
cells. This mixture was then plated in 4 well plates (Nunclon Delta Surface, 
ThermoFisher scientific) coated with 300 µl of rat tail type I collagen (Corning). 
Cells were grown for 48 hours until confluent and fixed with 4% PFA. 
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 2.9.2 Ligand-Cell collision assay 
 
 To investigate the interaction of ephrin ligands with Eph receptors on 
pancreatic cells a stripe assay was carried out whereby cells are seeded into one 
well of a cell culture insert (Ibidi) with clustered ligand in the other (Porazinski et 
al., 2016). Once the insert is removed cells migrate and proliferate towards and 
then interact with the ligand stripe. This work was carried out by Rebecca 
Bennion, a Cardiff University undergraduate student under my supervision. 
 To begin, Fc- proteins are preclustered with goat anti-human IgG antibody 
(Jackson Immunoresearch) at 1:2 molar ratio. To precluster Fc-proteins and for 
each well to be coated, 10 µg of Fc-ephrin A ligand and 10 µg of Fc control (R&D 
Systems) were incubated for 30 minutes at room temperature with 2.4 µl of IgG 
antibody, with PBS added to make a final volume of 100 µL.  One well of a cell 
culture insert (Ibidi) was then coated with 100 µL of this suspension for 30 
minutes at 37°C, followed by washing with PBS and standard ductal epithelial 
growth media (Table 2.3) once for 1 minute each. To visualise the stripe, a 
secondary anti-goat antibody (ThermoFisher scientific) was incubated with the 
stripe in the cell culture insert for 1 hour before washing with PBS and standard 
ductal epithelial growth media as before. Cells were then seeded into the 
neighbouring well of the insert and allowed to adhere for 3 hours before the cell 
insert was carefully removed. Samples were then fixed after approximately 96 
hours once cells had migrated and interacted with the stripe. 
Immunofluorescence was then carried out for F-actin and nuclei stained with 
Hoescht 33342 as described in Section 2.10.3.  
  
2.10 Immunofluorescence 
 
2.10.1 Preparation of Mowial 
 
 Coverslips were mounted using Mowiol solution. To prepare Mowiol 
solution 12 g glycerol (Sigma) and 4.8 g Mowiol 4-88 (Calbiochem) were added 
to 12 mL of H2O and mixed overnight at room temperature. The following day 24 
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mL of 0.2 M Tris (pH 8.5) was added and the solution mixed at 50°C for at least 
45 minutes until dissolved. Aliquots were then stored at -20°C until required. 
   
2.10.2 Staining of Acinar cells 
 
 Staining of 3D acinar clusters was optimised for clusters of primary cells 
within collagen gel and was carried out in the glass-bottomed culture dishes. 
Cells were initially fixed in 4% PFA for 30 minutes at RT before permeablisiation 
in 0.5% TritonX100 in PBS for 30 minutes. Samples were then washed in PBS 
once and Glycine Wash buffer (0.1 M glycine in H2O) three times for 10 minutes 
each. Blocking was then carried out in cyst block buffer (Table 2.5) for 1 hour 
before overnight incubation with primary antibody at specific concentrations 
(Table 2.6) at 4°C. This was followed by 3 x 20 minute washes of cyst block buffer 
were used. Following this, incubation with a suitable fluorescent secondary 
antibodies (Alex FluorTM 488 or 647 conjugate, Life technologies) at 1:200 dilution 
in cyst block buffer for 3 hours at RT in the dark. Secondary antibodies with 
emission spectra in green (488) and far red (647) were chosen to permit 
visualisation of cell tracker.  Following this, three more washes in cyst block buffer 
were carried out, each for 20 minutes. Nuclei were then stained for by incubation 
in Hoescht 33342 (Life technologies) for 15 minutes at room temperature in the 
dark before mounting of samples in Mowial. Imaging was carried out on a Zeiss 
LSM 710 confocal microscope. 
Reagent 
Concentratio
n Supplier 
NaCl            130 mM Sigma 
Bovine Serum Albumin (BSA) 1% Sigma 
Tritonx100 0.20% Sigma 
Tween20 0.05% Sigma 
FBS 10% ThermoFisher scientific 
Table 2.6 Cyst block buffer components. Added to distilled H2O 
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2.10.3 Staining of Ductal cells 
 
Immunofluorescence staining of 2D pancreatic ductal epithelial monolayers was 
carried out following established protocols. Throughout this protocol 
phosphatase inhibitors; sodium orthovanadate and sodium fluoride were both 
added to all solutions at 1 mM when staining for phosphorylated proteins to inhibit 
any residual phosphatase activity. All steps were carried out at RT unless 
otherwise stated. To begin staining, cells were fixed for 10 minutes in 4% PFA 
followed by 3 x 5 minute washes in TBS. Cells were then permeabilised in 0.25% 
TritonX-TBS for 10 minutes before blocking in 3% BSA-TBS for 1-2 hours.  Cell 
were then incubated in primary antibody (Table 2.7) in 3%-TBS overnight at 4oC. 
Following this samples were washed in TBS for 3x 5 minutes before incubating 
in secondary antibody (1:200, Life technologies) and phalloidin (1:200, 
Invitrogen) for 1 hours at room temperature. Samples were washed thrice more 
for 5 minutes each in TBS before incubation with Hoescht 33342 (Life 
technologies) for 2 minutes. Following this a final H2O wash was carried out for 
5 minutes before mounting in Mowiol. Imaging was carried out on a Zeiss LSM 
710 confocal microscope. 
Antibody Supplier Concentration Source 
anti-EphA2 D7 Millipore 05-480 1:200 Mouse 
anti-EphA2 8B6 CST-129275 1:200 Mouse 
anti-E-cadherin 
BD Transduction 
610182 1:500 Mouse 
anti-Sox9 Millipore AB5535 1:1000 Rabbit 
anti-Amylase Sigma A8273 1:200 Rabbit 
anti-phosphorylated Src 
(Y416) CST-21015 1:50 Rabbit 
anti-phosphorylated Myosin II 
(Thr18/Ser19) CST-36745 1:50 Rabbit 
anti-RFP 
Creative Diagnostics 
H83194 1:500 Rabbit 
Table 2.7 Antibodies for Immunofluorescence 
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2.11 3D Immunofluorescence Tomography 
  
To visualise interactions of normal and KrasG12D pancreatic cells in vivo in 3D a 
recently developed technique known as 3D immunofluorescence tomography 
was utilised (Parfitt et al., 2012). This involves embedding of tissue in butyl-
methyl methacrylate (BMMA) plastic and cutting serial sections of 2 µm. Slides 
can be filled with up to 3 ribbons of serial section with each ribbon up to 20 slices 
or 40 µm. Immunofluorescence of serial sections on slides and subsequent 
imaging of each section was carried out. Each image can then be aligned to 
generate a 3D reconstruction of the tissue. 
 
2.11.1 Butyl-methyl Methacrylate (BMMA) formulation 
 
 To formulate BMMA, butyl methacrylate and methyl methacrylate 
monomer solutions (Polysciences) were mixed 1:4 and the reducing agent 
dithiothreitol was added to a concentration of 5 mM. The photo-initiator, benzoin 
ethyl ether (Sigma) was also added (0.3% of total volume). Finally, BMMA 
solution was degassed with N2 for 30 minutes to remove oxygen which inhibits 
polymerisation. BMMA solution was stored at -20°C to prevent heat and ambient 
light inducing polymerisation. 
 
2.11.2 Sample processing 
 
 Following fixation of tissue in 2% PFA in PBS for at least 24 hours, 
samples were embedded in low melting point 3% agarose (Bioline) to orient 
tissue appropriately. Tissues were then dehydrated in 50%, 70% then 95% 
ethanol for 30 minutes each at room temperature before a final incubation in 
100% ethanol for a further 30 minutes. Following dehydration, samples were 
infiltrated with BMMA. Samples were incubated with 25%, 50% and 75% BMMA 
in ethanol for at least 12 hours each at room temperature. Then tissues were 
submerged and rotated in 100% BMMA for 24 hours at 4°C. For polymerisation 
of BMMA each sample was placed in a BEEM gelatin capsule and sealed before 
being placed under UV light for 20 hours at 4oC. 
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2.11.3 Serial Sectioning 
 
 Serial sections 2 µm thick were cut using a diamond knife (DiATOME) on 
a Leica EM UC7 Ultramicrotome. Cutting was carried out by Dr Geraint Parfitt, a 
research fellow at Cardiff University. By addition of an adhesive (Pattex) to the 
top and bottom of the block to bind each section together forming a ribbon. 
Ribbons of 12-20 sections were then floated onto a Poly-L-Lysine coated slide 
(ThermoFisher scientific). Chloroform vapour was used when required to expand 
the sections ensuring sections lay flat before mounting onto slides.  
 
2.11.4 Immunostaining of Serial Sections 
 
 Ribbons of serial sections were incubated in acetone for 10 minutes to 
remove BMMA before rehydration in 95%, 75%, 50% ethanol and PBS each for 
10 minutes. Antigens were unmasked by heating sections in 1X citrate buffer 
(2.94 g Sodium citrate tribasic dehydrate (Sigma) in 1 L H2O, pH 6) in a pressure 
cooker. Citrate buffer was heated in a microwave at 1000 W for 10 minutes before 
submersing slides in the buffer. The pressure cooker was then heated in a 
microwave for a further 10 minutes. Slides were then cooled in PBS before 
blocking of non-specific antibody binding. This was carried out by incubating in 
5% normal goat serum in PBS for 30 minutes. Tissues were then incubated in 
primary antibody at the appropriate concentration (Table 2.5) overnight at 4oC. 
Slides were then washed in PBS for 3 x 5 minutes before incubation in secondary 
antibody (Life technologies) for 2 hours at room temperature. Sections were then 
incubated in Hoescht 33342 (1:5000 in PBS) for 5 minutes before mounting in 
50:50 Glycerol:PBS. 
 
2.11.5 Three-Dimensional Reconstruction 
 
 Individual sections were imaged on a Zeiss LSM 710 confocal 
microscope. The same position in each section was manually selected, checked 
for focus and then imaged in each channel. The individual montage images were 
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then merged in Fiji (Version 2.0) to form a single stack maintaining the sequence 
of sections. For every image acquisition, at least two channels of information 
were collected with one representing nuclei. Data sets could then be interleaved 
and co-aligned using the common nuclei channel. Image alignment and three-
dimensional reconstruction was performed with the AlignSlices module in the 
Amira 5.4 Software package (Visage Imaging) with semi-automated alignment. 
Reconstructions were then exported as TIFF files for analysis in Fiji and Imaris 
software packages. 
 
 
2.12 Imaging 
  
 Fluorescent imaging was carried out on a Zeiss LSM 710 confocal 
microscope. Samples were stored at 4°C and brought up to room temperature 
before imaging. Imaging settings were kept the same for each individual protein 
in each system. All image files were saved and analysed as .CZI files.   Samples 
from IHC were imaged using a Zeiss Axioscan Z1 slide scanner to image the 
whole tissue section.  
 
2.13 Image Analysis 
 
2.13.1 Calculating RFP percentage area 
 
 The percentage area of RFP in a whole tissue section was calculated as 
the area of RFP as a proportion of the total tissue area and quantified in Fiji 
software (Version 2.0). RFP and brightfield image channels captured from 
cryosections were split and then a ROI was drawn around intact tissue and area 
measured. The RFP channel was then cropped using the tissue ROI to remove 
any fluorescence outside the tissue. The maximum was then increased to the 
same level for all images to improve quality of thresholding. Fluorescence was 
then defined using Auto Threshold by the Default method. The area of RFP was 
then calculated by Analyse Particles using a size threshold of 100 µm to remove 
background and count masks generated. The total area of RFP was then 
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calculated in excel and normalised to tissue area to produce a percentage area 
of RFP for each slice. For each biological replicate 5 whole tissue slices were 
analysed. 
 
2.13.2 In Vivo Cluster Analysis 
 
 To calculate the density of clusters of RFP in vivo individual clusters were 
quantified using Fiji software and total area of tissue quantified as before. 
Clusters were then binned on size using GraphPad Prism6 and normalised to the 
area of each tissue slice. This generated the density of different sized clusters 
per tissue and was repeated for each biological replicate. This was then plotted 
in GraphPad. 
 
 
2.13.3 In Vitro Quantification 
 
 To quantify contractility and segregation of transformed cells from 2D 
ductal epithelial cultures cell area and Index of Sphericity were calculated. Cell 
area was calculated by manual segmentation of cells based on membrane 
fluorescence using Fiji. Area was then measured for each cell. Index of Sphericity 
is a recently described mathematical model that quantifies how much an object 
shape deviates from the ideal shape of a circle (Ionescu-Tirgoviste et al., 2015). 
As the Index of Sphericity tends more towards 1, the object is more spherical. It 
considers two parameters: i) the shape perimeter measured on a 2D surface and 
ii) a relative parameter, namely the mean shape diameter. The mean shape 
diameter is determined from the perimeter and area of an irregular shape. The 
ratio between the perimeter and mean diameter of a perfect circle is p and thus 
the deviation from this can be quantified to measure the divergence from a 
perfect circle. The area and perimeter of a CMRA labelled cluster was measured 
manually in Fiji before calculation of the Index of Sphericity. 
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2.13.4 3D In Vivo Quantification of Volume 
 
 To calculate the volume of RFP positive cells in vivo, tissue stained for E-
cadherin and RFP and nuclei was imaged and 3D reconstructions generated 
using immunofluorescence tomography. Three-dimensional reconstructions 
were then imported into Imaris (Version 9.2, Bitplane). Segmentation was then 
carried out using the ImarisCell module using Cell Membrane Region Detection 
based on E-cadherin immunofluorescence. Cell membrane detection algorithms 
are a collection of automatic tools and were adjusted and optimised for a small 
ROI before expanding to the whole 3D image. RFP positive cells were then 
selected and volume recorded. 
 
2.14 Statistical Analysis 
 
 Statistical analysis was carried in GraphPad Prism6. Error bars on graphs 
represent standard deviation. Data was tested for normal distribution using a 
Shapiro-Wilk normality test. For comparison of normally distributed data an 
unpaired Welch’s t-test was carried out with a p value of <0.05 taken as a 
significant difference. Data that were found to be not normally distributed were 
compared using a Mann Whitney U two-tailed test with significant difference 
accepted with p <0.05. 
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Chapter 3: Characterising KrasG12D normal heterotypic 
cell-cell interactions in vivo  
 
3.1 Introduction 
 
At the initial stage of carcinogenesis transformation occurs in a single cell within 
a normal epithelium. However, what happens at the interface between the mutant 
cells and the surrounding normal neighbours is not clearly understood. Recent 
studies have demonstrated that mutant cells can be eliminated from epithelial 
tissues in vitro via cell competition with normal neighbours. For example, it has 
been shown that RasV12-, Src- or ErbB2- transformed cells are apically extruded 
when surrounded by normal epithelial cells (Hogan et al., 2009; Kajita et al., 
2010; Leung and Brugge, 2012). Extrusion in vitro is dependent on E-cadherin-
based cell-cell adhesions and signalling to the actin-myosin cytoskeleton. 
Importantly, when transformed cells are cultured alone apical extrusion does not 
occur suggesting that extrusion is cell-context dependent. Recently, differential 
EphA2 has been demonstrated to be the underlying signalling causing repulsion 
and extrusion of Ras mutant cells in vitro and was found to be evolutionary 
conserved in Drosophila (Porazinski et al., 2016). Cell-cell interactions between 
normal and RasV12 cells triggers ephrin-A-EphA2 signalling which induces 
repulsion of mutant cells. In the absence of EphA2 signals, RasV12 cells integrate 
with normal cells and adopt a pro-invasive morphology.  
 EphA2 is a member of the Eph family of receptor tyrosine kinases, which 
are involved in cell segregation and tissue boundary formation required through 
development and to maintain organised tissues in complex organisms (Kania and 
Klein, 2016). Alterations to EphA2 has been linked with breast, prostate, lung, 
ovarian, cervical, oesophageal and colorectal cancer (Andres et al., 1994; 
D’Amico et al., 2001; Duxbury et al., 2004; Kataoka et al., 2004; Landen et al., 
2006; Walker-Daniels et al., 1999; Zelinski et al., 2001). Moreover, increased 
EPHA2 expression in tumour cells correlates with poor prognosis in breast and 
oesophageal cancer with EphA2 knockout reducing tumour growth and 
metastasis in ErbB2-driven breast cancer in mice (Brantley-Sieders et al., 
2008).EphA2 has also been studied in pancreatic cancer patient samples; with 
EphA2 is elevated in primary tumour and the loss of EphA2 was associated with 
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metastasis (Mudali et al., 2006). Although abnormal expression of EphA2 has 
been reported during tumourigenesis the precise role is unclear, with a role in 
cell competition not explored.  
 Recently, a number of studies have begun elucidating a role for cell 
competition at the earliest stages of Ras-driven carcinoma. Using mouse-derived 
organoid and in vivo imaging has demonstrated that single RasV12 cells are 
apically extruded from the intestinal epithelium (Kon et al., 2017) and cleared in 
adult murine skin models (Brown et al., 2017). In the developing pancreas, there 
is some evidence that selective loss of KrasG12D mutant cells occurs (Morton et 
al., 2010). Moreover, cellular extrusion has been identified from precursor lesions 
in the pancreas (Hendley et al., 2016; Rhim et al., 2012). Recently, one study 
found evidence of extrusion of single RasV12 cells from the pancreatic ductal 
epithelium in vivo (Sasaki et al., 2018). This work also investigated the process 
by which extrusion is overcome and found a high-fat diet and chronic 
inflammation could inhibit extrusion. The number of mutant cells has also been 
demonstrated to determine if cell competition promotes or prevents 
tumourigenesis. Small clusters of oncogenic Ras expressing cells can be 
eliminated from Drosophila epithelia by contractile forces between aberrant and 
normal cells however these forces drive cyst formation in larger mutant clusters 
(Bielmeier et al., 2016). In very large clusters of Rab5 mutant cells (around 400 
cells) cell competition-dependent apoptosis at the boundary of normal:mutant 
cells can drive proliferation and tumour formation (Ballesteros-Arias et al., 2014). 
These studies suggest that cell context-dependent changes occur to extrude 
cells with oncogenic Ras. However, whether this impedes tumourigenesis or can 
promote tumour formation and invasion and precisely how it occurs in vivo is still 
unclear. 
 Mutations to Ras are integral to many forms of cancer with Kras mutations 
known to have a causal role in human pancreatic ductal adenocarcinoma 
(PDAC). Mutational activation of KRAS is present in >90% of PDAC and 
represents the most frequent and earliest genetic alteration, being found in >95% 
of low-grade human pancreatic intraepithelial neoplasia (PanIN) 1A lesions 
(Habbe et al., 2008; Kanda et al., 2012; Morris et al., 2010a). Moreover, KrasG12D 
expression in the murine pancreas is sufficient to initiate pancreatic intraepithelial 
neoplasias (PanINs) which can progress with long latency to PDAC, fully 
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recapitulating the human disease in mouse models (Hingorani et al., 2003). 
Furthermore, using an inducible and reversible expression of KrasG12D mouse 
model has demonstrated that continuous KrasG12D is required; with rapid 
regression of primary and metastatic lesions and tumours following inactivation 
of KrasG12D (Collins et al., 2014). KrasG12D mutations are predicted to occur 
decades before tumour formation (Yachida et al., 2010), indicating a large 
window for diagnosis and disease monitoring. Therefore, KrasG12D mutations can 
be considered the initial and driver mutation of the early disease states in PDAC 
and may occur long before tumour formation.  
 Pancreatic cancer is the fifth leading cause of cancer deaths in the UK. It 
has a median survival measured in months and a 5-year survival of <5 % (Cancer 
Research UK, 2017). The poor prognosis is due to the aggressive nature of the 
disease and a lack of symptoms resulting in only 10-20 % of patients diagnosed 
with surgically resectable cancer, the only cure (Mayo et al., 2012). Better 
understanding of the initial stages of pancreatic cancer is imperative to improving 
patient prognosis. 
 The aims of this chapter were to investigate the role of cell-cell interactions 
on the fate of newly emerged mutant cells in the murine pancreas in vivo. It aims 
to answer: i) whether KrasG12D expressing mutant cells are eliminated by normal 
neighbours, ii) is EphA2 required for the loss of transformed cells and iii) if cluster 
size dependent changes are occurring in vivo. 
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3.2 Results 
 
 
3.2.1 Pdx1-CreERT drives recombination in the pancreas with high 
efficiency 
 
In order to study the interaction of KrasG12D expressing mutant cells 
(KrasG12D cells) and normal neighbours it was first necessary to generate an in 
vivo model of mosaic KrasG12D cells. To this end animals bearing the Pdx1-CreERT 
transgene (Gu et al., 2002) were crossed with (Lox-STOP-Lox) LSL-KrasG12D/+ 
mice (Jackson et al., 2001). To label recombined cells, animals were crossed 
with the ROSA26LSL-RFP reporter transgene (Luche et al., 2007). This resulted in 
Pdx1-Cre; Rosa26tdRFP; KrasG12D mice which will be referred to as KC from now 
on. In these animals, tamoxifen drives Cre-mediated excision of the LSL cassette 
and expression of KrasG12D and RFP. Control mice for RFP studies were Pdx1-
CreERT; ROSA26LSL-RFP with tamoxifen leading to RFP labelling of Kras wild-type 
pancreatic cells. Breeding pairs were kindly provided by Jen Morton and Owen 
Sansom at the Beatson Institute, Glasgow and re-derived into a SPF unit. 
To investigate the interaction of normal and mutant cells it was necessary 
to generate tissue with mosaic expression of KrasG12D. To achieve this a low level 
of tamoxifen was administered to induce low levels of recombination within the 
tissue. Control animals at 6-8 weeks of age were injected with 1 µg and 1mg of 
tamoxifen by IP injection. At 7 days post-induction (dpi) the pancreas was 
harvested, frozen in optimal cutting temperature (OCT) compound and sectioned 
on a cryostat. Five sections of 10 µm each and at least 50 µm apart were cut and 
imaged using the tile-scan function on a Zeiss LSM710 confocal microscope to 
capture the whole section (Figure 3.1A). The area of RFP was then quantified 
using ImageJ and calculated as a percentage of the total tissue area (Figure 
3.1B). Induction using 1 µg “low dose” of tamoxifen resulted in 20.8% ± 3.7 (± 
standard deviation, n=5) of the tissue positive for RFP. As animals were all of a 
similar weight and due to the precision of induction it was not necessary to control 
dose based on animal weight to generate a reproducible percentage area with 
low inter-variation. Induction with 1mg of tamoxifen led to 24% ± 17 ( n=2) and 
as this was similar to 1 µg but with higher variation the 1 µg dose was used in 
future experiments. The pancreata from animals not bearing the RFP transgene 
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were found to be negative for RFP fluorescence. Age-matched animals that had 
not been induced with tamoxifen had a percentage area of RFP of 1.3% ± 0.4 
(n=2) (Figure 3.1B). This indicates low level induction with tamoxifen results in 
around 20% recombination within the tissue with minimal background induction. 
As a control for studying heterotypic cell-cell interactions it was also 
necessary to generate tissue with widespread KrasG12D expression. To induce 
widespread recombination, and hence most cells expressing KrasG12D and RFP, 
previous work has used a dosage system consisting of one intraperitoneal (IP) 
injection of 9 mg /40 g of bodyweight every other day for a total of 3 injections 
(Gidekel Friedlander et al., 2009). Control mice (Pdx-1-CreERT; ROSA26LSL-RFP) 
at 6 – 8 weeks of age were injected following this regime and the pancreas was 
harvested and RFP area quantified as before (Figure 3.1A, B). Using this “high” 
tamoxifen dosage resulted in a percentage area of RFP positive tissue (± 
standard deviation) of 80.5 % (Figure 3.1B). This indicates that at this dose using 
a Pdx1-driven Cre, most cells in the pancreas have undergone recombination as 
the vast majority of the tissue is RFP positive. This demonstrates the capability 
of the system to generate a model of cell-cell interactions whereby most 
recombined cells are surrounded by recombined neighbours.  
Together, this shows that the levels of recombination within the murine 
pancreas can be controlled by dosage of tamoxifen and the system can generate 
two scenarios; one with a large number of normal-mutant cell interaction (low 
dose) and a second with a predominance of mutant-mutant cell interactions (high 
dose). This allows characterisation of the fate of Ras-transformed cells over time 
in the murine pancreas in vivo and recapitulates the initial genetic event occurring 
in a single cell within a healthy epithelium. 
The RFP transgene consists of a “tandem-dimer2” RFP (tdRFP) variant 
which consists of two genetically modified DsRed subunits covalently fused 
resulting in a very bright variant. Due to this brightness even spurious read-
through across the transcript could result in background fluorescence (Luche et 
al., 2007). To overcome this the tdRFP was inserted in reverse orientation 
relative to ROSA26 transcription. This in combination with two unique pairs of 
loxP sites, one pair in parallel and the other in opposite orientation, means that 
two Cre-mediated recombination events are required for activation (Luche et al., 
2007). As Cre-mediated recombination can vary between loci (Liu et al., 2013), 
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and two recombination events are required for RFP but only one for KrasG12D 
expression it was necessary to confirm that RFP faithfully labelled cells 
expressing KrasG12D. To this end laser capture microscopy was used to excise 
RFP positive and RFP negative tissue from induced KC animals 7 dpi. Genomic 
DNA was then extracted from these samples and a PCR was carried out for the 
recombined, non-recombined and wild-type allele (Figure 3.1C). It was observed 
that RFP positive tissue produced two bands corresponding to the 622bp product 
from the WT allele and the 650bp product from the recombined Kras allele with 
no band identified at 500bp from the unrecombined Kras allele (Figure 3.1D). 
This suggests a similar level of recombination efficiency at the two loci and that 
RFP accurately labels cells with mutant KrasG12D. Laser capture microdissection 
was also carried out for RFP negative tissue. This produced two bands at 500bp 
and 622bp corresponding to the non-recombined LSL-KrasG12D locus and the WT 
allele respectively. However, a faint band was also observed at 650bp suggesting 
that a low level of RFP negative cells have undergone Cre-mediated 
recombination at the KrasG12D locus. This suggests that some cells have 
recombined at the mutant KrasG12D allele but are not expressing RFP. Although 
it could not be ruled out that some KrasG12D cells are not RFP positive this 
demonstrates that the system is robust and RFP accurately marks mutant cells.  
The pancreas consists of both exocrine and endocrine compartments with 
Pdx1 reported to be expressed in both compartments in the adult (Jonsson et al., 
1994; Offield et al., 1996). During development Pdx1 is expressed in all 
pancreatic lineages, however in the adult the expression pattern is less clear. To 
investigate which cell type was undergoing recombination, fixed tissue was 
stained with anti-RFP and anti-E-cadherin to examine recombined cells and allow 
identification of cell type by morphology (Figure 3.1E). It was observed that of the 
exocrine compartment both acinar and ductal cells were positive for RFP (Figure 
3.1E, white arrows and white arrowheads, respectively). RFP positive cells were 
also identified within islets (Figure 3.1E, dashed line). This suggests that Pdx1 is 
expressed within both the exocrine and endocrine compartment in the adult. 
Furthermore, acinar cells were observed to make up the largest contribution to 
the RFP positive area.  
Expression of KrasG12D leads to constitutive activation of KRAS and the 
MAPK signalling pathway (Macrae et al., 2005). To investigate markers KRAS 
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activation immunohistochemistry for phosphorylated ERK (pERK) was carried 
out however no positive signal was observed at 7 or 35 dpi. in KC mice (data not 
shown) and it has previously been reported that pERK is not a robust read-out of 
KRAS activation in the pancreas (Ji et al., 2009). However, expression of 
KrasG12D is sufficient to induce PanIN lesions and increase the amount of KRAS-
GTP present, demonstrating activation of oncogenic KRAS (Bailey et al., 2016; 
Collins et al., 2012; Ferreira et al., 2017; Guerra, 2013; Habbe et al., 2008; 
Hingorani et al., 2003, 2005). Moreover, we have previously found pERK levels 
to be cyclical upon Ras activation in MDCK cells. Therefore, pERK is not 
appropriate to use as a readout of KrasG12D. 
Together, this describes the development of an in vivo model of 
normal:mutant cell interactions in the adult murine pancreas in vivo with RFP 
providing a surrogate for KrasG12D expression.  
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Figure 3.1: Developing a model of KrasG12D:normal cell interaction with an RFP 
reporter. By regulating the dose of tamoxifen the level of recombination as measured by 
RFP % area can be controlled (A). High dose (3x9mg/40g) achieves 80.5% (n=1) area of 
recombination in the tissue, medium dose (1x 1mg) resulted in 24%±20 (n=2) and low dose 
(1x 1ug) induced 20.8%±3.7 (n=5). Background induction in uninduced mice is low at 
1.3%±0.4 (n=2) (B). A diagram of primer binding sites (C) shows the method of detection 
of Kras locus recombination by PCR. Using laser capture microscopy to extract RFP 
positive cells followed by PCR using the primers from (C) indicates RFP positive cells have 
also recombined at the KrasG12D locus. In RFP negative tissue wild-type (WT) and 
unrecombined KrasLSL-G12D  alleles were detected. However, a weaker band 
correspondingly to recombined Kras1LOX-G12D was detected in RFP negative tissue 
indicating in a small proportion of non-RFP labelled cells express oncogenic KrasG12D. (E) 
Confocal image of fixed murine pancreas tissue harvested 7 dpi. with low dose tamoxifen. 
Fixed tissue is stained with anti-RFP antibody (red), anti-E-cadherin (green) and Hoescht 
(blue). RFP is detected in exocrine acinar cells (white arrows), ductal epithelial cells (white 
arrowheads) and endocrine islets (dashed white line), indicating Pdx-1-driven Cre 
expression. Scale bars, 500 µm (A), 100 µm (E). 
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3.2.2 Developing a sample representative of intravariation through the 
pancreas 
 
 Once the method of induction had been established it was investigated 
whether an RFP sample from the tail was representative of the whole pancreas. 
As the pancreas is the second largest gland in the body and is reported to have 
differences in cell composition, blood supply and innervation through the tissue 
(Dolenšek et al., 2015) the RFP levels through the pancreas were quantified. A 
whole KC pancreas was harvested 14 days after induction with 1 µg of tamoxifen, 
embedded in OCT for sectioning on a cryostat. Initially, a 10 µm slice was 
collected every 50 µm for the first 300 µm from the tail as the tail sample. Then 
a slice was collected every 250 µm throughout the rest of the pancreas with 
representative tile scans from the beginning, middle and end depicted in Figure 
3.2A. The RFP percentage area of each slice was then calculated by quantitative 
analysis of both the total tissue and RFP area using ImageJ (Figure 3.2B). It was 
observed that the average percentage area of RFP in the tail sample (first 300 
µm) was 4.1 % ± 0.7. Through the rest of the pancreas the percentage area of 
RFP appears to have only low variation with all values except one within 2% of 
the average tail sample. Moreover, no general trend of RFP change was 
observed through the pancreas. This quantifies the variation of recombination 
within the pancreas and suggests that values attained from a tail sample provide 
an approximate representation of the whole pancreas.  
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Figure 3.2: Levels of recombination are similar through the murine pancreas. 
(A) At 14 dpi the whole pancreas was sectioned from the tail, imaged with tile scans 
and are stitched to show entire tissue sections representative images of RFP (red) 
from tissue sections from the start, middle and end (left to right). (B) Quantification 
of RFP percentage area identified the variation through the pancreas and suggests 
5 slices from 300 µm in the tail is representative of the whole organ. Scale bar, 500 
µm. 
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3.2.3 The percentage area of cells expressing oncogenic Kras decreases 
over time 
 
Having validated the low dose model of KrasG12D recombination in the 
pancreas to establish mosaic expression in the pancreas, the fate of mutant cells 
was investigated over time.  
 Cohorts of KC and control animals (Kras wild-type) were injected with 1 
µg of tamoxifen at 6-8 weeks of age and tissue harvested at 7 and 35 days post 
induction. These time points were chosen as loss of KrasG12D cells from the 
pancreas was previously suggested to take place over a period of 28 days using 
constitutive Cre activation in utero (Morton et al., 2010). A section of 10 µm was 
cut every 50 µm in the tail of the pancreas until 5 sections were collected. Tile-
scans of the tissue were then captured and stitched before quantification of the 
total tissue area and RFP area using ImageJ (Figure 3.3A). All images were 
captured using the same settings and analysed using the same parameters and 
thresholding method. Quantification of RFP percentage levels (± standard 
deviation) at 7 dpi revealed similar levels of recombination in control and KC 
pancreata (Control = 20.8 % ± 3.7 Vs. KC = 27.6 % ± 5.0) (Figure 3.3B). This 
suggests that the initial levels of recombination within control and KC animals are 
similar. No difference was observed between male and female animals so both 
sexes were pooled in all experiments. To understand tissue dynamics over time 
in the pancreas, Pdx1-Cre; Rosa26tdRFP control cohorts were also generated for 
later time points (Figure 3.3B). It was found that the percentage area of RFP 
positive tissue in controls did not significantly change between 7 and 35 dpi (7 
days = 20.8 % ±3.7 Vs. 35 days = 24.6 % ±1.8, Welch’s t-test, p= 0.09). This 
suggests that RFP is stable and provides a robust model to track cellular changes 
over time. 
 Next, the percentage area of RFP in KC animals was analysed over time. 
Interestingly, at 35 dpi the percentage area of RFP was significantly decreased 
compared to 7 dpi (7 days = 27.6% ± 5.0 Vs. 35 days = 8.5% ± 3.0, Welch’s 
unpaired t-test, p= 0.0036) (Figure 3.3B). This indicates that over 28 days 
approximately 69% of KrasG12D expressing cells are lost from the tissue. As 
separate cohorts of induced animals were generated for each time point, rather 
than lineage tracing in single animals, Kras wild-type controls were compared to 
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KC animals at each time point. Quantification of RFP demonstrated that a 
significantly decrease between control and KC mice had occurred by 35 dpi 
(Control = 24.6% ± 1.83 Vs. KC = 8.5% ±3.03, Welch’s unpaired t-test, p= 
<0.0001). This suggests that stochastic induction of mutant KrasG12D expression 
in a low number of cells drives drastic changes to the tissue resulting in a large 
decrease in RFP area, implying a loss of mutant cells. 
 Together, this data indicates that labelled, Kras wild-type cells are 
relatively unchanged over 28 days but when KrasG12D cells are present at low 
numbers, they are eliminated. 
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Figure 3.3: Loss of KrasG12D mutant cell area over time. KC (Pdx1-Cre; 
Rosa26tdRFP; KrasG12D) animals and controls (Pdx1-Cre; Rosa26tdRFP) were induced 
using a low dose of tamoxifen via IP injection and tracked over time. Representative 
images of sectioned pancreata harvested at 7 and 35 dpi. with RFP imaged using tile-
scans (A). The percentage area of RFP was then quantified as a readout of KrasG12D 
cell area (black bars) and Kras wild type cell area (Control, white bars) (B). A 
significant decrease in area of KrasG12D expressing cells was observed at 35 dpi. 
compared to 7 days. Moreover, at 35 dpi. the area of mutant Kras cells was 
significantly lower than Kras WT controls. Data represents mean ± s.d. n = 4-6 
biological replicates. Statistical analysis was carried using Welch’s two-tailed t-test 
with *P<0.05 and ****P<0.0001. Error bars are standard deviation. Scale bar, 500 µm 
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3.2.4 The loss of RFP is not a cell-autonomous process and requires 
normal neighbours 
  
 After observing that the presence of KrasG12D cells at low numbers in the 
pancreas resulted in a decrease in RFP area, it was necessary to test whether 
this is a result of a cell intrinsic mechanism or requires normal neighbours. We 
have previously identified the autonomous upregulation of EphA2 as the process 
by which Ras mutant cells are triggered to be eliminated from epithelial 
monolayers (Porazinski et al., 2016). Ras mutant cells were not eliminated when 
surrounded by other Ras mutant cells suggesting a requirement of non-
transformed epithelial cells. To test the requirement of non-transformed 
neighbours the dose was increased to generate widespread recombination within 
the pancreas and the RFP area over time was tracked. 
 Cohorts of KC animals, at 6-8 weeks of age, were injected with the high 
dose and the pancreas was harvested at 7 and 35 dpi. Sections of frozen tissue 
were then imaged using tile-scans to image RFP in the whole section as before 
and quantified using ImageJ (Figure 3.4A). By increasing the amount of 
tamoxifen administered the percentage area of RFP increased to 70.7 % ± 8.7 in 
KC animals 7 dpi (Figure 3.4B). In this setting, the interaction of normal and 
mutant cells decreases whilst homotypic KrasG12D:KrasG12D cell interactions 
increase. Control mice (Kras wild-type) were also induced in the same manner 
and resulted in a RFP area of 80.5 % at 7 dpi. This suggests that the levels of 
recombination induced in KC and controls is similar at 7 dpi and allows direct 
comparison at later time points. 
 The RFP distribution was then imaged at 35 dpi to investigate how mutant 
cell area changes over time in this scenario. It was found that no significant 
change in RFP percentage area was observed between 7 and 35 days in the KC 
model (35 days = 75.3 % ± 7.1 Vs. 7 days = 70.7 % ± 8.7, Welch’s t-test p = 
0.5012) (Figure 3.4B).  This indicates that over the same time period that led to 
loss of RFP when mutant cells are present at low numbers, RFP area is stable 
when mutant cells are present at high numbers. Furthermore, no significant 
difference in RFP percentage area was observed between Kras WT and KrasG12D 
tissues at 35 dpi following high dose induction (Control = 66.3 % ± 10.0 Vs. KC 
= 75.3 % ± 7.1, Welch’s t-test p = 0.2636). The area of RFP was also compared 
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at high dose for Kras wild-type, RFP labelled cells over time. Between 7 and 35 
dpi levels of RFP in control mice were observed to undergo a small decrease (7 
days = 80.5 % Vs. 35 days = 66.3 % ± 10.0). However, further investigation is 
required to increase the number of biological replicates to understand if the loss 
of RFP area in controls over time is a consistent and significant trend. 
 Together these data demonstrate that when KrasG12D expressing cells are 
present at a high number within the pancreas the overall percentage area of 
mutant cells does not decrease over time. This suggests that mutant cells are 
not lost when present in tissues at high numbers and indicates a requirement for 
normal neighbours in the elimination of KrasG12D cells. 
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Figure 3.4: Area of RFP is unchanged over time in high dose. To examine the 
requirement of heterotypic interactions between normal and mutant cells for the 
decrease in RFP area widespread recombination was induced using a high dose 
of tamoxifen. KC (Pdx1-Cre; Rosa26tdRFP; KrasG12D) and control mice (Pdx1-Cre; 
Rosa26tdRFP) were injected with 1 injection of 9 mg/40 g every other day for a total 
of 3 injections and tissue harvested at 7 and 35 days post-induction. (A) 
Representative images of cryosections of whole tissue slices imaged as a tile-
scan. (B) Quantification of RFP area demonstrates no significant change in control 
(hite bars) or KC mice (black bars) between 7 and 35 dpi. At 35 dpi the area of 
Kras mutant cells is similar to RFP labelled Kras WT cells suggesting that mutant 
cell area does not decrease when Kras cells at present at high numbers. Statistical 
analysis was carried using Welch’s two-tailed t-test. Data represents mean ± s.d. 
n = 3 biological replicates except for control 7 days where n = 1. Scale bar, 500 
µm 
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3.2.5 Elimination of sporadic KrasG12D cells from normal tissues requires 
EphA2 
 
Previously, we have demonstrated that cells expressing oncogenic Ras 
are detected by normal neighbours by elevated EphA2 in mutant cells (Porazinski 
et al., 2016). Cell-cell interactions between normal and Ras-transformed cells 
triggers EphA2 signalling in mutant cells. This leads to repulsion and extrusion of 
Ras-transformed cells from non-transformed monolayers. It follows that the 
EphA2 signalling could be driving the decrease in RFP area of KrasG12D cells in 
the pancreas by elimination.  
To investigate if EphA2 signalling is required for the loss of KrasG12D cells, 
the KC model was crossed onto animals expressing an inactive form of EphA2 
(Brantley-Sieders, 2004), generating Pdx1-CreERT; LSL-KrasG12D/+; Rosa26LSL-
RFP; EphA2tm1Jrui, referred to from now on as KC-Eph. This model uses an in-
frame translation stop-codon inserted into exon 5 (Shi et al., 2012), that renders 
the absence of a full length or truncated protein (Amato et al., 2016), similar to a 
null. Controls for this cohort included Pdx1-CreERT; Rosa26LSL-RFP; EphA2tm1Jrui 
and will be referred to as RFP-Eph. To explore whether functional EphA2 is 
required for the decrease in RFP area, animals were induced at 6-8 weeks of 
age and harvested 7 and 35 days later.  
First it was necessary to investigate whether EphA2 deficiency altered the 
induction level by tamoxifen injection, by analysing RFP area at 7 dpi in RFP-
Eph controls. Quantification of RFP percentage area at 7 dpi in RFP-Eph controls 
showed a similar level of recombination to KC and control mice (Figure 3.5B). 
There was no significant difference in RFP area at 7 days post-induction between 
control and RFP-Eph (Control = 20.8 % ± 1.8 Vs. RFP-Eph = 29.1 % ± 11.6 
Welch’s unpaired t-test, p = 0.1928). This suggests that EphA2-deficiency does 
not alter initial levels of induction and demonstrates that at 7 dpi this EphA2-
deficient mouse model is comparable with the KC model allowing direct 
comparison at later time points. 
Next, RFP-Eph mice were used to investigate the effect of loss of 
functional EphA2 on RFP over time. At 35 dpi it was found that the area of RFP 
was 24.0 % ± 3.2 (Figure 3.5A, C). There was no significant difference between 
 81 
control and RFP-Eph in this model at 35 days post-induction (Control = 24.6 % ± 
1.8 Vs. RFP-Eph = 24.0 ± 3.2, Welch’s unpaired t-test, p =0.71). Furthermore, 
there is no significant change in RFP area over time in RFP-Eph mice (7 days = 
29.1 % ± 11.6 Vs. 35 days = 23.98 % ± 3.2, Welch’s unpaired t-test, p = 0.3910). 
Together, these data show that EphA2-deficiency alone does not alter RFP area 
over time following induction with low dose tamoxifen. 
Having established that EphA2-deficiency had no effect on RFP area in 
controls, the functional requirement of EphA2 in elimination of KrasG12D cells in 
KC mice could be studied. Analysis of RFP area at 7 dpi showed that the 
percentage area of RFP was not significantly different to controls at the same 
time point (Control = 20.8 % ± 3.7 Pdx1-CreERT; KC-Eph= 32.9 % ± 15.5, Welch’s 
unpaired t-test, p = 0.216). This indicates that induction levels are similar at early 
time-points. The loss of mutant cells over time was then investigated in the KC-
Eph model. At 35 dpi it was observed that there was significantly more RFP in 
KC-Eph then KC mice (KC-Eph = 23.12 % ± 1.34 Vs. KC = 8.5 % ± 3, Welch’s 
unpaired t-test, p = <0.0001). Moreover, the area of KrasG12D cells returned to 
similar levels as controls suggesting that EphA2-deficiency is sufficient to 
completely rescue loss of RFP within the context of normal neighbours. 
In conclusion, these data indicate that functional EphA2 is required for the 
loss of RFP when labelling KrasG12D cells surrounded by normal neighbours in 
vivo which could infer that EphA2-deficiency leads to retention of mutant cells. 
  
 
 
 
 
 
 
 
 
 
 
 82 
 
Figure 3.5: Loss of RFP area at low dose requires functional EphA2 in vivo. 
(A) Representative images of RFP from tile scans of whole tissue sections at 35 
dpi. of control (Pdx1-CreERT; Rosa26LSL-RFP), KrasG12D (Pdx1-CreERT; LSL-
KrasG12D; Rosa26LSL-RFP), KrasG12D EA2 (Pdx1-CreERT; LSL-KrasG12D; 
Rosa26LSL-RFP; EphA2tm1Jrui) and EA2 (Pdx1-CreERT; Rosa26LSL-RFP; EphA2tm1Jrui) 
mice. (B) Quantification of RFP percentage area at 7 days post induction shows 
similar levels of recombination between Kras EA2 and controls. Loss of functional 
EphA2 also had no effect on RFP area over time with EA2 (Pdx1-CreERT; 
Rosa26LSL-RFP; EphA2tm1Jrui) comparable to controls. (C) At 35 days post-induction 
there is no significant difference between Kras EA2 and controls. However, EphA2-
deficiency leads to a significant increase in RFP area compared to KrasG12D cells 
and a return to levels similar to controls. Statistical comparison was carried out 
using Welch’s unpaired t-test. Data represent mean ± s.d. with n = 4-6 biological 
replicates. P < 0.0001 = ****. Scale bar, 500 µm. 
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3.2.6 Clusters of KrasG12D expressing cells are eliminated from normal 
pancreatic tissue 
 
 Characterising RFP levels in the tissue provides a global view of changes 
to labelled cells however it does not provide information on RFP cluster 
dynamics. Clusters can undergo dynamic changes such as merging, splitting 
and/or elimination. Moreover, RFP percentage area considers both number and 
size of individual cells and so to gain insight into these dynamic changes 
individual clusters were defined and treated discretely (Figure 3.6A). As the loss 
of RFP was only observed in the low dose this was the focus of this analysis. 
 Using the same tile-scans used for RFP area analysis, segmentation and 
quantification of clusters was carried out for KC and control animals. The data 
were then visualised using a boxplot to observe the distribution of KrasG12D 
cluster sizes over time and compared to control (Figure 3.6B). In control mice at 
7 dpi the median was 1263 µm2 with 25% percentile and 75% percentile 466 µm2 
and 3487 µm2 respectively, with an interquartile range (IQR) of 3021 µm2. There 
is no significant change in the distribution of cluster sizes in control mice between 
7 and 35 dpi (p = 0.11, Mann-Whitney t-test). This suggests that over time the 
distribution of Kras wild type clusters is similar. Next, the clusters from KC 
animals were analysed (Figure 3.6B). Direct comparison between control and KC 
mice at 35 days could not be carried out as cluster distributions are significantly 
different at 7 dpi (p = <0.0001, Mann Whitney t-test). This could be a result of 
difference in the induction profile between animal models or indicate dynamic 
changes to KrasG12D clusters have occurred by 7 days. At 35 dpi a significant 
increase in the distribution of KrasG12D cluster sizes was observed (p = <0.0001, 
Mann Whitney t-test). This has resulted in a 39% increase in the median mutant 
cluster size in KC mice between 7 days (1051 µm2) and 35 dpi (1710 µm2). When 
compared to the stable cluster distribution over time observed in control mice this 
suggests a dynamic shift towards an increase in the size distribution of KrasG12D 
clusters. 
 To characterise further the changes to KrasG12D clusters over time, the 
total number of clusters was calculated for each biological replicate and 
normalised to area (Figure 3.6C). This provided an overview of how the number 
of clusters was changing over time. At 7 dpi it was found that the density of 
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clusters induced was similar in KC and control animals (Control = 37.5 mm-2 ± 
5.6 Vs. KC = 31.3 mm-2 ± 5.4). Over time in controls, no significant change in the 
number of Kras wild-type clusters was observed (7 days = 37.5 mm-2 ± 5.6 Vs. 
35 days = 44.3 mm-2 ± 10.0, Welch’s unpaired t-test, p =0.2314). A significant 
decrease in clusters was observed between KC and control animals at 35 dpi 
(Control = 44.4 mm-2 ± 10.0 Vs. KC = 18.1 mm-2 ± 5.7, Welch’s unpaired t-test, p 
= 0.0072). In addition, there was a significant decrease in the number of KrasG12D 
clusters over time (7 days = 31.3 mm-2 ± 5.4 Vs. 35 days = 18.1 mm-2 ± 5.8, 
Welch’s unpaired t-test, p = 0.0252). This suggests approximately 43% of mutant 
clusters are lost within this time frame. 
 Together, these results demonstrate that clusters of KrasG12D cells are 
eliminated from normal pancreatic tissue over time. Moreover, dynamic changes 
appear to be occurring to clusters leading to an increase in the size distribution 
of KrasG12D clusters over time. These data provide insight into changes to 
KrasG12D clusters at the level of the tissue over time. 
 
 
 85 
 
Figure 3.6: Cluster analysis indicates that clusters of KrasG12D cells are lost in vivo. 
(A) Method of segmentation of RFP clusters resulting in labelling and quantification of 
individual cluster. (B) Tukey-style boxplot showing distribution of clusters in control (Pdx1-
CreERT; Rosa26LSL-RFP) at 7 dpi (n= 17892 clusters) and 35 dpi (n = 12967 clusters) and 
KrasG12D (Pdx1-CreERT; LSL-KrasG12D; Rosa26LSL-RFP) at 7 dpi (n = 15263 clusters) and 35 
dpi. (n = 6089 clusters). There is no significant difference between control cluster 
distributions over time (p = 0.11, Mann-Whitney test). There is a significant increase in the 
size of KrasG12D clusters (p=<0.0001, Mann-Whitney test). ≥4 mice for each time point and 
genotype were analysed in B. Line across box is median. Box boundaries indicate 25th and 
75th percentile. Whiskers indicate 1st and 99th percentiles. (C) There is no significant 
difference in density of clusters at 7 dpi between control (circles) and KrasG12D clusters 
(squares). There is a significant decrease in the density of KrasG12D clusters at 35 days 
compared to 7 days. There is also significantly less clusters at 35 days in KC compared to 
control mice. Cluster density was compared using Welch’s unpaired t-test. Each point 
represents a biological replicate with horizontal line depicting mean ± s.d. P <0.05 = *, 
P<0.01 = **. Scale bar, 500 µm. 
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3.2.7 Cluster size dependent changes to KrasG12D mutant clusters in vivo 
 
Previously, within this chapter I have demonstrated that the area of 
KrasG12D cells decreases over time, and this is accompanied by a decrease in 
the number of mutant clusters indicating that changes to the size of mutant 
clusters may be occurring. Understanding changes to clusters of specific sizes 
could help elucidate the mechanism by which transformed cells are being lost in 
the pancreas. Furthermore, previous work using Drosophila and in silico models 
of extrusion has demonstrated that the size of an aberrant cluster impacts its fate 
(Bielmeier et al., 2016), with the mechanical force generated from heterotypic 
interactions sufficient to extrude small mutant clusters but not larger clusters. In 
larger clusters of mutant cells competition-dependent apoptosis can even 
promote tumourigenesis (Ballesteros-Arias et al., 2014). 
 To investigate how the distribution of KrasG12D clusters was changing over 
time the density of clusters was broken down by cluster size. Previous studies 
have used this to understand changes to specific cluster sizes over time and a 
loss of small clusters (Bielmeier et al., 2016). Attempts at identifying nuclei whilst 
retaining endogenous RFP signal proved technically challenging and so 
individual cells were not able to be counted in clusters. Thus, size of cluster was 
used as a readout. This was done for each biological replicate with cluster sizes 
binned every 200 µm2 as this is the approximate size of a normal acinar cell 
(Houbracken and Bouwens, 2017); with the mean and standard deviation plotted 
at the centre of each bin. The x-axis was cropped at a point where all samples 
had reached a plateau to improve clarity of visualisation. 
 First, it was necessary to examine labelled Kras wild-type clusters to 
observe how these change over time in vivo. As expected with stochastic 
labelling of cells, as the cluster size increases the frequency of that cluster 
decreases; smaller clusters are more frequent than larger clusters (Figure 3.7A).  
In control animals, the density of clusters of different sizes was observed to be 
similar between 7 and 35 days post-induction. This supports the distribution of 
cluster sizes observed in Figure 3.6. However, a slight increase in the number of 
small clusters (<1000 µm2) was observed in control mice over time. Overall, this 
suggests that labelled Kras wild-type clusters are relatively unchanged during 
this timeframe. 
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 Next, the distribution of RFP labelled KrasG12D clusters of different sizes 
was examined over time.  The number of small clusters decreased between 7 
and 35 dpi in KC mice (Figure 3.7B). A significant decrease was observed for the 
cluster bin 200 µm2 (Welch’s t-test, p = 0.0051), with a trend to decreasing density 
of clusters <600 µm2. Whereas the density of larger clusters (>600 µm2) at the 
later time point is comparable to 7 dpi. This suggests that small KrasG12D clusters 
are lost in vivo over time. This could explain the increased size of KrasG12D 
clusters, when comparing distributions, observed in Figure 3.6.  This suggests 
that small clusters of KrasG12D cells are being eliminated from normal pancreatic 
tissue in vivo.  
 As individual clusters were not traced over time it is also necessary to 
compare control (Pdx1-CreERT; Rosa26LSL-RFP) with KC animals at 35 days post-
induction. The distribution of KC and controls at 35 dpi can be directly compared 
because the distribution of clusters is similar at 7 dpi (Figure 3.7C), although KC 
animals appeared to have slightly more clusters <500 µm2 at this time point. 
Examining KC and control at 35 dpi it appears that the number of KrasG12D 
clusters of all comparable sizes is decreased. A significant decrease in the 
density of most cluster sizes up to and including 4400 µm2 was observed 
between control and KC mice (Table 3.1). This is in contrast to comparing KC 
animals over time which suggested that only small clusters are decreased. 
Together, these data provide evidence that cluster size may have an impact on 
the fate of a cluster with small clusters of KrasG12D cells preferentially lost from 
tissues. Although dynamic changes to larger cluster cannot be ruled out, this 
work provides further insight into size-dependent changes to KrasG12D clusters 
over time and identifies a possible threshold size below which mutant cluster are 
eliminated by normal tissue. 
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Figure 3.7: Small clusters of KrasG12D cells are preferentially eliminated in vivo 
when surrounded by normal neighbours. Frequency distribution graphs of different 
cluster sizes. (A) The distribution of Kras WT control (Pdx1-CreERT; Rosa26LSL-RFP) 
clusters is similar at 7 and 35 days post induction. (B) The density of small KrasG12D 
clusters (<600 µm2) decreased between 7 and 35 dpi in KrasG12D (Pdx1-CreERT; LSL-
KrasG12D; Rosa26LSL-RFP) with a similar number of larger clusters present at these two 
time points. (C) The frequency of clusters of different sizes is similar between control 
and Kras at 7 days post induction. Shown for clarity (D) The density of KrasG12D clusters 
of all sizes is lower at 35 dpi when compared to control at the same time point. Data 
represents mean ± s.d. (shaded area) from 4-6 biological replicates.  
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  p-value 		 		 	
Cluster size 
(µm2) 
Control 35 days Vs. 
KrasG12D 35 days Fold	
change	
Control	
clusters	
analysed	
(n=4)	
KrasG12D	
clusters	
analysed	(n=4)	
200 0.0095 2.5	 2190	 1035	
400 0.0121 2.7	 1303	 478	
600 0.0067 2.7	 991	 378	
800 0.0044 3.3	 805	 269	
1000 0.0381 2.4	 637	 278	
1200 0.01 2.7	 554	 202	
1400 0.0194 2.5	 516	 214	
1600 0.019 2.7	 435	 183	
1800 0.0144 2.5	 357	 164	
2000 0.0357 1.7	 284	 170	
2200 0.0907 2.1	 286	 135	
2400 0.0095 2.3	 228	 120	
2600 0.0217 2.4	 257	 122	
2800 0.0317 1.9	 200	 106	
3000 0.1251 1.8	 178	 103	
3200 0.0628 1.9	 168	 93	
3400 0.0095 3.8	 176	 79	
3600 0.0337 1.9	 140	 79	
3800 0.0011 2.1	 116	 68	
4000 0.0272 1.8	 109	 79	
4200 0.0003 2.0	 99	 63	
4400 0.0008 2.2	 98	 62	
4600 0.4276 1.2	 90	 77	
4800 0.2399 1.6	 80	 67	
5000 0.0879 1.8	 85	 61	
5200 0.2974 1.4	 77	 60	
 
 
 
Table 3.1: Table of p-values for comparing control and KC at 35 days. Table 
listing p-values calculated to test for statistical difference in relative loss RFP 
clusters per cluster size bin utilising either a Welch’s unpaired t-test or a Mann-
Whitney t-test. Red = p-value <0.05. The analysis suggests KrasG12Dexpressing 
clusters of less than 4600 µm2 are significantly under-represented in the data set.  
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3.2.8 Characterising the effects of EphA2-deficiency on mutant and 
normal clusters over time 
  
 As clusters of KrasG12D cells are eliminated and as EphA2 is required for 
the decrease in RFP area in vivo the requirement of EphA2 for the elimination of 
mutant clusters was investigated. 
 First it was necessary to establish whether loss of functional EphA2 affects 
RFP cluster density over time (Figure 3.8A). As expected, in the RFP-Eph model 
RFP clusters occur at a similar density to controls at 7 dpi (RFP-Eph = 38.3 mm-
2 ± 12.76 Vs. Control = 37.5 mm-2 ± 5.6). The loss of functional EphA2 also did 
not result in changes to the number of clusters over time in RFP-Eph mice (7 
days = 38.3 mm-2 Vs. 35 days = 36.2 mm-2 ± 11.0). Furthermore, the distribution 
of clusters of different sizes in RFP-Eph mice is similar at 7 and 35 dpi (Figure 
3.9A). In summary, this suggests that loss of EphA2 alone does not lead to 
changes to total number of clusters or clusters of a specific size. 
 Next the effect of EphA2-deficiency on KrasG12D clusters was investigated. 
At 7 dpi, the density of KrasG12D clusters in KC-Eph mice was similar to controls 
and KC (Figure 3.8A). However, at 35 dpi significantly more RFP clusters were 
observed in KC-Eph mice compared to KC (KC = 18.1 mm-2 ± 5.8 Vs. KC-Eph = 
44.3 mm-2 ± 11.8, Welch’s unpaired t-test, p = 0.0048). This suggests that loss 
of functional EphA2 is required for the observed decrease in clusters. As the 
density of clusters in KC-Eph animals not only increased but returned to similar 
levels as controls this suggests that EphA2-deficiency inhibits KrasG12D cell loss 
and is sufficient to completely abrogate the loss of KrasG12D clusters. 
 Following this the density of clusters was broken down by cluster size to 
further elucidate the effect of EphA2-deficiency on KrasG12D clusters. This 
demonstrated that in EphA2-deficient animals the density of KrasG12D clusters of 
all sizes was similar over time (Figure 3.9B). Analysis of individual cluster sizes 
up to 5000 µm2 showed no significant change in density between 7 and 35 dpi 
(Welch’s t-test and Mann-Whitney test, all p >0.05). Moreover, a significant 
increase in KrasG12D clusters up to 4200 µm2 in size was observed KC-Eph mice 
when compared with KC mice (Table 3.2). This supports the hypothesis that 
EphA2-deficiency leads to the retention of clusters of KrasG12D cells up to 4200 
µm2. Not only was a significant increase in the density of clusters <4200 µm2 
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observed but the density in an EphA2-deficient model returned to a similar level 
as controls (Figure 3.9C), with no significant difference between the density of 
clusters up to 5000 µm2 in KC-Eph mice compared with Kras wild-type control. 
 In summary, EphA2-deficiency alone does not alter the distribution of 
clusters of different sizes over time. However, EphA2-deficiency leads to a 
significant increase in the number of KrasG12D clusters present at 35 dpi up to 
4200 µm2 in size. Furthermore, the number of clusters in KC-Eph mice at 35 dpi 
is similarto Kras wild-type controls. This suggests a size threshold of around 4400 
µm2 below which KrasG12D clusters surrounded by normal neighbours are 
preferentially lost in an EphA2-dependent manner. 
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Figure 3.8: EphA2 is required for the elimination of mutant clusters within the 
context of a normal epithelium. (A) At 7 dpi there is no significant difference in 
cluster density between control (Pdx1-CreERT; Rosa26LSL-RFP, n = 17892 clusters), 
KrasG12D (Pdx1-CreERT; LSL-KrasG12D; Rosa26LSL-RFP, n = 15263 clusters) 
KrasG12D;EA2 (Pdx1-CreERT; LSL-KrasG12D; Rosa26LSL-RFP; EphA2tm1Jrui,n = 13422 
clusters) and EA2 (Pdx1-CreERT; Rosa26LSL-RFP; EphA2tm1Jrui,n = 16942 clusters). 
This allows direct comparison of later time points between genotypes. (B) After 35 
dpi the number of Kras WT clusters on a background of EphA2-defiency (EA2) is not 
significantly different to control or KrasG12D; EA2. There are significantly more 
KrasG12D clusters in EphA2-deficient mice at 35 dpi. than KC mice. With the number 
of clusters in Kras EA2 similar to control this suggests loss of EphA2 completely 
inhibits normal neighbour driven elimination. Data represents mean ± s.d. with each 
point representing a biological replicate. Cluster density was compared using 
Welch’s unpaired t-test. P<0.001 = ** 
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 Figure 3.9: Elimination of small clusters of KrasG12D cells requires EphA2 in vivo. 
(A) The distribution of Kras WT clusters in a model of EphA2 loss of function, EphA2 
(Pdx1-CreERT; Rosa26LSL-RFP; EphA2tm1Jrui), remains relatively changed between 7 
(n=16942 clusters) and 35 dpi (n=23305). (B) The density of KrasG12D clusters on a 
EphA2 LOF background, KrasG12D EphA2 (Pdx1-CreERT; LSL-KrasG12D; Rosa26LSL-RFP; 
EphA2tm1Jrui) was also similar at 7 (n=13422 clusters) and 35 dpi. (n=18402 clusters). 
(C) KrasG12D clusters in EphA2-deficient mice appear at similar levels to Kras WT 
controls (n=12967 clusters) at the same time point, suggesting EphA2 is required for the 
elimination of small clusters from the pancreas. Data represents mean ± s.d. (shaded 
area) from 4-6 biological replicates. 
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 p-value    
Cluster size 
(mm2) 
Kras EA2 
35 days Vs. 
KrasG12D 
35 days Fold change 
KrasG12D 
clusters 
analysed (n=4) 
KrasG12D EA2 
clusters 
analysed (n=5) 
200 0.0094 3.1 1035 3686 
400 0.0125 2.9 478 1951 
600 0.0254 2.7 378 1462 
800 0.0057 2.9 269 1053 
1000 0.016 2.3 278 897 
1200 0.0211 2.3 202 687 
1400 0.0313 2.1 214 604 
1600 0.0047 2.2 183 503 
1800 0.0133 2.4 164 494 
2000 0.0823 1.7 170 408 
2200 0.0603 1.8 135 334 
2400 0.0303 2.1 120 331 
2600 0.0168 2.1 122 317 
2800 0.0318 1.8 106 274 
3000 0.069 1.7 103 226 
3200 0.139 1.7 93 227 
3400 0.0043 3.1 79 218 
3600 0.0766 1.7 79 183 
3800 0.0041 1.9 68 157 
4000 0.0138 1.8 79 161 
4200 0.0091 1.8 63 143 
4400 0.0584 1.8 62 134 
4600 0.7836 1.1 77 121 
4800 0.2017 2.0 67 123 
5000 0.0643 1.9 61 131 
5200 0.2931 1.3 60 105 
 
 
 
Table 3.2: Table of p-values for EphA2-deficient and KC mice at 35 dpi. Table 
listing p-values calculated to test for statistical difference in relative loss RFP 
clusters per cluster size bin utilising either a Welch’s unpaired t-test or a Mann-
Whitney t-test. Red = p-value <0.05. The analysis suggests KrasG12D expressing 
clusters of less than 4600 µm2 are significantly increased in an EphA2-deficient 
model in the data set.  
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3.2.9 Tissue-wide homeostasis is unaltered by mosaic KrasG12D expression 
 
Homeostasis of a tissue can lead to several population changes which would 
alter the dynamics of RFP area and cluster distribution. For example, proliferation 
and apoptosis of RFP positive tissue can lead to increased or decreased cluster 
size respectively. Moreover, labelling of a stem cell pool can lead to neutral drift 
and clone expansion or loss (Lopez-Garcia et al., 2010; Snippert et al., 2010).  
 To elucidate tissue homeostasis of the pancreas, tissue-wide changes in 
proliferation and apoptosis were examined using the cell specific markers Ki67 
(Scholzen and Gerdes, 2000) and cleaved caspase 3 (CC3)(Kujoth et al., 2005) 
respectively. Staining and counting was carried out by Dr. Andreas Zaragkoulias, 
a Postdoctoral research associate in the lab after I had generated the tissue. 
Cohorts of mice at 6 - 8 weeks of age were injected with 1 ug of tamoxifen and 
pancreas harvested at 7 and 35 days post-induction and analysed by 
immunohistochemistry (Figure 3.10). The limitation of the assay was the 
technical inability to co-localise RFP with homeostasis specific markers, 
therefore whole tissue sections were quantified. At 7 dpi there was no significant 
difference between the number of Ki67 positive cells in KC and controls (Control 
= 71.1 mm-2 ±11.8 Vs. KC = 79.0 mm-2 ± 16.8, Welch’s unpaired t-test, p= 0.84). 
This suggests at 7 dpi proliferation is similar in KrasG12D expressing mosaic 
tissues and Kras wild-type controls. Moreover, at 35 dpi the density of Ki67 
positive nuclei is no significantly different (Control = 26.7 mm-2 ± 3.7 Vs. KC = 
25.5 mm-2 ± 12.8, Welch’s unpaired t-test, p= 0.87). However, a significant 
decrease occurs between 7 and 35 dpi in both Kras wild-type control (7 days = 
71.1 mm-2  ± 11.8 Vs 35 days = 26.7 mm-2 ± 3.7, Welch’s unpaired t-test, p= 
0.0032) and KC mice (7 days = 79.0 mm-2 ± 16.8 Vs 35 days = 25.5 mm-2 ± 12.8, 
Welch’s unpaired t-test p=0.0018). Although this suggests that proliferation 
decreases between 7 and 35 dpi in both experimental and control; the level of 
proliferation is similar between control and KC mice at both time points. This 
suggests that proliferation of tissue is unchanged by expression of KrasG12D. 
 In cell competition, a number of studies have demonstrated that loser cells 
undergo apoptosis and are eliminated from epithelial tissues (Amoyel et al., 2014; 
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Clavería et al., 2013; Moreno et al., 2002; Norman et al., 2012; Wagstaff et al., 
2016). Moreover, the dynamics of RFP clusters can be altered by differential 
apoptosis between tissues. However, analysis of the apoptotic marker CC3 
demonstrated a similar number of apoptotic cells in KC mice and controls at both 
time points. No significant change to the number of CC3 positive nuclei was found 
between control and KC mice at 7 (Control = 1.46 mm-2 ±0.19 Vs. KC = 1.24 mm-
2 ±0.54, Mann Whitney test p = 0.1667) or 35 dpi (Control = 1.07 mm-2 ± 0.44 Vs. 
1.08 mm-2 ± 0.23, Welch’s unpaired t-test p = 0.9679). This suggests that the rate 
of apoptosis is unchanged in tissues by expression of KrasG12D in tissues. 
Furthermore, the density of apoptotic cells is unaltered over time. Although it can 
not be ruled out that Ras-transformed cells undergo apoptosis and are eliminated 
before 35 dpi, by which point levels of apoptosis returns to normal. These data 
suggest that apoptosis is not driving the loss RFP and hence KrasG12D mutant 
cells from the pancreas over time. This suggests cell competition is not inducing 
apoptosis of loser cell and compensatory proliferation of winner cells is not 
occurring.  
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Figure 3.10: Homeostasis is unperturbed during KrasG12D cell elimination. 
Immunohistochemistry for proliferation (Ki67) and apoptosis by Cleaved Caspase 3 
(CC3) in control (Pdx1-Cre;Rosa26LSL-RFP) and KrasG12D (Pdx1-Cre;Rosa26LSL-RFP; 
KrasG12D). Levels of Ki67 were not significantly different between control and KrasG12D 
mice at 7 and 35 dpi although a decrease was observed over time in both conditions (A, 
B). Levels of CC3 were not significantly different between control and KrasG12D mice at 
either time point (C, D). Moreover, CC3 did not significantly change over time in control 
or KrasG12D mice. Data represents mean ± s.d. with each point a biological replicate. 
Scale bar, 50 µm. 
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3.3 Discussion 
 
A number of studies have investigated the interaction of normal and Ras 
mutant cells in vitro. In MDCK cell lines, Hogan et al. (2009) demonstrated that 
RasV12-transformed cells surrounded by normal epithelia cells are apically 
extruded from a monolayer. When RasV12 cells are cultured alone apical 
extrusion does not occur suggesting that normal neighbours are required. More 
recently, we have demonstrated that differential EphA2 signalling between 
normal and mutant cells promotes the detection and elimination of RasV12 cells 
(Porazinski et al., 2016). Differential EphA2 expression between normal and 
mutant cells triggers repulsion between normal:mutant cells and increased 
contractility of RasV12 cells. Mutations to Kras are sufficient to drive the earliest 
stages and are considered the initial mutation in pancreatic cancer (Collisson et 
al., 2012; Hingorani et al., 2003; Kopp et al., 2012) Recent studies have 
suggested that Ras mutant cells can be extruded in vivo (Kon et al., 2017; Sasaki 
et al., 2018). Moreover, cell competition is typically studied in developing or rapid 
turnover tissues (Amoyel et al., 2014; Bowling et al., 2018; Moreno et al., 2002) 
using constitutive activation of oncogenic Hras (RasV12) (Hogan et al., 2009; 
Kajita et al., 2014).. However, whether cell competition is occurring between 
normal and Ras-transformed pancreatic cells is unclear. Therefore, this study 
aimed to characterise the effect of mosaic KrasG12D expression in the adult 
pancreas, which is a slow turnover tissue (Magami et al., 2002). 
 
3.3.1 Modelling heterotypic cell-cell interactions in the murine pancreas in 
vivo  
 
 Animal models of pancreatic cancer have provided new insight into 
disease initiation and progression. In this study, the Pdx1-CreERT; Rosa26tdRFP; 
KrasG12D/+ (KC) mouse model was used to provide temporal and spatial control 
over expression of oncogenic Kras in the adult pancreas and trace transformed 
cells using an RFP reporter. By titrating the level of tamoxifen, single or small 
clusters of cells could be induced to express KrasG12D and investigate the 
requirement of heterotypic interactions with non-transformed neighbours in fate 
of mutant cells. Using genetic mouse models requires careful consideration of a 
number of factors. 
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 One important consideration for murine models is the timing of Cre 
expression. A previous study has investigated the fate of KrasG12D transformed 
cells from the pancreas using the same promoter (Pdx1) without the tamoxifen-
sensitive human oestrogen ERT domain (Morton et al., 2010). This results in 
recombination in every cell of the pancreas from E8.5 and it was observed that 
GFP positive KrasG12D mutant cells were lost 2-6 weeks after birth from the 
developing pancreas. From this the authors suggested that KrasG12D expressing 
cells are outcompeted by wild-type pancreatic cells via differential cell fitness 
between the two populations of cells. This suggests that interactions between 
normal and KrasG12D mutant cells could lead to the selective loss of mutant cells 
but use of an embryonic activation model of PDAC has several limitations. Firstly, 
the developing pancreas has proliferation rates and   a dynamic cellular 
composition markedly different to the adult pancreas (Grapin-Botton, 2005; 
Magami et al., 2002). The turnover in the adult pancreas is relatively slow with 
the half-life of an acinar cell around 132 days (Nakayama et al., 2003).  Moreover, 
expression of KrasG12D during the development of the epithelium of other tissues 
has been reported to cause defects in the adult (Fan et al., 2008). Expression of 
KrasG12D in ovary development was found to block differentiation causing 
abnormal ovary follicle development and impaired response to hormone in the 
adult. Finally, human PDAC is an adult-onset malignancy (Gidekel Friedlander et 
al., 2009) with almost half (47%) of new cases in people aged 75 and over in the 
UK (Cancer Research UK, 2017). Thus, to better understand the relevance to 
adult disease, KrasG12D expression was induced and studied in adult mice. 
 Generating tissues mosaic for KrasG12D expression is required to 
understand normal-mutant cell-cell interactions. This can be achieved by 
controlling the number of pancreatic cells in which Cre recombinase drives 
recombination at the LSL-KrasG12D locus. This level of control can be achieved 
by fusion of Cre-recombinase with an altered ligand-binding domain for the 
human oestrogen receptor (Hoess et al., 1984). This results in a CreERT construct 
and a protein that will only enter the nucleus and drive recombination at LoxP 
sites in the presence of tamoxifen. Therefore, by titrating the amount of tamoxifen 
delivered to animals the number of cells undergoing recombination can be 
altered. However, use of the Cre-LoxP system requires careful interpretation and 
experimental approach. For example, it is not always possible to extrapolate from 
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one recombination event to another as alleles can have different susceptibilities 
to Cre-mediated recombination (Liu et al., 2013; Vooijs et al., 2001). To 
investigate whether RFP recombination was associated with recombination of 
KrasG12D we used laser capture microdissection to verify that RFP positive tissue 
only contained cells which had also recombined at the LSL-KrasG12D allele. This 
suggests that RFP accurately marks mutant cells in this system.  
 Another consideration of the Cre-LoxP system is the promoter which 
drives Cre expression. The use of pancreas-specific Cre driver lines has allowed 
targeting of the specific compartments and lineages within the pancreas 
(Magnuson and Osipovich, 2013). In this study, the pancreatic progenitor Pdx1 
gene was used to drive expression of Cre. The Pdx1 gene is expressed in pre-
pancreatic endoderm starting at E8.5 and as development progresses it 
becomes more abundant in Beta-cells with lower levels in the exocrine 
compartment (Jonsson et al., 1994; Offield et al., 1996). Thus, during 
development Pdx1-Cre driver lines can drive recombination in all pancreatic cell 
types, however, the expression pattern of Pdx1 in the adult is less clear. Although 
Pdx1 is typically associated with the endocrine lineage in adults; in this study 
recombination also occurred in the acinar compartment and ductal compartment. 
This suggests that in this mouse model Pdx1 expression is sufficient in these cell 
types to produce Cre-recombinase. It is also possible that Pdx1 marks a 
subpopulation of adult pancreatic cells. Several studies have indicated that the 
acinar cell population is heterogeneous (Wollny et al., 2016) and Pdx1 has been 
proposed to mark adult stem/progenitor cells (Gidekel Friedlander et al., 2009). 
However, the high dose in this system was sufficient for recombination in the vast 
majority of cells. This suggests that Pdx1 expression is not the limiting factor in 
selecting which cells recombine and indicates that a subpopulation of Pdx1 
positive cells are not being selected to recombine. In the analysis used within this 
study it was difficult to distinguish specific cell types within and therefore make 
conclusions on the different compartments. However, although different cell 
types were found to be labelled using this promoter acinar cells were mainly 
considered in RFP analysis as acinar cells make up over 80% of the pancreas 
and made up the vast majority of labelled cells. Therefore, it was assumed that 
changes in RFP was a result of changes predominantly from the exocrine acinar 
compartment, although changes to other cells types cannot be ruled out. 
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 In summary, this study has generated a model to study heterotypic 
interactions of normal and KrasG12D mutant cells in the adult murine pancreas. 
This model provides both temporal control and control over the amount of tissue-
wide recombination within the pancreas. 
 
3.3.2 KrasG12D mutant cells are lost in vivo when surrounded by normal 
neighbours 
 
 Once a system of mosaic KrasG12D expression in the murine pancreas had 
been established the fate of KrasG12D transformed cells could be investigated 
over time. No significant change to RFP area in low dose Kras wild type controls 
was observed overtime. However, when RFP-labelled KrasG12D cells were 
present in the pancreas at low numbers a significant decrease in RFP was 
observed. The human body has evolved a number of defence mechanisms for 
the removal of aberrant cells (Fuchs and Steller, 2015). In the initiation of 
pancreatic cancer, a single normal cell acquires an initiating driver gene mutation, 
however, it is thought that in most cases this initiating mutation causes the cell to 
undergo apoptosis or senescence, or to be lost owing to immune surveillance or 
during a bottleneck event of tissue turnover (genetic drift) (Makohon-Moore and 
Iacobuzio-Donahue, 2016). To investigate if autonomous changes to mutant cells 
is inducing a decrease in RFP area widespread recombination was induced 
resulting in around 75% of the pancreas expressing KrasG12D. With this high level 
of Ras-transformed cells present in the tissue, between 7 and 35 days post 
induction, no significant decrease in RFP level was observed. Previous work has 
also demonstrated that in zebrafish immune cells are recruited to single Ras-
transformed cells and can engulf and eliminate the mutant cell (Feng et al., 2010). 
Ras-transformed cells can also be cleared in murine models by natural killer cells 
(Johnson et al., 1990). However, as no change in RFP was observed when 
mutant cells were present at high numbers this suggests the immune system is 
not the primary method of clearance for KrasG12D cells in the pancreas. Indeed, 
although immune infiltrate is considered to occur early within tumourigenesis they 
are typically associated with ADM events and PanIN lesions (Liou et al., 2015, 
2017).  Therefore, this work suggests that KrasG12D cells in the pancreas are 
eliminated by non-transformed epithelial neighbours. 
 102 
 Normal epithelial cells can eliminate mutant neighbours by cell 
competition (Morata and Ripoll, 1975). The loss of mutant cells from the pancreas 
could be a result of competitive interactions with normal neighbours. Previous 
work has also demonstrated that the adult skin can eliminate aberrant cells 
through a mechanism that uses wild-type neighbours (Brown et al., 2017). 
Moreover, elimination has been observed in the murine intestine (Kon et al., 
2017) and pancreatic ductal compartment (Sasaki et al., 2018). Therefore, these 
studies support a model of competitive epithelial interactions within the pancreas. 
However, these systems used mutational activation of Hras which although it 
shares a high sequence homology with Kras (Bar-Sagi, 2001), Hras is mutated 
in 0.1% of human pancreatic tumours (Forbes et al., 2017). Therefore, 
competitive interactions between normal and Kras mutated cells in the pancreas 
is a novel process that is more relevant to the initiation of pancreatic cancer. This 
could represent an inherent ability of the pancreas to remove aberrant cells. 
Rapidly dividing tissues such as the intestine can remove aberrant cells via 
neutral drift (Lopez-Garcia et al., 2010). Neutral drift is the theory that stem cell 
fate is determined stochastically and cells can be lost by differentiation and 
replacement by the stem cell pool. But this may not be suitable for slow dividing 
tissues such as the pancreas (Magami et al., 1990) that lack a well-defined stem 
cell niche  (Minami, 2013). So cell competition provides a proliferation 
independent mechanism in the pancreas. 
 The tissue from low dose Cre positive; RFP positive pancreata was also 
generated and included as controls. This can provide insight into tissue 
homeostasis and dynamics (Alcolea et al., 2014). Using these controls, over time 
it was found that few changes occur to the labelled cell population. For example, 
no significant change in RFP percentage area occurred between 7 and 35 days 
post-induction and the analysis of cluster distribution showed that the two profiles 
were remarkably similar. However, overall proliferation decreased between 7 and 
35 dpi in both control and experimental setting. This could be a remnant of 
postnatal development of the pancreas which can still stabilise up to 8 weeks 
after birth (Herbach et al., 2011; Magami et al., 2002). A previous study using 
Nestin-CreERT2 combined with rainbow labelling found evidence that within 28 
days most acinar cells do not divide (Wollny et al., 2016). Even at 365 dpi the 
overall clone distribution was similar to shorter time points. This suggests that 
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tissue dynamics affecting cluster size and distribution are relatively slow in the 
pancreas and supports a mechanical mechanism of mutant cell elimination 
based on cell-cell interactions. 
 Elimination of less fit cells during normal development has been identified 
as highly important for embryogenesis (Bowling et al., 2018). In cell competition, 
cells with higher levels of p53 are recognised as less fit and lead to elimination 
of p53 high cells (Bowling et al., 2018; Zhang et al., 2017). Through the 
progression of PDAC, mutation of p53 has been shown to occur after the an initial 
KrasG12D mutation and is mutated in up to 85% of pancreatic cancers (Yachida 
et al., 2010). Thus, it could be hypothesised that mutation of p53 could promote 
the retention of KrasG12D mutant cells within the tissue as one mechanism by 
which p53 drives PDAC progression. Indeed, p53 mutant cells have recently 
been shown to undergo necroptosis when surrounded by normal neighbours but 
when under a RasV12 mutant background these mutant cells survive (Watanabe 
et al., 2018). This highlights the importance of the order of oncogenic mutations 
in retention of mutant cells within a normal epithelium. 
 Precisely how risk factors can promote the initiation and progression of 
PDAC is also currently unclear. One study has demonstrated that a high-fat diet 
can suppress the extrusion of mutant cells from normal epithelia in vivo (Sasaki 
et al., 2018). Although the use of a CK19-driven Cre limited analysis to the ductal 
compartment, this study supports the hypothesis that Ras-transformed cells are 
extruded in vivo and indicates a potential mechanism how cell elimination may 
be overcome in patients. It is known that most late-stage PDAC contains KrasG12D 
mutations (Biankin et al., 2012) so this process must be overcome in the vast 
majority of cases. It is conceivable that alterations to cell-cell interactions caused 
by risk factors such as inflammation lead to retention of transformed cells, 
facilitating the initial steps of carcinogenesis. Indeed, it has been demonstrated 
that in pancreatitis cell contacts between acinar cells rapidly disassociate (Lerch 
et al., 1997; Schnekenburger et al., 2005). With pancreatitis known to accelerate 
PDAC in KrasG12D expressing mouse models  (Guerra et al., 2007).  
  
3.3.4 EphA2 is required for the loss of mutant cells surrounded by normal 
neighbours 
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 EphA2 is a membrane-bound receptor tyrosine kinase that can regulate 
cell repulsion and adhesion to promote cell sorting (Pasquale et al., 2008). 
Differential EphA2 has previously been identified as the mechanism by which 
mutant cells are identified and extruded from MDCK monolayers in vitro 
(Porazinski et al., 2016). The study by Porazinski et al, describes a potential 
novel mechanism by which mutant cells could be detected and extruded by 
repulsive forces at the initial stages of cancer. Therefore, in this study the 
requirement of EphA2 in the elimination of KrasG12D mutant cells from the 
pancreas was investigated. To this end a EphA2-deficient mouse model was 
crossed with KC animals to generate mutant cells surrounded by normal 
neighbours on a background of EphA2-deficiency. Previous characterisation of 
N-terminal and C-terminal EphA2 expression demonstrated that neither the full 
length nor a truncated form of EphA2 is present in these mice and thus can be 
considered an EphA2 deficient mouse (Amato et al., 2016). As whole-body LOF 
models can have wide-ranging effects throughout the body (Eisener-Dorman et 
al., 2009), it was necessary at each stage to control for any change induced by 
loss of EphA2. Importantly, it was observed that loss of functional EphA2 alone 
had no quantifiable impact on the labelling of cells or dynamics of RFP labelled 
cells over time in the pancreas; with all metrics similar to controls. Therefore, any 
change in KC-Eph animals can be considered a result of both mutant KrasG12D 
expression and EphA2-deficiency. Using this model, it was found that the area of 
KrasG12D cells significantly increased in EphA2-deficient animals and returned to 
levels comparable to controls. This suggests that EphA2-dependent elimination 
of KrasG12D cells is occurring in the adult murine pancreas. Furthermore, it 
supports an emerging role for pathways previously implicated in axon guidance, 
but are now found to be implicated in cell competition (Vaughen and Igaki, 2016) 
and pancreatic cancer (Biankin et al., 2012). 
 Although a requirement for EphA2 in the elimination of mutant cells was 
identified, EphA2 can have a variety of different effects both autonomously and 
non-autonomously which may result in mutant cell retention. For example, EphA2 
is a direct transcriptional target of the MAPK pathway and can negatively regulate 
Ras signalling (Macrae et al., 2005). Therefore, it could be hypothesised that loss 
of EphA2 could remove feedback inhibition of Kras further activating MAPK 
signalling, as observed in lung adenocarcinoma (Yeddula et al., 2015). However, 
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the increased proliferation associated with this mechanism was not observed 
suggesting another mechanism of EphA2-dependent clearance of mutant cells.  
 We have previously demonstrated that Ras-transformed cells are 
detected via elevated EphA2 in mutant cells compared to surrounding normal 
neighbours (Porazinski et al., 2016). With cell-cell interactions between normal 
and mutant cells triggering EphA2 dependent repulsion of Ras-transformed cells. 
In combination with increased contractility of mutant cells this drives the 
separation and extrusion of mutant cells from normal neighbours. In this study, 
several lines of evidence were found to support this hypothesis. A decrease in 
mutant cells was observed to occur in a process that requires non-transformed 
neighbours and EphA2. Moreover, the difference in cluster sizes observed at 7 
dpi in KC and controls is consistent with a model of elimination based on 
repulsion at the boundary between normal and mutant cells; driving a decrease 
in clusters >800 µm2 and resulting in an increase in clusters <800 µm2. The loss 
of mutant clusters without an observed increase apoptosis could also indicate 
that cell competition is not leading to apoptosis but supports a mechanical 
extrusion of mutant cells via cell competition (Hogan et al., 2009). 
 This study identifies a fundamental role of EphA2 in the elimination of 
KrasG12D mutant cells by normal neighbours. It could then be expected that 
mutations to EphA2 are associated with human PDAC cases. However, 
mutations to EphA2 occur in less than 1% of PDAC cases in the COSMIC 
database (Forbes et al., 2017). This could be in part explained by the different 
roles EphA2 could play through PDAC tumourigenesis. It has been found that 
EphA2 is present in 95% of human pancreatic cancer patient samples and levels 
change with disease stage (Mudali et al., 2006). Levels of EphA2 were found to 
be higher in primary carcinomas than PanIN lesions and advanced, metastatic 
carcinomas showed relatively less strong staining than primary carcinomas that 
had not metastasised. EphA2 has also been implicated in driving PDAC 
dissemination with cell:cell repulsion generated by trafficking of EphA2 causing 
metastasis (Gundry et al., 2017). As the role of EphA2 in pancreatic cancer 
progression is still unclear, it is possible that wild-type EphA2 is important for 
pancreatic cancer progression. Therefore, inactivation of EphA2 would promote 
retention of transformed cells but could inhibit tumour growth or spread. It is also 
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possible that EphA2 is not regulated at the genetic level but at the protein level 
by endocytosis and degradation (Boissier et al., 2013). Another possible 
explanation is that cell-cell contacts are lost at the initial stages of tumourigenesis 
for example by pancreatitis (Lerch et al., 1997) which would overcome direct cell-
cell interactions. Although further characterisation of EphA2 in pancreatic cancer 
is required to understand the role it plays in tumourigenesis. These results 
suggest that EphA2 has a functional role in the removal of mutant cells to 
maintain homeostasis, however if these cells are retained they can go on to 
initiate carcinogenesis (Hingorani et al., 2003). 
 
3.3.5 Elimination of small clusters of KrasG12D mutant cells 
 
 Cell competition is considered to be a short-range phenomenon with the 
direct interaction of neighbouring cells allowing fitness comparison and 
elimination (Martín et al., 2009). Therefore, in this study clusters of KrasG12D cells 
were discretely investigated. It was found that the total number of mutant clusters 
decreased in a EphA2 dependent manner. Moreover, clusters up to 4400 µm2 
were significantly underrepresented with an increase to control levels of these 
clusters in EphA2-deficient mice.  
 It has been demonstrated in Drosophila that juxtaposition of aberrant cells 
with normal neighbours leads to an enrichment of actomyosin at the interface 
(Bielmeier et al., 2016). This increased contractility at the interface of normal and 
mutant cells is sufficient to alter the fate of aberrant cells in a cluster size-
dependent manner. It was observed that single or small clusters of up to six cells 
were eliminated whereas clusters larger than this were retained. Contractility at 
the interface still occurs in larger clusters but this force drives mutant cluster 
invagination and cyst formation. It was not possible in this study to differentiate 
clusters based on cell number due to the technical difficulty in visualising nuclei 
and retaining RFP signal. However, a significant underrepresentation of clusters 
up to 4400 µm2 in KC mice at 35 dpi was observed. As the average acinar cell is 
approximately 200 µm2 (Houbracken and Bouwens, 2017), this implies that 
clusters up to 22 cells are being eliminated. But cells can also become contractile 
from Eph signalling and repulsion (Porazinski et al., 2016) which would alter the 
size of an acinar cell and so the threshold number of cells being eliminated could 
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be higher. However, this work does suggest a higher threshold number of cells 
than previous work (Bielmeier et al., 2016) but lower than another study 
(Ballesteros-Arias et al., 2014). This could reflect tissue-specific differences or 
result from differences between Drosophila and murine models. Previous 
Drosophila models use 2D epithelial sheets whereas the in vivo pancreas is a 3D 
environment which could also alter the threshold of cells required to overcome 
elimination. 
 Another question arising from this study is the fate of mutant clusters over 
4400 µm2. Previous work has demonstrated that once clusters of oncogenic cells 
reach around 400 cells they overcome tumour suppressive cell-competition 
effects and form tumours in Drosophila (Ballesteros-Arias et al., 2014). Mutant 
cells at the boundary were still eliminated by cell competition, however those cells 
inside the large cluster and further away from the normal:mutant interface 
survive. Furthermore, the apoptosis of mutant cells by normal neighbours was 
found to drive proliferation and promote tumourigenesis. In this study, the range 
of sizes of large clusters and the low frequency made inferring any changes to 
larger clusters difficult. Apoptosis and proliferation was not found to be elevated 
in this study suggesting apoptosis is not promoting proliferation in the pancreas 
at this time point. However, this work could suggest a size threshold for the 
elimination of clusters. Moreover, if Eph-dependent repulsion is driving 
elimination of smaller clusters it could also be acting on larger clusters but with a 
different outcome. Interface contractility can drive cyst formation in Drosophila 
(Bielmeier et al., 2016). Moreover, EphB interactions in the intestine 
compartmentalises tumour cells into a cyst in the villus where tumour growth is 
restricted (Batlle et al., 2005; Cortina et al., 2007). Therefore, larger clusters 
could be compartmentalised into a cyst structure similar to PanIN lesions. So 
EphA2 signalling from cell-cell interactions may eliminate small clusters and 
segregate larger clusters into cysts. 
 
3.4 Summary and Future Directions 
 
 In summary, three major conclusions can be drawn from the data in this 
chapter. First, KrasG12D cells are lost when present at low numbers in vivo. 
Second, clusters below a critical size may be preferentially eliminated. Finally, 
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EphA2 is required for both of these processes to occur. Together, this work in 
combination with previous studies suggests that a mechanical form of cell 
competition is occurring between normal and mutant pancreatic cells in vivo to 
eliminated Ras-transformed cells. 
 These conclusions raise a number of interesting questions with regard to 
removal of mutant cells, heterotypic cell interactions and the role of EphA2 in 
PDAC, and provide a number of avenues that warrant further investigation. 
 The results in this chapter suggest KrasG12D mutant cells are eliminated 
from the pancreas by normal neighbours. However, as Kras mutations are 
present in >90% of PDAC tumours it raises the question of how it is overcome 
for tumourigenesis to occur. To understand how single KrasG12D cells overcome 
elimination, the model described in this chapter could be combined with known 
risk factors of PDAC to determine if it leads to retention of transformed cells. For 
example, pancreatitis is an established risk factor for pancreatic cancer and can 
be modelled by caerulein administration in murine models (Niederau et al., 1985). 
Therefore, caerulein could be given at 10 dpi to test if this promotes retention of 
transformed cells in vivo. Tissue health during aging could also be studied using 
this system. Age is the biggest risk factor in PDAC (Bosetti et al., 2014) but the 
mechanism of how aging increases risk is unclear. The mechanical properties of 
tissues are known to alter in aging which may alter the efficiency of mutant cell 
elimination (Phillip et al., 2015). With temporal control over emergence of 
KrasG12D cells provided by this system, mutations could be induced in aged 
animals to study if elimination still occurs. Multiple mutations in a single cell can 
also alter the effect of cell competition on aberrant cells. In Drosophila epithelium, 
polarity deficient cells induced by mutations to Scribble are eliminated by 
apoptosis, but Ras mutation in the same cell causes synergistic effect and 
neoplastic overgrowth (Brumby and Richardson, 2003). Moreover, p53 mutant 
cells are basally extruded and undergo necroptosis when surrounded by normal 
neighbours but p53 mutant cell elimination does not occur in Ras-transformed 
epithelia (Watanabe et al., 2018). Therefore, combining this model with an 
inducible p53 mutation could investigate if KrasG12D and p53 mutations would 
inhibit elimination by normal neighbours. One way to combine KrasG12D mutations 
with a variety other genetic changes would be orthotopic injection of pancreatic 
cells with defined mutations. Mutations to p53 are highly prevalent in pancreatic 
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cancer with up to 85% of tumours carrying a mutation (Yachida et al., 2010), and 
are associated with more advanced PanIN3 lesions and therefore could provide 
a mechanism of overcoming cell elimination. This could further elucidate how cell 
competition influences the order of genetic mutations in tumour evolution 
(Watanabe et al., 2018). Thus, this model could be used to study a range of 
factors that may alter mutant cell elimination to promote tumourigenesis. 
 Further investigation is also required into the fate of transformed cells. 
Mechanical cell competition can drive both extrusion or apoptosis of mutant cells 
(Hogan et al., 2009; Wagstaff et al., 2016). Answering if either of these processes 
are occurring is key to understanding whether this process is tumour suppressive 
or could promote disease. For example, if mutant cells are being extruded into 
the circulatory system it could drive metastasis from the earliest stages of 
disease. To this end probing for circulating tumour DNA could be used to detect 
if mutant cells are entering the blood. Whole tissue imaging would also further 
our understanding of whether cells are being extruded or segregated. Recent 
genetic analysis has established that precancerous, mutant cells can spread 
through the pancreas and seed precursor lesions in distal sites (Makohon-Moore 
et al., 2018). By further elucidating whether this process promotes or suppresses 
cancer it will inform the research moving forward. If it tumours suppressive then 
therapies to promote mutant cell elimination could be tested. Conversely, if it 
promotes metastasis then it could provide novel targets to detect and inhibit the 
spread of PDAC from the earliest stages
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Chapter 4: Modelling heterotypic cell-cell interactions in 
a 3D acinar cell culture model 
 
4.1 Introduction 
 
 An increasing body of evidence indicates cell competition is occurring at 
the initiation of cancer (Hogan et al., 2009; Kon et al., 2017; Leung and Brugge, 
2012). However, direct evidence for a role in tumourigenesis can be difficult to 
obtain in vivo. In chapter 3, by modelling these interactions in vivo it was found 
that mutant cells were eliminated from the pancreas. This process of elimination 
was only observed when KrasG12D cells were present at low numbers but the 
mechanism of elimination and fate of transformed cells was unclear. Use of ex 
vivo models can provide a tractable system to study cell-cell interactions over 
time at the level of the single cell. Moreover, 3D acinar cell culture systems can 
model disease initiation (Liou et al., 2013; Shi et al., 2013) and hence may further 
elucidate the fate of mutant cells. 
 The initial stages of pancreatic ductal adenocarcinoma (PDAC) are poorly 
understood. Due to the duct-like nature of precursor lesions the ductal 
compartment was thought to be the cell of origin of PDAC (Cubilla and Fitzgerald, 
1976). However, early targeting of KrasG12D to the pancreas found the ductal 
compartment resilient to transformation. It was later found that expression of 
KrasG12D in the acinar compartment was sufficient to give rise to pancreatic 
intraepithelial neoplasia (PanIN) lesions and PDAC (Habbe et al., 2008; 
Hingorani et al., 2003; Kopp et al., 2012). It is now believed that the acinar 
compartment goes through a de-differentiation process, known as acinar-ductal 
metaplasia (ADM), to give rise to the PDAC cell of origin (Crawford et al., 2002). 
 ADM is a common and reversible process upon pancreatic damage and 
is thought to protect the pancreas and aid regeneration once the injury has 
passed (Mills and Sansom, 2015; Storz, 2017). However, KrasG12D mutations can 
initiate ADM and lock cells in this duct-like state, leading to precancerous lesion 
development (Kopp et al., 2012). During ADM, acinar cells shut off specific 
transcription factors characteristic of mature acinar cell fate. This involves 
downregulation of transcription factors that control acinar cell maturation and 
architecture (MIST1, PTF1A, NR5A2) and expression of mature duct cell 
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transcription factors like Sox9 and Hnf6. They also express transcription factors 
associated with pancreatic embryonic progenitors (Sox17)(Jensen et al., 2005; 
Mills and Sansom, 2015; Morris et al., 2010). To better understand the processes 
underlying the early events in pancreatic cancer an ex vivo acinar model has 
been developed (Liou et al., 2013; Means et al., 2005). 
 Signalling mechanisms regulating early KrasG12D driven changes to acinar 
have been studied using this ex vivo explant three-dimensional (3D) cell culture 
model in which primary acinar cells are isolated and cultured (Ardito et al., 2012). 
This allows visualisation of the de-differentiation process in real-time as clusters 
of cells undergoing ADM change from a “berry” shape to a duct-like cyst structure 
in 3 days (Shi et al., 2013). Therefore, ADM represents an early disease state 
that can be studied at the level of the single cell using this ex vivo explant model.  
 Recently, the microenvironment has been identified as a key component 
in the earliest stages of PDAC. It has been demonstrated that macrophages 
infiltrating the pancreas can drive the dedifferentiation process and promote 
PDAC development (Liou et al., 2013). Moreover, evidence that normal 
neighbouring cells inhibit the de-differentiation associated with ADM has also 
been found in a murine model (Krah et al., 2015). This suggests that normal acini 
can inhibit cells lacking key acinar transcription factors from undergoing ADM. 
Together, these results suggest that the local microenvironment can promote or 
suppress the progression of Ras-transformed cells through ADM. Thus, loss of 
this repressive environment by extrusion may promote tumourigenesis (Leung 
and Brugge, 2012). 
 In addition to altering progression through to an early disease state normal 
neighbours can also competitively interact with Ras-transformed cells leading to 
extrusion of mutant cells (Hogan et al., 2009; Kajita et al., 2014). Recent work 
has demonstrated that sporadic induction of RasV12 in the murine intestine and 
using organoid culture can lead to extrusion of mutant cells (Kon et al., 2017). 
Aberrant activation of MAPK signalling has also been implicated in extrusion of 
single cells from 3D mammary acini (Leung and Brugge, 2012). This suggests 
that Ras-transformed cells can be extruded from a variety of different tissues and 
could indicate that KrasG12D acinar cells are being extruded in the pancreas. 
 As a loss of acinar cells was identified in vivo the aim of this chapter was 
to develop an ex vivo model of these interactions. This would allow the 
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investigation of two main hypotheses: 1) do heterotypic interactions between 
normal and mutant acinar cells drive elimination of the mutant cell and 2) Do 
normal acinar cells promote or inhibit KrasG12D cells undergoing ADM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
4.1 Results 
 
4.2.1 Generation of a 3D ex vivo model of pancreatic acinar cells 
 
To investigate the fate of mutant cells surrounded by normal neighbours in the 
acinar compartment it was first necessary to develop a mouse pancreatic acinar 
cell primary culture system (Liou et al., 2013). This ex vivo model is based on a 
previously established cell culture model in which growth factors or genetic 
changes, such as KrasG12D, have been shown to induce ADM within 3 days (Shi 
et al., 2013). To investigate if this is conserved using the Pdx1-CreER; LSL-
KrasG12D/+; ROSA26tdRFP animal model these mice were treated with tamoxifen 
via intraperitoneal injection (I.P) to activate KrasG12D expression. Pancreata were 
then harvested 48 hours later, digested with collagenase and individual acini 
clusters plated in a 3D collagen matrix (Figure 4.1A).   
 To determine if acinar cells generated using this system retained features 
of acinar biology immunofluorescence was carried out directly after plating (day 
zero; D0) (Figure 4.1B). As described previously, acinar cells initially retain 
normal apical-basal polarity with zymogen granules present at the apical pole, 
positive for the acinar specific marker amylase (Figure 4.1B). This demonstrates 
that both polarity and presence of acinar specific amylase are retained ex vivo 
suggesting that features of acinar cells are retained. 
 Induction of recombination within acinar cells was also examined using 
RFP as a readout. After in vivo induction with 1 mg of tamoxifen and plating, RFP 
expression (red) was present in a mosaic fashion in clusters (Figure 4.1B). As 
the pancreas was stochastically digested and mechanically broken-down to 
produce clusters, clusters with varying numbers of RFP positive cells were 
generated. This allowed clusters with different numbers of RFP positive cells to 
be compared within the same well. 
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Figure 4.1: Generation of mosaic acinar clusters ex vivo. (A) Cartoon of  
protocol for acinar cell culture; the pancreas was broken down into clusters which 
were plated in collagen. (B) Following plating of mouse primary acinar cells ex vivo 
immunofluorescence was carried out on the same day as plating (day 0). Cells 
express the acinar specific marker amylase (green) at this time point. 
Administration of tamoxifen in vivo to Pdx1-Cre; Rosa26tdRFP; KrasG12D animals 48 
hours before harvesting the pancreas for ex vivo culture, is sufficient to generate 
clusters with mosaic RFP (red) and hence KrasG12D expression. Scale bar, 20 µm. 
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4.2.2 Heterotypic cell-cell interactions associated with morphological 
changes in KrasG12D cells 
 
Once optimised, ex vivo cultures, were used to investigate the effects of 
heterotypic cell-cell interactions between KrasG12D mutant acinar cells and normal 
neighbours. For this Pdx1-CreER; LSL-KrasG12D/+; ROSA26tdRFP (KC) mice were 
induced and cultured. Acinar cultures derived from Pdx1-CreER; ROSA26tdRFP 
animals following the same induction procedure were included as controls. 
 Single cell induction of oncogenes has been demonstrated to lead to 
small, round and contractile cells that are extruded in 3D (Leung and Brugge, 
2012). To investigate if single cell induction of KrasG12D in clusters of acinar cells 
leads to a similar phenotype, acinar clusters were generated and fixed 24 hours 
after induction and stained for F-actin. After 24 hours in culture (day 1; D1) 
morphological changes were observed between normal and mutant cells. Single 
KrasG12D (RFP positive) cells surrounded by RFP negative cells had an apparent 
decrease in volume, and F-actin accumulated at the interface between normal 
and transformed cells (Figure 4.2, top). Strikingly, elevated levels of F-actin 
appeared to occur within Ras-transformed cells; rather than from normal 
neighbouring cells (Rosenblatt et al., 2001; Slattum et al., 2014). These changes 
were not observed in clusters containing KrasG12D cells only (Figure 4.2, middle) 
or RFP positive cells from Pdx1-CreER; ROSA26tdRFP control mice (Figure 4.2, 
bottom). This suggests that KrasG12Dcells are induced to undergo morphological 
changes indicative of repulsion when surrounded by normal neighbours. 
However, single RFP cells were uncommon at this time point, with the vast 
majority of clusters containing more mutant cells. Therefore, this this 
phenomenon was a rare event. Although mutant cells were found to adopt this 
morphology, evidence for extrusion of KrasG12D was not observed in ex vivo 
cultures. Timelapse microscopy was also carried out, however the system was 
not sufficiently robust to allowing tracking of cells over time. Together, these 
observations indicate that KrasG12D expressing acinar cells adopt a contractile 
morphology when surrounded by normal neighbours within 24 hours of ex vivo 
culture. 
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Figure 4.2: KrasG12D acinar cells adopt a contractile morphology upon 
interaction with normal neighbours. After 24 hours in culture KrasG12D(RFP; 
red) expressing cells adopt a small, contractile morphology when surrounded by 
normal neighbours and accumulate F-actin (top row). These changes do not occur 
when mutant cells are surrounded by mutant neighbours (middle row). Control 
acini from Pdx1-CreER;ROSA26tdRFP mice also did not undergo these 
morphological changes ex vivo (bottom row). Scale bar, 20 µm. 
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4.2.3 Characterisation of ADM in KrasG12D expressing clusters ex vivo 
 
 The next aim was to investigate the role of normal neighbours in acinar-
ductal metaplasia (ADM). Previous work has identified a role for the normal 
neighbourhood in inhibiting ADM in vivo upon mosaic loss of the acinar-specific 
transcription factor Ptf1a (Krah et al., 2015). Furthermore, during development 
the interaction with similar neighbours or a ‘community effect’, is required for the 
activation of certain genes and differentiation (Gurdon et al., 1993; Ho, 1992). It 
follows that non-transformed acinar cells may inhibit the ADM process. 
Therefore, the role of normal neighbours in inhibiting Kras-driven ADM was 
investigated using the established ex vivo model. ADM is associated with acinar 
cells dedifferentiating to a duct-like progenitor cell type which is associated with 
both transcriptional and morphological changes and so readouts of both of these 
changes were examined.  
First it was necessary to validate that ADM was occurring in my model 
system using cells derived from Pdx1-CreER; LSL-KrasG12D/+; ROSA26tdRFP 
animals following in vivo induction. It has previously been demonstrated that 
KrasG12D expression drives the de-differentiation ADM process to a more duct-
like cell (Habbe et al., 2008; Hingorani et al., 2003; Kopp et al., 2012). To test 
whether this process was conserved using the Pdx1-CreER; LSL-KrasG12D/+; 
ROSA26tdRFP mouse model, acinar cells were plated 48 hours after in vivo 
induction and visualised over time. After plating (Day 0), both control and 
KrasG12D cells were observed to have the many-lobed acinar morphology 
apparent from the F-actin stain (Figure 4.3, top). However, by day 3 it was 
observed that KrasG12D expressing, RFP positive clusters adopted a ductal cyst 
morphology comprising of a single layer of epithelial cells in a circular ring with 
an expansion of the hollow, luminal space (Figure 4.3), similar to previously 
published reports (Ardito et al., 2012; Liou et al., 2013; Shi et al., 2013). Control 
acinar cultures from Pdx1-CreER; ROSA26tdRFP animals did not undergo this 
morphological change by day 3 (Figure 4.3). Widespread cell death was 
observed at later time points in acinar cells not expressing KrasG12D as observed 
previously (Shi et al., 2013). This indicates that clusters of KrasG12D cells undergo 
the morphological changes associated with ADM over 3 days ex vivo. 
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 The ADM de-differentiation process is also associated with changes in 
transcription. As ADM progresses, a number of ductal and pancreatic embryonic 
markers are expressed (Storz, 2017). One such transcription factor is Sox9, a 
ductal lineage specific marker that is upregulated ADM in vivo and ex vivo (Kopp 
et al., 2012; Prévot et al., 2012). As Sox9 expression is required for ADM (Kopp 
et al., 2012), immunofluorescence for Sox9 was used as a second readout of 
ADM. After plating (day 0), Sox9 staining was not detectable in RFP positive cells 
in control or experimental cultures (Figure 4.4). After 3 days in culture, RFP 
positive, KrasG12D mutant cells had adopted a ductal cyst shape that was strongly 
positive for nuclear Sox9 (Figure 4.4). Sox9 staining was not detected in clusters 
from Pdx1-CreER; ROSA26tdRFP after 3 days in culture. This suggests that the 
morphological changes associated with ADM are accompanied by a 
transcriptional switch to a more duct-like fate in KrasG12D cells ex vivo. 
 Together, this work describes the generation of a 3D acinar model that 
recapitulates ADM in clusters of cells expressing oncogenic KrasG12D as 
observed by both morphological and transcriptional changes consistent with 
previous reports (Ardito et al., 2012; Liou et al., 2015; Shi et al., 2013). It also 
highlights some of the limitations of the system with most non-transformed acini 
unable to survive beyond 3 days in culture. 
 
 
 
 
 
 
 117 
 
 
 
 
 
 
 
 
 
Figure 4.3: KrasG12D drives morphological changes to a duct-like cyst ex vivo. 
Acinar cells isolated from Pdx1-CreER;LSL-KrasG12D/+;ROSA26tdRFP (KrasG12D) 
animals 48 hours post-induction were cultured ex vivo. After 3 days in culture (D3) 
KrasG12D cells identified by RFP (red) have lost the round shape and adopted a duct-
like structure with lumen expansion as apparent from F-actin (grey). Control cultures 
from Pdx1-CreER; ROSA26tdRFP did not undergo this morphological transformation 
and retained an acinar morphology. Scale bar, 20 µm. 
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Figure 4.4. ADM ex vivo is associated with genetic reprogramming to express 
Sox9. Ex vivo cultures were isolated from Pdx1-CreER;LSL-KrasG12D/+;ROSA26tdRFP 
(KrasG12D) animals  48 hours after in vivo induction. On day 0 (D0) clusters have a 
‘berry’ like shape and no Sox9 (yellow) was detectable. After 3 days in culture (D3) 
KrasG12D clusters have adopted a ductal cyst morphology, positive for the ductal 
marker Sox9. In control Pdx1-CreER; ROSA26tdRFP acini, Sox9 was not observed at 
day 0 or day 3. Scale bar, 20 µm. 
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4.2.4 Normal neighbours decrease the efficiency of duct-like cyst formation 
of KrasG12D transformed cells. 
 
 ADM is an initiating event for the development of PDAC in mice. It is 
associated with changes to a duct-like progenitor gene expression profile and 
morphological changes. After establishing that clusters of KrasG12D cells can 
progress through ADM in this system the effect of mosaic KrasG12D expression 
was explored. 
To investigate this question the impact of normal neighbours was studied 
in two ways: i) with respect to morphological changes with the formation of a 
ductal cyst as a readout, and ii) at the level of cell fate with Sox9 as a readout. 
 This ex vivo model has been widely used to elucidate the underlying 
signalling mechanisms of ADM and role of the tumour microenvironment in both 
mice and humans (Ardito et al., 2012; Liou et al., 2017; Liu et al., 2016; Shi et al., 
2013). So to examine the role of normal epithelial neighbours in ADM, ex vivo 
acinar clusters were generated from Pdx1-CreER;LSL-KrasG12D/+;ROSA26tdRFP 
(KC) animals 48 hours after induction with 1 mg of tamoxifen. After 3 days in 
culture, the percentage of a clusters positive for RFP was calculated and each 
cluster was then scored as either converting to a duct-like cyst with an expanded 
lumen and associated cell shape changes, or retaining acinar features. After 
plating (day 0) no ductal cyst structures were observed (Figure 3.5A). However, 
by day 3 a stark difference was observed between clusters with low and high 
percentages of mutant cells. Clusters consisting of less than 60% RFP positive 
cells had an approximately 10% likelihood of forming a duct-like cyst (Figure 
3.5B). This could indicate a basal level of transformation within the system as 
clusters from KC mice that contained no mutant cells (0%), or in control clusters, 
a similar level of duct-like cyst formation was observed. Conversely, clusters 
consisting of over 60% RFP positive cells (and hence KrasG12D cells) would 
efficiently progress through ADM, with the vast majority forming a duct-like cyst. 
This suggests that to form a duct-like cyst ex vivo a threshold number of KrasG12D 
cells per cluster is required. 
 It was noted that clusters with a high proportion of mutant cells (but less 
than 100%) are able to form a duct-like cyst. This suggests that normal cells when 
present at low numbers can also be induced to the duct-like cyst morphology 
(Figure 4.6). Strikingly, it was found that non-transformed cells surrounded by 
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KrasG12D cells are able to undergo ADM and become part of the duct-like cyst 
structure. These normal cells were also found to genetically reprogram and 
express Sox9 (Figure 3.6, asterisks), suggesting that mutant cells recruit non-
transformed cells to form a duct-like cyst.  
 These data illustrate that in order to efficiently progress to a duct-like cyst 
a threshold of mutant cells is required ex vivo. This suggests that normal 
neighbours have an inhibitory effect on mutant cell disease progression as 
clusters with low numbers of KrasG12D cells are unable to efficiently adopt a duct-
like cyst morphology. It also indicates that once KrasG12D cells overcome this 
effect they can recruit normal cells into a duct-like cyst in culture. 
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Figure 4.5: A threshold of KrasG12D cells is required to efficiently progress 
through ADM ex vivo. (A) After plating Pdx1-CreER;LSL-KrasG12D/+;ROSA26tdRFP acini 
cells have a round morphology (day 0). At day 3, clusters with a high percentage of 
RFP (red) and hence mutant cells adopted a duct-like structure with an expanded 
lumen. Whereas clusters with a low percentage of transformed cells retain acinar-like 
features. At day 3, the proportion of RFP positive (red) cells in a cluster was counted 
and then each cluster was scored as whether duct-like with a lumen or retaining acinar 
morphology (B,C). (B) In control clusters (Pdx1-CreER;ROSA26tdRFP) a low number of 
clusters were observed to have undergone ADM independent of the percentage of 
RFP positive cells within the cluster.(C) However, in clusters where RFP marks 
KrasG12D cells the ratio of normal to mutant cells plays an important factor in 
determining whether a cluster progresses through ADM. A cluster with less than 60 % 
mutant cells has a similar efficiency of ADM as the basal control level whereas the vast 
majority of clusters with over 60 % transformed cells went through ADM efficiently 
within 3 days. Data represents >30 clusters/experiment, n = 3 biological replicates. 
Scale bar, 20 µm. 
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Figure 4.6: Recruitment and reprogramming of wild-type cells by KrasG12D 
mutant neighbours. (A) Non-transformed, RFP negative cells are recruited to form 
a duct-like cyst the normal cells (asterisks) and reprogram to express Sox9 (yellow). 
Cells were fixed at day 3 and stained for F-actin (grey), RFP (red), Sox9 (yellow) and 
Nuclei (blue). (B) RFP negative cells (white arrows) from clusters with a large 
proportion of KrasG12D cells reprogram to Sox9 positive cells. Images are 
representative of 4 biological replicates. Scale bar, 20 µm. 
A 
B 
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4.2.5 KrasG12D transformed cells reprogram to express Sox9 autonomously. 
 
 ADM requires both a genetic reprogramming process and a morphological 
change. Having found evidence suggesting that normal neighbours decrease the 
efficiency of forming duct-like cysts in 3 days the next aim was to investigate if 
normal neighbours were inhibiting the genetic changes associated with ADM in 
single KrasG12D cells. 
 Acinar cell cultures were generated from KC and control mice 48 hours 
after in vivo induction of Cre recombinase by tamoxifen. After plating, Sox9 was 
not detectable in single KrasG12D expressing acinar cells or RFP positive, Kras 
wild-type controls (Figure 4.7). However, after 3 days in culture de-differentiation 
to a Sox9 positive cell was observed. Single KrasG12D expressing acinar cells 
surrounded by RFP negative, normal cells stained positively for nuclear Sox9 
(Figure 3.7 bottom, white arrowhead). This suggests that single mutant cells 
surrounded by normal neighbours autonomously reprogram to Sox9 expressing 
duct-like cells. Clusters containing single RFP positive cells from Pdx1-CreER; 
ROSA26tdRFP controls did not show any positive staining for Sox9 (Figure 3.7, 
white asterisks).  
 These data indicate that normal neighbours do not inhibit the transition of 
KrasG12D to Sox9 positive cells on day 3 in an ex vivo model of ADM and it is 
autonomous. 
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Figure 4.7: Single KrasG12D acinar cells autonomously reprogram to Sox9 
positive cells. Acinar cells from either Pdx1-CreER;LSL-KrasG12D/+;ROSA26tdRFP 
(KrasG12D) or Pdx1-CreER; ROSA26tdRFP (Control) animals following Cre induction in 
vivo were cultured for 3 days ex vivo. On day 0, Sox9 (yellow) staining was not 
observed in RFP positive cells controls or KrasG12D expressing cells. At day 3, single 
KrasG12D cells stained positively for the ductal marker Sox9 (white arrow, bottom 
row), whilst single RFP positive cells in controls were Sox9 negative (asterisks). 
Scale bar, 20 µm. 
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Chapter 4.3 Discussion. 
 
 Previous work has found that targeting KrasG12D to the acinar 
compartment drives precancerous lesion development in vivo (Habbe et al., 
2008; Kopp et al., 2012), suggesting that the acinar cell is the cell of origin for 
PDAC and activating mutations in Kras are sufficient to drive the early stages 
beginning with ADM (Collins et al., 2012, 2014; Zhu et al., 2007). The 
microenvironment plays an important role in ADM with macrophages shown to 
drive ADM (Liou et al., 2013). In chapter 3, acinar cells are eliminated in vivo 
when surrounded by normal neighbours the aim of this chapter was to develop 
an ex vivo model of heterotypic cell-cell interactions in the acinar compartment, 
to provide insight on this interaction at the level of the single cell. Extrusion of 
oncogenic cells has also been shown to promote disease progression after 
evasion of the suppressive epithelial microenvironment (Leung and Brugge, 
2012). As this model also allows short-term modelling of ADM it allowed 
examination of whether normal neighbours repress the initiation of disease with 
extrusion promoting ADM. 
  
4.3.1 Morphological changes in KrasG12D cells surrounded by normal 
neighbours 
 
 To examine the fate of a KrasG12D cell surrounded by normal neighbours 
an acinar cell culture system was employed as described previously (Shi et al., 
2013). KC and control animals were first injected with tamoxifen to activate Cre, 
and 48 hours later the pancreas was harvested and acinar cells isolated and 
cultured in collagen. This resulted in a large number of clusters with different 
numbers of RFP positive cells. To investigate short term morphological changes 
in KrasG12D mutant cells surrounded by normal neighbours; cells were fixed 24 
hours after plating and immunofluorescence carried out for the cytoskeletal 
component F-actin. It was found that subset of KrasG12D expressing cells undergo 
morphological changes to a compact, contractile shape when surrounded by 
normal acinar neighbours. Importantly, this was not observed when transformed 
cells were surrounded by other transformed cells suggesting it is a result of the 
heterotypic interaction of normal and KrasG12D expressing cells. The increase in 
contractility and time frame is consistent with morphological changes identified 
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using in vitro models (Hogan et al., 2009), supporting the idea that KrasG12D cells 
are becoming contractile when surrounded by normal neighbours.  In addition, F-
actin accumulated at the periphery between normal and KrasG12D cells. Previous 
work has demonstrated that contractile rings form around cells destined to 
extrude either induced by overcrowding (Eisenhoffer et al., 2012) or apoptosis 
(Rosenblatt et al., 2001). The recruitment of F-actin did not occur between 
KrasG12D cells suggesting that heterotypic interactions between normal and 
KrasG12D cells results in actin cytoskeleton rearrangements (Hogan et al., 2009). 
E-cadherin-based cell-cell contacts can couple with the actin cytoskeleton 
leading to junctional contractility, which has also been implicated in apical 
constriction and extrusion (Roh-Johnson et al., 2012; Wu et al., 2015). Further 
characterisation of the interface of normal and transformed acini by 
immunofluorescence for E-cadherin and other cytoskeletal markers such as 
phosphorylated myosin-II would further elucidate the mechanism underlying 
increased contractility of mutant cells surrounded by normal neighbours (Hogan 
et al., 2009; Porazinski et al., 2016). These results suggest that non-autonomous 
changes occur to KrasG12D acinar cells surrounded by normal neighbours with 
parallels to other competitive interactions. 
 Although increased contractility and modulation of cytoskeleton of 
KrasG12D cells were observed (Hogan et al., 2009; Leung and Brugge, 2012), 
cells were not extruded within the time frame. Extrusion is reported to occur over 
8 days in other 3D mammary cultures (Leung and Brugge, 2012) and so extrusion 
may occur over longer periods in pancreatic acinar cultures. It has also been 
reported that loss of tight junctions and polarity can occur in acinar culture after 
24 hours (Amsterdam and Jamieson, 1974; Marciniak et al., 2013; Park et al., 
2004). Moreover, extrusion of Src-transformed cells in zebrafish requires mitosis 
and proliferation is not observed in this acinar ex vivo model (Anton et al., 2018; 
Shi et al., 2013). Therefore, further investigation is required to elucidate if 
KrasG12D acinar cells are extruded by normal neighbours. 
 In summary, the acinar ex vivo culture is not a robust system however 
KrasG12D cells adopt a contractile morphology when surrounded by normal 
neighbours. This could suggest that competitive interactions are initiated 
between normal and KrasG12D mutant acinar cells. This could be expanded on in 
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the future to further investigate the molecular signalling underlying these 
interactions. 
 
4.3.2 Characterising the impact of normal neighbours on KrasG12D cells 
progressing through ADM ex vivo 
 
 Next, to investigate the role of normal epithelial neighbours in ADM 
recombination was induced with tamoxifen in Pdx1-CreER; LSL-KrasG12D/+; 
ROSA26tdRFP mice and Pdx1-CreER+; ROSA26tdRFP controls and 3D acinar 
cultures were produced. For the identification of cells undergoing ADM two 
readouts were used: the morphological change to a duct-like cyst and the genetic 
change to a Sox9 expressing cell. Firstly, it was necessary to validate the model. 
It was observed that over time clusters of KrasG12D cells adopted a duct-like cyst 
morphology and expressed Sox9. Whereas, control acinar retained acinar 
morphology and did not genetically reprogram, suggesting that this model 
faithfully recapitulates previously defined features of ADM ex vivo (Kopp et al., 
2012; Shi et al., 2013).  
 Using the morphological change to a duct-like cyst as a read-out of ADM 
it was found that clusters consisting of over 60% KrasG12D cells efficiently 
underwent ADM whereas activation of Kras in <60% of cells did not produce duct-
like cyst formation above the background level. This suggests a non-cell 
autonomous protective mechanism working to offset ADM or retain the acinar-
specific lineage (Krah et al., 2015), similar to the community effect in embryonic 
development (Gurdon et al., 1993). Although the mechanisms of a community 
effect are not well understood it has been demonstrated that cell-cell interactions 
drive homogeneous fate changes in small clusters of cells. Using micropatterning 
to produce small colonies of 1-8 human embryonic stem (hESC) cells, it has been 
shown that the community impacts differentiation (Nemashkalo et al., 2017). In 
response to very low concentrations of BMP, clusters of cells differentiated 
together whereas non-contacting neighbouring colonies often had alternate 
fates. It was found that cell-cell interactions maintain a high BMP signalling 
response and enforce differentiation in the whole cluster. Single cell colonies 
lacked this reinforcement and consequently differentiated less efficiently. 
Moreover, it has been demonstrated that single cells transplanted to developing 
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embryos change fate but clusters do not (Gurdon et al., 1993; Ho, 1992). Thus, 
single KrasG12D cells may be inhibited to progress through ADM by the 
surrounding normal neighbours through a community effect and this suggests a 
signalling threshold underlies ADM.   
 Interestingly, normal cells surrounded by KrasG12D neighbours were found 
to be recruited into the duct-like cyst structure when a cluster consists of >60% 
KrasG12D cells. This could indicate that the presence of KrasG12D cells drive a pro-
ADM signal to the whole cluster which has been theorised to drive the community 
effect (Bolouri and Davidson, 2010; Saka et al., 2011). Examination of pancreatic 
cancer patient samples has shown an upregulation of epidermal growth factor 
receptor (EGFR) (Tobita et al., 2003) and ligands (Zhu et al., 2000). Moreover, 
treatment of ex vivo acinar cultures with EGFR ligands, such as transforming 
growth factor alpha (TGF-a) drives ADM (Means et al., 2005). Expression of 
KrasG12D can upregulate EGFR expression and activation which can activate 
wild-type Kras alleles (Ardito et al., 2012; Ji et al., 2009). Therefore, EGFR is a 
good candidate for the underlying mechanism of how KrasG12D cells promote 
ADM in normal neighbouring cells. 
 A recent study found adjacent healthy tissue can be induced by PDAC to 
form PanIN-like lesions (Ferreira et al., 2017), suggesting wild-type cells can 
progress through ADM and form a PanIN-like lesion. Although multicolour 
lineage tracing demonstrated that malignant PanIN lesions are clonal (Maddipati 
and Stanger, 2015), a meta-analysis of low-grade PanIN lesions from human 
PDAC samples found that over half of PanIN lesions do not harbour a Kras 
mutation (Löhr et al., 2005). A more recent study using sensitive sequencing 
techniques detected Kras mutations in most human PanIN lesions, but only in a 
subset of cells within the lesion (<10% of cells) which does not fit with a clonal 
origin (Kanda et al., 2012). This strongly supports these findings that Kras 
induces metaplastic features in normal adjacent epithelial cells lacking Kras 
mutations, recruiting them to form a precancerous lesion. Further work to 
investigate the molecular mechanism underlying this interaction is required and 
this could lead to the development of therapeutics that promote the protective 
effect of normal neighbours and decrease the likelihood of precancerous lesion 
development. 
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 Together, these findings support the hypothesis of a community effect in 
two contrasting ways; firstly, that normal cells inhibit the morphological formation 
of a precancerous lesion and secondly that clusters of Kras mutant cells can 
recruit adjacent, normal neighbours into a metaplastic lesion.  
 After investigating ADM from a histological perspective, the underlying 
genetic alterations associated with ADM were explored. In normal conditions 
Sox9 is expressed in ductal cells and not acinar cells (Seymour et al., 2007). 
Furthermore, Sox9 promotes and is required for PanIN formation from the acinar 
compartment (Kopp et al., 2012). Immunofluorescence for Sox9 in this ex vivo 
model found that initially all acinar cells are negative for Sox9 and that Sox9 is 
expressed in duct-cyst like structures that form from KrasG12D mutant clusters.  
 After 3 days in culture, single KrasG12D cells surrounded by normal 
neighbours were positive for Sox9. The expression of the ductal marker Sox9 in 
single KrasG12D mutant cells within a cluster of transformed cells suggests that 
the genetic reprogramming to Sox9 positive cell is a cell-autonomous process 
and normal neighbours do not influence this change in this model. This is 
consistent with a recent study that found in human pancreatic ductal cells 
overexpression of oncogenic Kras induces Sox9 expression (Zhou et al., 2018). 
However, this is only looking at one marker of ADM and further confirmation is 
required looking at the loss of acinar specific markers such as amylase or Cpa1. 
This is important because previous work has demonstrated that Sox9 expression 
is initiated before Kras-active acinar cells progress to a duct-like state (Kopp et 
al., 2012).  This study used the acinar specific Cre Ptf1a to drive KrasG12D 
expression in utero and found that at 2 months after birth a subset of cells with 
acinar morphology co-expressed the acinar marker Cpa1 and the ductal marker 
Sox9. Therefore, although KrasG12D cells surrounded by normal neighbours can 
express Sox9 by day 3 it is unclear whether mutant cells could go on to form a 
lesion at later time points.  
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4.4 Summary and Future Directions  
 
 In summary, several major conclusions can be made from the data 
presented in this chapter. Firstly, that interaction with normal acinar cells induces 
morphological changes in single KrasG12D cells after 24 hours ex vivo. Secondly, 
that normal acinar neighbours inhibit the progression of KrasG12D cells to a 
precancerous lesion. Finally, when KrasG12D cells are present at high numbers 
they can promote ADM in neighbouring normal cells. This provides further 
evidence that heterotypic interactions are occurring between normal and 
transformed cells in the pancreas and they may impact upon pancreatic cancer 
initiation. However, several interesting questions arise from this work regarding 
the heterotypic cell-cell interaction of normal and KrasG12D acinar cells. 
 Although this model has provided a number of insights into cell-cell 
interactions in the pancreas it has several limitations. Proliferation does not occur 
within the system and normal cells undergo either apoptosis or spontaneous 
ADM at low levels after several days. Therefore, it is important to investigate the 
role of normal neighbours using in vivo models. This study provides evidence 
that wild-type cells can be included in precancerous lesions similar to previous 
reports (Kanda et al., 2012). The implications of this for disease progression are 
unclear. It raises the question of whether these normal cells are “bystanders” 
(Ferreira et al., 2017), or play an active role in early lesion development to 
suppress tumourigenesis. Further characterising these normal-mutant cell 
interactions in vivo could provide insight into a potential role of the normal cells 
in precancerous lesions. Recent work has supported the stepwise progression of 
PanIN lesions to pancreatic ductal adenocarcinoma but also that multiple lesions 
can progress in parallel through the pancreas (Makohon-Moore et al., 2018). With 
PanIN lesions present in up to 77% of patients without clinically evident 
pancreatic neoplasia (Matsuda et al., 2017) it suggests precursor lesions have 
different capacities to progress to PDAC. It is conceivable that interaction of 
normal neighbouring cells with mutant cells in precursor lesions inhibits precursor 
lesion progression and could elucidate how low grade lesions differ from 
malignant lesions. Analysis of human samples of normal pancreas in 
combination with recent in situ mutational detection techniques (Baker et al., 
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2017) could test for the presence of Kras wild-type cells in PanIN lesions and if 
there is an association with disease stage. 
 Using ex vivo acinar model this study has identified a threshold of KrasG12D 
mutant cells required to efficiently drive ADM. How this threshold is reached 
independent of proliferation to allow PanIN formation in human tissue is not clear. 
Risk-factors such as pancreatitis may help mutant cells overcome the 
suppressive environment of normal cells. As pancreatitis is associated with 
immune infiltrate (Montecucco et al., 2014) combining the culture system and 
model with macrophages as used previously (Liou et al., 2013) could test whether 
immune cells could facilitate mutant cells to reach this threshold. Chronic 
pancreatitis can increase the risk of pancreatic cancer by more than tenfold 
(Bosetti et al., 2014) and pancreatitis promotes pancreatic cancer via EGFR 
signalling (Ardito et al., 2012). If KrasG12D cells are promoting ADM in normal 
neighbours via EGFR signalling pancreatitis may also alter the threshold of 
mutant cells required to form a duct-like cyst and could promote normal 
neighbours to undergo ADM. Use of EGFR inhibitors could test if this signalling 
is driving normal neighbouring cells to undergo ADM when surrounded by 
KrasG12D cells (Ardito et al., 2012) and hence increase the threshold of mutant 
cells required to drive a cluster to form a duct-like cyst. 
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Chapter 5: Characterisation of the interface between 
normal and KrasG12D pancreatic ductal epithelia in vitro 
 
5.1 Introduction 
 
 It is increasingly apparent that extrusion of aberrant cells provides a 
mechanism for normal epithelial tissues to maintain homeostasis (Brown et al., 
2017; Hogan et al., 2009). However, precisely what happens at the interface 
between newly emerged transformed cells and the surrounding normal epithelial 
cells is unclear.  
 Previous studies have revealed that various molecules and signalling 
pathways are modulated in transformed cells during apical extrusion. Prior to 
apical extrusion, RasV12 cells significantly increase in cell height, accumulate F-
actin and demonstrate higher activity of myosin-II and Cdc42 (Hogan et al., 
2009). This and other studies (Kajita et al., 2010, 2014) have identified that 
normal neighbouring cells influence the cytoskeletal organisation of mutant cells. 
Activation of myosin-II and F-actin accumulation leads to enhanced surface 
tension and cell-cell adhesion of mutant cells, respectively (Lecuit and Yap, 
2015); With these two parameters reported to be involved in cell sorting (Canty 
et al., 2017; Cayuso et al., 2015). 
 More recently, elevated EphA2 has been identified as the mechanism by 
which normal cells detect Ras-transformed neighbours (Porazinski et al., 2016). 
Eph-ephrin signalling has a general role in cell repulsion and cell segregation 
required for tissue boundary formation in development and maintenance in 
homeostasis (Batlle and Wilkinson, 2012). Cell-autonomous upregulation of 
EphA2 in Ras-transformed cells (Macrae et al., 2005; Porazinski et al., 2016) 
leads to detection by normal neighbours. EphA2 forward signalling then occurs 
in a ligand dependent manner driving repulsion and segregation of mutant cells. 
This drives increased contractility of RasV12 cells and extrusion from epithelial 
monolayers. Extrusion is dependent on E-cadherin-based cell-cell adhesions 
(Hogan et al., 2009) and signalling via Src family kinases (SFK) and myosin-II 
are required for RasV12 cell contractility downstream of EphA2 (Porazinski et al., 
2016). Moreover, it has been demonstrated that even small clusters of normal 
cells can induce repulsion of Ras-transformed cells indicating a cell-cell signalling 
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event driving repulsion (Hill and Hogan, 2017) and not a mechanical compressive 
force induced by proliferation (Shraiman, 2005).  
 In this thesis, I present data to show that KrasG12D cells are eliminated from 
the pancreas via a process that requires non-transformed neighbours and 
EphA2. To further delineate the heterotypic cell-cell interactions between 
KrasG12D and normal cells at the single cell level, primary ductal epithelial (PDE) 
cell culture were used. These cells provided a robust model of epithelial cell 
interactions in the pancreas and hence allowed further characterisation of 
normal-mutant cell-cell interactions. This chapter set out to explore: i) whether 
KrasG12D ductal epithelial cells were segregated by normal neighbours, ii) if 
signalling pathways previously identified in EphA2-dependent extrusion of 
mutant cells by normal neighbours are conserved in this system (Hogan et al., 
2009; Porazinski et al., 2016), iii) and whether cell mediated changes identified 
in vitro are relevant in vivo. 
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5.2 Results 
 
5.2.1 Segregation of KrasG12D cells in an EphA2 dependent manner in vitro  
 
 Heterotypic interactions between normal and oncogenic Ras epithelial 
cells can drive extrusion of mutant cells (Hogan et al., 2009; Kajita et al., 2014; 
Kon et al., 2017; Ohoka et al., 2015; Wu et al., 2015). Previous work using MDCK 
cell lines has demonstrated that mutant cells are repulsed leading to extrusion 
when surrounded by normal neighbours (Porazinski et al., 2016). In this study 
KrasG12D mutant cells were also found to be eliminated in a process that requires 
normal neighbours in vivo. Modelling and characterising these interactions using 
an acinar model was difficult as the system was not robust; normal acinar cells 
surviving only days in culture. Therefore, to better understand heterotypic cell-
cell interactions in the pancreas a 2D pancreatic ductal epithelial (PDE) model 
was used, similar to previous work (Morton et al., 2010; Tape et al., 2016). This 
allowed mixing of normal and transformed cells at defined ratios and 
characterisation of KrasG12D cells surrounded by normal neighbours at the level 
of the single cell over time.  
 First, KrasG12D mutant cells surrounded by normal neighbours were 
modelled using PDE and the fate of transformed cells quantified. For this, the 
pancreas of wild-type animals was harvested and digested before plating on to 
collagen. Once confluent monolayers of epithelia had formed, normal PDE cells 
were split and mixed with primary PDE tumour-derived cell lines (with different 
mutational status) at 1:50 (normal:mutant) ratios. This generates a system of 
heterotypic cell-cell interactions with a small number of KrasG12D mutant cells 
surrounded by normal epithelia. Mutant cells were labelled in vitro using a 
commercial cell tracker dye (Porazinski et al., 2016). Following mixing, cells were 
plated and upon reaching confluency (48 hours after plating) cells were fixed and 
stained for F-actin to visualise cell morphology (Figure 5.1A). When surrounded 
by normal neighbours, clusters of KrasG12D expressing cells adopted a tightly 
packed morphology with a smooth border at the interface between normal and 
mutant cells (Figure 5.1A, top). Pre-labelled KrasG12D cells mixed with non-
labelled KrasG12Dcells at 1:50 ratios had a regular morphology consisting of 
random shapes and intermingled with an uneven border (Figure 5.1A, second 
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row). Furthermore, mixing pre-labelled wild-type PDE cells with non-labelled wild-
type cells at 1:50 ratio also resulted in intermingling with jagged borders and a 
uniform morphology in both cell populations (Figure 5.2). This suggests KrasG12D 
PDE cells are undergoing morphological changes when surrounded by normal 
neighbours. 
 To investigate the observed changes in KrasG12D cell shape, cell area was 
used as a readout of contractility and area of labelled cells was quantified using 
ImageJ (Figure 5.1B). A significant decrease in KrasG12D cell (KR) area was 
observed when surrounded by normal (N) neighbours (KR:N = 172.7 µm2  ± 25.3 
Vs. KR:KR = 355.2 ± 109.5, Welch’s t-test p = 0.0412). This shows that KrasG12D 
cells surrounded by normal neighbours have decreased cell area indicating 
increased compactness and contractility of mutant cells. 
 At the interface of KrasG12D mutant and normal cells a smooth boundary 
was formed. Quantification of the linearity of the boundary between cells can 
provide a readout of the local intermingling of cells (Canty et al., 2017; Javaherian 
et al., 2015). Here the Index of Sphericity was used to quantify how much an 
irregular 2D shape deviates from the ideal shape of a circle (Figure 5.1C) 
(Ionescu-Tirgoviste et al., 2015). As the value tends more towards 1, the object 
becomes rounder. It was observed that clusters of KrasG12D mutant cells were 
significantly more round when surrounded by normal (KR:N) neighbours than 
KrasG12D cells (KR:KR) (KR:N = 1.092 ± 0.029 Vs KR:KR = 1.319 ± 0.073, 
Welch’s unpaired t-test p=0.0048). This suggests that KrasG12D cells segregate 
from normal neighbours and separate to form a smooth boundary. Together, 
these data suggest that KrasG12D cells surrounded by normal neighbours become 
more tightly packed and segregated indicative of cell repulsion by normal 
neighbours. 
 Eph-ephrin signalling regulates cell segregation and cell repulsion (Xu et 
al., 1999), and EphA2 has previously been demonstrated to drive repulsion of 
Ras-transformed cells from normal cells (Porazinski et al., 2016). To test the 
functional role of EphA2 in this system, primary cells with KrasG12D mutation and 
EphA2-deficiency (KRE) were used in cell mixing experiments. A replacement 
vector within the extracellular domain of EphA2 results in a non-functional, 
truncated protein (Brantley-Sieders, 2004; Brantley-Sieders et al., 2008), the 
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same EphA2-deficient model as used in vivo in chapter 3. When KRE cells were 
mixed with non-transformed, normal cells it was observed that mutant clusters 
no longer adopted a tightly packed morphology, however a smooth boundary was 
still observed at the interface with normal neighbours (Figure 5.1A, third row). 
KRE mutant cells mixed with non-labelled KRE cells had a regular morphology 
similar to N:N co-cultures and intercalated with neighbours (Figure 5.1A, bottom). 
Quantification of cell area showed KRE cells had significantly larger cell area 
compared to KrasG12 cells when surrounded by normal cells (KR:N = 172.7 µm2  
±25.3 Vs. KRE:N = 426.9 µm2 ± 68.2, Welch’s unpaired t-test p = 0.0026 ). This 
indicates KRE cells do not adopt a contractile and compact morphology when 
surrounded by normal neighbours. Moreover, KRE cells surrounded by normal 
cells had a similar area to KRE:KRE co-cultures (KRE:N = 426.9 µm2 ± 68.2 Vs. 
KRE:KRE = 494.5 µm2 ± 71.5). Analysis of mutant cell segregation by Index of 
Sphericity also demonstrated that KRE clusters are significantly less round and 
hence intermingle more with normal neighbours than KR cells (KR:N = 1.092 ± 
0.029 Vs. KRE:N = 1.196 ± 0.061, Welch’s unpaired t-test, p = 0.034). Mixing of 
KRE:KRE cells (Figure 5.1A, bottom row) demonstrated that KRE cells have a 
comparable Index of Sphericity (Figure 5.1B,C) (KRE:N = 1.196 ± 0.061 Vs. 
KRE:KRE = 1.285 ± 0.044, Welch’s unpaired t-test, p= 0.08). Overall, this 
suggests that KRE cells surrounded by normal neighbours are not compacted or 
triggered to become round, suggesting a requirement for EphA2 in the repulsion 
of KrasG12D cells by normal neighbours. However, the boundary between KRE 
cells and normal neighbours was found to be more blunt than controls, and Index 
of Sphericity is lower than KRE:KRE mixes indicating a level of segregation of 
KRE cells from normal neighbours. In summary, KrasG12D PDE cells are triggered 
to become contractile and compact when surrounded by normal neighbours, 
which is dependent on functional EphA2 in mutant cells. Moreover, although 
mutant cells are triggered to become round in an EphA2-dependent manner 
other factors are involved in segregation of the two cell populations as KRE cells 
have a smooth boundary with wild-type cells. 
 Interestingly, it was observed that some clusters of KrasG12D cells 
surrounded by normal neighbours had rounded up and were apically extruded 
from the monolayer (Figure 5.3A). In KR:N co-cultures, 49% of KrasG12D clusters 
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(38/77 clusters, n = 2) were extruded out of the monolayer within 48 hours. 
Extrusion was observed at low levels in KR:KR co-cultures (Figure 5.3B) (3/71 
cells n = 2). When KrasG12D cells were EphA2-deficient (Figure 5.3C) the 
efficiency of extrusion decreased to 18% (14/76 cells n = 2). Although, the rate 
of extrusion in KRE:N mixing assays did not decrease to comparable levels to 
KRE:KRE mixes (Figure 5.3D)(4/68 cell n = 2).  
 Overall, this suggests that KrasG12D transformed cells are actively repulsed 
by normal neighbouring cells which can result in apical extrusion of mutant cells. 
Moreover, it suggests this process is dependent on EphA2 in the mutant cell 
population. 
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Figure 5.1: Increased contractility and segregation of KrasG12D cells when 
surrounded by normal neighbour. (A) Representative images of mixing assays of 
normal (N) and labelled mutant cells populations (red) of either KrasG12D (KR) mutated 
cells or KrasG12D, EphA2 deficient (KRE) cells. F-actin grey; CMRA cell tracker red; 
Hoescht blue. Clusters of KrasG12D mutant cells adopt a compact and round morphology 
when surrounded by normal neighbours in an EphA2 dependent manner. This suggests 
mutant cells are repulsed by normal neighbours via EphA2. (B) Quantification of cell 
area shows a significant decrease in KrasG12D cells surrounded by normal cells (n= 552 
cells) compared to KrasG12D:KrasG12D assays (n=241 cells). EphA2 deficiency in KRE 
cells surrounded by normal cells (n= 316 cells) significantly increased the area of 
transformed cells. KRE cells surrounded by normal neighbours have similar area as 
KRE:KRE cell assays (n= 119 cells). (C) Index of Sphericity quantifies how much an 
irregular shape deviates from a circle with rounder shapes tending towards 1. KR 
clusters surrounded by normal cells (n= 25 clusters) are significantly rounder than 
clusters from KR:KR assays (n= 36 clusters). Loss of functional EphA2 in KrasG12D cells 
significantly increased Index of Sphericity (n=21 clusters) and were more similar to KRE 
cells from KRE:KRE assays (n= 22 clusters). Data represents mean ± s.d. with each 
point representing a biological replicate. Statistical analysis was carried out using 
Welch’s unpaired t-test. P < 0.05 = *, P<0.001 = **. Scale bar, 20 µm. 
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Figure 5.2 Normal cell interactions do not drive morphological changes in 
labelled normal cells. F-actin (grey) was used to analyse morphological changes to 
CMRA (red) labelled normal cells (N) mixed with non-labelled populations of normal 
cells (N). No apparent changes to morphology were observed in labelled normal cells. 
This suggests normal:normal (N:N) interactions do not lead to segregation of labelled 
cells. Scale bar, 20 µm. 
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Figure 5.3: Extrusion of KrasG12D cells surrounded by normal neighbours. 
(A) Clusters of KrasG12D labelled (red) cells are extruded out of the monolayer by 
normal neighbours. Whereas KrasG12D cells (KR) integrate and form a flat 2D 
monolayer with other KrasG12D cells (KR:KR, B). KrasG12D; EphA2-deficient cells 
integrate and are not extruded when surrounded by normal (C) or other KRE (D) 
cells. This suggests KrasG12D are extruded by normal neighbours in an EphA2 
dependent manner. xy images are max projections in z and are representative of 
2 independent experiments. xz are orthogonal views. F-actin grey; CMRA cell 
tracker red; Hoescht blue. Scale bar, 20 µm. 
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5.2.2 Characterisation of EphA2 downstream signals in vitro 
 
 Signalling through Eph receptors and ephrin ligands is highly complex and 
acts through multiple pathways (Cayuso et al., 2015; Pasquale et al., 2008) to 
affect cell migration, proliferation and differentiation. EphA receptors bind to 
glycosylphosphatidylinositol (GPI) –anchored ephrinA ligands and with both 
components membrane-bound, signalling requires direct cell-cell contact (Davis 
et al., 1994). To investigate the downstream signals from heterotypic cell-cell 
interactions in PDE cells immunofluorescence was carried out on cell mixing 
assays as before. 
 Ras-transformed MDCK cells are detected by normal neighbours by 
autonomous upregulation of EphA2 in mutant cells (Macrae et al., 2005; 
Porazinski et al., 2016). To investigate levels of EphA2 in normal and transformed 
pancreatic cells mixing assays were stained for EphA2. When KrasG12D cells 
were surrounded by normal neighbours EphA2 levels appeared high at cell-cell 
contacts between transformed cells than in the surrounding wild-type cells 
(Figure 5.4, top), suggesting EphA2 levels are higher in mutant cells. Moreover, 
a large amount of EphA2 positive puncta were observed in mutant cells 
surrounded by normal neighbours but with a lack of membrane EphA2 staining 
observed at the heterotypic cell-cell boundary. When KrasG12D cells were mixed 
with labelled KrasG12D cells low levels of membrane localised EphA2 was 
observed, whereas a large number of EphA2 positive punctate were observed 
(Figure 5.4, second row). This suggests that EphA2 is autonomously higher, 
similar to previous reports (Macrae et al., 2005; Porazinski et al., 2016), but 
localisation appears to be primarily cytoplasmic. Importantly, EphA2 levels were 
depleted in KRE cells surrounded by normal neighbours and monolayers of KRE 
cells formed by KRE:KRE co-cultures (Figure 5.4 bottom). This indicates that 
EphA2 protein is depleted in KRE cells. Together, these results suggest that 
EphA2 protein is upregulated in Ras-transformed cells and that KRE cells are 
depleted of EphA2 protein. 
 Following investigation of EphA2 levels the activation of EphA2 signalling 
was studied. Initially, immunofluorescence for markers of EphA2 activation such 
as phosphorylated EphA2 (Y594) were used but this proved inconsistent so 
activity of EphA2 downstream signals was examined. Global phosphoproteome 
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analysis has demonstrated that activated Ephs function upstream of RAS/RHO 
GTPases, Src, phospholipase Cg2 and mitogen-activated protein kinases 
(MAPKs) (Fang et al., 2008; Jørgensen et al., 2009). Signalling via the Src has 
previously been shown to be required for RasV12 cell extrusion (Hogan et al., 
2009) and to be activated downstream of EphA2 (Porazinski et al., 2016). 
Therefore, immunofluorescence for phosphorylated (Y416) active Src was 
carried out. Elevated phosphorylated Src (pSrc), and hence active Src, was 
specifically detected in KrasG12D cells surrounded by normal neighbours (Figure 
5.5); inferring that EphA2 is activated specifically in KrasG12D cells when 
surrounded by normal neighbours. However this requires further investigation to 
confirm the accurate staining of the pSrc antibody, including a control with no 
secondary antibody staining and a control with only secondary antibody staining 
to test for auto-fluorescence and non-specific staining respectively. Therefore 
this work only tentatively suggests pSrc is activated in KR cells surrounded by 
normal neighbours. 
 To test that Epha2 on mutant cells is functional a ligand-cell repulsion 
assay was used. Pre-clustered recombinant ephrin ligand can bind to Eph 
receptors on cells and induce Eph receptor clustering and activate signalling 
(Davis et al., 1994; Knöll et al., 2007; Porazinski et al., 2016). This can be 
observed as a repulsion phenotype upon interaction with pre-clustered ligand. 
Using this approach PDE cells were seeded into one of two compartments of a 
cell culture insert separated by a fixed gap. Pre-clustered recombinant ephrin-Fc 
proteins were used to coat the second compartment (Knöll et al., 2007; 
Porazinski et al., 2016). After removing the culture insert cells migrate and close 
the gap and interact with immobilised ligand. EphA2 interacts with ephrinA1 
which results in forward EphA2 signalling and inhibition of cell migration 
(Deroanne et al., 2003; Fero et al., 2011; Miao et al., 2000), therefore ephrinA1 
was used to coat the second compartment. As KR cells lacked motility and did 
not grow to confluence forming clusters rather than sheets, another PDE tumour-
derived line was used which had KrasG12D and p53R127H mutations. These data 
were generated by Rebecca Bennion, a Cardiff University undergraduate, under 
my supervision. 
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 First, it was necessary to confirm that Fc alone did not inhibit the migration 
of KP or KRE cells (Figure 5.6).  Both cell populations migrated over Fc stripes. 
However, KP cells failed to efficiently migrate over ephrinA1 ligands, indicating 
cell repulsion by ephrinA1 (Figure 5.6).  In contrast, KRE cells were not inhibited 
by ephrinA1 ligand and migrated over EphrinA1-Fc stripes similar to Fc control. 
This indicates that in tumourigenic PDE cells, EphA2 is functional. Moreover, this 
is consistent with the hypothesis that EphA2 expressed on mutant cells is 
activated by ephrin-presenting normal neighbours. Although further work is 
required to investigate this interaction in KR cells with EphrinA1 as it is not 
possible to extrapolate the results of KP cells due to the additional p53 mutation. 
 Another key aspect of EphA2 downstream signalling is modulation of 
cytoskeletal dynamics. Eph-ephrin signalling is associated with increased 
phosphorylated MLC (Rohani et al., 2011) and EphA2 is a known regulator of 
RhoA (Brantley-Sieders et al., 2008; Wakayama et al., 2011), which acts 
upstream of myosin-II (Gallo, 2006). This can regulate the contractile properties 
of a cell to generate force between cells and drive extrusion (Bielmeier et al., 
2016; Hogan et al., 2009; Kajita et al., 2014; Wu et al., 2015). To study myosin-
II activity, staining for phosphorylated MLC (pMLC) was carried out in cell mixing 
assays. In contrast to previous studies, elevated levels of phosphorylated MLC 
were not observed in KrasG12D when surrounded by normal cells (Figure 5.7). A 
ring of membrane localised staining of pMLC was observed at the boundary 
between normal and mutant cells, however this appears to arise from the normal 
cell population and is at a similar intensity to other normal:normal interfaces 
(Figure 5.7). When KrasG12D cells were mixed with labelled KrasG12D cells, a low 
level of diffuse pMLC was observed. Thus, pMLC staining of KrasG12D cells when 
surrounded by normal neighbours is not elevated in mutant cells and appears 
similar to KrasG12D monolayers. This indicates that myosin-II activity is 
autonomously lower in KrasG12D cells than non-transformed pancreatic cells and 
is not increased when mutant cells are surrounded by normal neighbours. 
However, a ring of p-myosin-II is observed at the boundary between normal and 
clusters of KrasG12D cells. Changes to pMLC requires further investigation to 
confirm the accurate staining of the pMLC antibody to pMLC protein. This would 
include a negative control with no secondary antibody staining and a control with 
only secondary antibody staining to test for auto-fluorescence and non-specific 
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staining respectively. A positive control such as the previously characterised cell 
lines MDCK could also be used to confirm specific staining of the antibody to 
pMLC (Porazinski etal., 2016). 
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Figure: 5.4: Characterisation of EphA2 in cell mixing assays. Normal (N) cells 
were mixed with pre-labelled (CMRA, red) KrasG12D (KR) cells or pre-labelled EphA2-
deficient KrasG12D cells (KRE) at a ratio of 1:50 and stained for EphA2 (grey).  Levels of 
EphA2 appear higher in KR cells than surrounding normal neighbours and localises at 
the membrane between mutant cells and as punctate cytoplasmic staining. EphA2 in 
KR:KR mixes appears diffuse and cytoplasmic. KRE cells appear depleted of EphA2 
when surrounded by normal neighbours (KRE:N) or non-labelled KRE cells 
(KRE:KRE). Images are representative of 2 biological replicates. CMRA cell tracker 
red; EphA2 grey; Nuclei blue. Scale bar, 20 µm. 
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Figure 5.5 Characterisation of EphA2 downstream signalling in 
KrasG12D cells. Mixing CMRA (red) labelled KrasG12D (KR) mutant cells with 
normal (N) have elevated pSrc (yellow) compared to KR:KR mixing assays. 
Images are representative of 2 biological replicates. CMRA cell tracker red; 
pSrc yellow; Hoescht blue; F-actin grey. Scale bar, 20 µm 
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Figure 5.6 Cell-ligand repulsion assay. KrasG12D; p53R172H (KP) cells and 
KrasG12D; EphA2tm1jrui (KRE) cells were plated in one well of an insert and Fc 
or Fc-ephrinA1 ligand used to coat the second compartment. Once the insert 
is removed cells migrate and interact with Fc-stripe. Both KP and KRE cells 
migrate over Fc-stripes. However, KP cells are unable to migrate over 
ephrinA1 ligand whereas EphA2 depleted KRE cells efficiently migrate over 
ephrinA1-stripes. Images are representative of 3 biological replicates. Black 
dotted line indicates stripe boundary; F-actin grey; Nuclei blue; Fc stripe red. 
Scale bar, 20 µm 
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Figure 5.7 Characterisation of p-MLC in KrasG12D cells surrounded by 
normal neighbours. Co-cultures of CMRA (red) labelled KrasG12D (KR) mutant 
cells and normal (N) or KR:KR co-cultures were stained for phosphorylated-
myosin-II (p-MLC; green). Levels of phosphorylated p-MLC appears 
autonomously lower in KR cells than non-labelled normal cells and pMLC is not 
elevated in KR cells surrounded by normal neighbours. CMRA cell tracker red; 
pSrc yellow; Hoescht blue; F-actin grey; phosphor-MLC cyan. Scale bar, 20 µm 
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5.2.3 Characterisation of E-cadherin in KrasG12D cells surrounded by normal 
neighbours 
 
 Eph-ephrin signalling regulates the cytoskeleton as well as cadherin and 
integrin mediated adhesion to control segregation and boundary formation 
(Arvanitis and Davy, 2008). Previously, it has been demonstrated that E-cadherin 
is required in normal cells for the extrusion of mutant cells (Hogan et al., 2009). 
Super resolution microscopy also identified endocytosis of E-cadherin in Ras-
transformed cells as a key driver of extrusion (Saitoh et al., 2017). Ligand-
induced EphA2 forward signalling can also increase E-cadherin-based cell-cell 
contacts in RasV12 cells and E-cadherin is required in normal cells for boundary 
formation and segregation (Porazinski et al., 2016). Thus, immunofluorescence 
for E-cadherin was carried out in KrasG12D pancreatic cell mixing assays. 
 As expected, when KR:KR cells were mixed to generate monolayers of 
KrasG12D cells, E-cadherin mainly localised at cell-cell contacts (Figure 5.8, 
second row). However, when KrasG12D cells were surrounded by normal cells an 
accumulation of cytoplasmic puncta positive for E-cadherin was observed (Figure 
5.8, top). This was accompanied by an apparent decrease in E-cadherin at cell-
cell contacts of KrasG12D cells. E-cadherin cytoplasmic puncta were also 
observed in KrasG12D cells not in direct contact with normal cells. E-cadherin 
puncta were not diffuse throughout the cytoplasm as described previously in cell 
competition (Saitoh et al., 2017) but appeared polarised and adjacent to the 
nucleus, possibly indicative of endocytosis (Kimura et al., 2006; Lu et al., 2003). 
This suggests E-cadherin is internalised in KrasG12D cells surrounded by normal 
neighbours and mutant cells are segregating from normal neighbours.  
 KrasG12D cells segregate in an EphA2 dependent manner therefore E-
cadherin was also examined in KRE pancreatic cells mixed with normal cells. In 
monolayers of KRE cells from KRE:KRE mixing E-cadherin was detected mostly 
at cell-cell contacts (Figure 5.8, bottom), similar to monolayers of KrasG12D cells. 
Next KRE clusters surrounded by normal cells were investigated. E-cadherin was 
not observed to accumulate in KRE cells surrounded by normal neighbours, with 
membrane localisation of E-cadherin observed between normal and KRE cells 
(Figure 5.8, third row). This suggests EphA2-deficiency in KrasG12D cells permits 
the formation of E-cadherin-based cell-cell contacts between normal and mutant 
 151 
cells. Furthermore, it indicates that EphA2 acts upstream of E-cadherin 
internalisation to drive segregation of KrasG12D cells by normal cells.  
 The association of p120 catenin with E-cadherin at epithelial cell 
membranes is critical for the formation and maintenance of adherens junctions 
(Ireton et al., 2002). The loss or mislocalisation of p120 catenin can destabilise 
E-cadherin and impact the adhesive properties of a cell. Furthermore, p120 
catenin has shown to be required for apical and basal extrusion of KrasG12D cells 
from pancreatic PanIN lesions in vivo (Hendley et al., 2016). To investigate 
context-dependent changes in p120 catenin, immunofluorescence was carried 
out using the mixing assay. When KrasG12D cells (KR) were mixed with labelled 
KrasG12D cells, p120 catenin was predominately localised to the membrane in 
both cell populations (Figure 5.9). However, when KrasG12D cells were 
surrounded by normal cells diffuse cytoplasmic staining was observed in mutant 
cells (Figure 5.9). This was accompanied by an apparent decrease of p120 
catenin at the interface between normal and transformed cells. However, 
membrane localised p120 catenin was observed between KrasG12D mutant cells 
within a cluster. This supports the observed loss of E-cadherin-based cell-cell 
contacts between normal and Ras-transformed cells and could indicate 
decreased adhesion between the two cell populations. 
 In summary, the data presented here suggest that adherens junctions are 
absent between KrasG12D cells and surrounding normal cells, indicative of 
segregation of mutant cells by normal neighbours. As EphA2-deficient KrasG12D 
cells can form E-cadherin-based cell-cell contacts with normal neighbours this 
suggests EphA2-dependent repulsion of KrasG12D cells by normal neighbours is 
leading to loss of cell-cell contacts. 
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Figure: 5.8: Internalisation of E-cadherin in KrasG12D cells surrounded by 
normal neighbours. Normal (N) cells were mixed with labelled (CMRA, red) 
KrasG12D (KR) or KrasG12D;EphA2-deficient (KRE) cells at a ratio of 1:50. E-
cadherin (cyan) decreased from the membrane of KR cells surrounded by normal 
cells and accumulates in the cytoplasm. This was not observed in KR:KR, KRE:N 
or KRE:KRE mixing assays suggesting it is a result of heterotypic cell-cell 
interactions dependent on EphA2. CMRA red; E-cadherin cyan; Hoescht blue. 
Images are representative of three independent experiments. Scale bar, 20 µm 
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Figure: 5.9: Investigation of p120-catenin in KrasG12D cells surrounded 
by normal neighbours. Normal (N) cells were mixed with labelled (CMRA, 
red) KrasG12D (KR) cells at a ratio of 1:50. Immunofluorescence for p120 
catenin (grey) was observed to decrease at the membrane of KR cells 
surrounded by normal cells and appeared diffuse in the cytoplasm. This was 
not observed in KR:KR mixing assays suggesting it is a result of heterotypic 
cell-cell interactions. CMRA red; p120-catenin grey; Hoescht blue. Scale 
bar, 20 µm 
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5.2.5 Segregation of KrasG12D cells surrounded by normal neighbours in 
vivo 
 
 In chapter 3 it was found that KrasG12D cells are eliminated when 
surrounded by normal neighbours in an EphA2 dependent manner. Mixing of 
primary pancreatic ductal cells in this chapter demonstrated that mutant cells 
undergo repulsion when surrounded by normal neighbours and adopt a compact, 
contractile morphology. To investigate whether these characterised changes in 
cell morphology are also occurring in vivo, a three-dimensional (3D) imaging 
approach was carried out.  
 Computer reconstruction of physical serial sections has been 
demonstrated to allow visualisation of large tissue volumes (mm3) whilst 
maintaining high resolution (<1 µm) (Parfitt et al., 2012). This novel technique 
known as immunofluorescent computed tomography (ICT) was carried out on 
pancreata harvested 7 days post-induction (dpi) with low dose from both KC 
(Pdx1-CreERT; ROSA26RFP; KrasG12D/+) and control (Pdx1-CreERT; ROSA26RFP) 
mice. Two-dimensional sections 2 µm thick were stained for E-cadherin and anti-
RFP and imaged (Figure 5.8A), serial sections were then aligned and stacked to 
generate a 3D reconstruction of RFP positive clusters (Figure 5.10B). The 
volume of RFP positive cells could then be quantified using Imaris software 
(Bitplane). At 7 dpi, a decrease in the volume of KrasG12D cells surrounded by 
normal neighbours compared to Kras wild-type controls was observed (Figure 
5.8C). After 7 dpi KrasG12D cells have a median volume of 2.08 x104 µm3 
compared to the volume of control RFP cells (2.83 x104 µm3). This suggests an 
increase in contractility of KrasG12D cells surrounded by normal neighbours in 
vivo. Moreover, changes to E-cadherin at the interface between KrasG12D and 
normal cells may be occurring in vivo, with less apparent membrane staining 
between KrasG12D;RFP positive cluster and normal cells compared to control 
(Figure 5.8A). Although more biological replicates are required to allow statistical 
comparison, this is consistent with the hypothesis that mutant cells surrounded 
by normal neighbours in vivo are increasing in contractility. 
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Figure 5.10: Quantification of KrasG12D cell volume in vivo. Pancreata 
containing RFP (red) labelled cells from control (Pdx1-Cre; Rosa26RFP) or 
KrasG12D (Pdx1-Cre;Rosa26RFP; KrasG12D) 7 days post-induction were serial 
sectioned and imaged. (A) Representative 2D images of a single section from 
control and KrasG12D showing segregation of transformed cells. (B) 
Representative 3D image of aligned serial sections. RFP red; E-cadherin green; 
Hoescht blue. (C) Violin plot showing cell volume of control (n=100 cells) or 
KrasG12D (n=100 cells) at 7 days post-induction. The Tukey-style boxplot within 
violin plot has the median depicted as a horizontal line across the box, box 
edges are 25th and 75th percentile with whiskers 1st to 99th percentile. Data 
represents 2 independent experiments with 50 cells/experiment. Scale bar, 20 
µm (A); 50 µm (B). 
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5.3 Discussion 
 
 Cell competition is a cell fitness-sensing mechanism that eliminates cells 
that, although viable, are less fit than the surrounding neighbours. Ras-
transformed cells have been shown to undergo cell competition resulting in the 
extrusion and elimination of mutant cells (Hogan et al., 2009; Kajita et al., 2014; 
Kon et al., 2017; Wu et al., 2015). Extrusion depends on E-cadherin-based cell-
cell adhesion, activation of myosin-II and accumulation of F-actin at the interface 
between normal and transformed cells (Hogan et al., 2009; Wu et al., 2015). More 
recently, we have demonstrated that elevated EphA2 on Ras-transformed cells 
leads to ephrinA-EphA2 forward signalling driving repulsion and increased 
contractility of mutant cells (Porazinski et al., 2016). Oncogenic cells emerge 
within normal epithelial sheets and so extrusion may be occurring at the earliest 
stages of disease. However, whether segregation of abnormal cells is promoting 
or suppressing tumourigenesis is unclear. Previously in chapter 3 evidence for 
the selective elimination of KrasG12D cells by normal neighbours was found in 
vivo. To further elucidate the underlying mechanism of mutant cell elimination, 
primary pancreatic ductal cells were used in cell mixing assays. 
 Although acinar cells were primarily being labelled in vivo, modelling 
heterotypic acinar cell-cell interactions ex vivo was technically challenging 
(Chapter 4). This system is not robust as non-transformed cells rapidly undergo 
cell death in culture after several days (Liou et al., 2013; Shi et al., 2013). 
Therefore, this chapter set out to characterise a primary ductal epithelial (PDE) 
cell culture model to investigate heterotypic cell-cell interactions between normal 
and KrasG12D cells. This provided a more robust system in vitro, as non-
transformed cells grow as 2D monolayers on collagen and can be serially 
passaged and allowed elucidation of the underlying mechanism of heterotypic 
KrasG12D:normal cell interactions (Chen et al., 2009; Morton et al., 2010; Reichert 
et al., 2013). There is evidence that both acinar and ductal compartments can 
give rise to PDAC (Bailey et al., 2016; Ferreira et al., 2017). Furthermore, acinar 
cells are known to transdifferentiate to duct-like cells, via acinar-ductal 
metaplasia (ADM), that give rise to pancreatic intraepithelial neoplasia (PanIN), 
precursor lesions (Guerra et al., 2007; Habbe et al., 2008; Kopp et al., 2012). 
Human PanIN lesions also contain both KrasG12D cells and Kras wild-type cells 
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(Kanda et al., 2012), therefore heterotypic cell-cell interactions could occur in 
these lesions. Thus, ductal cultures can provide important information about 
pancreatic heterotypic cell-cell interactions between normal and KrasG12D cells 
that is pertinent to the earliest stages of pancreatic cancer.  
 
5.3.1 Segregation of KrasG12D cells in an EphA2 dependent manner 
  
 Differential EphA2 signalling drives repulsion and segregation of Ras-
transformed MDCK cells from surrounding normal cells (Porazinski et al., 2016). 
To investigate whether KrasG12D pancreatic ductal epithelial cells are also 
segregated; mutant and normal cells were mixed at a ratio of 1:50. This 
generated monolayers of normal cells with clusters of transformed cells at low 
densities; recapitulating the in vivo scenario. Quantification of cell area and the 
Index of Sphericity of a cluster can give an indication of contractility of cells and 
segregation and compactness of clusters (Javaherian et al., 2015; Kippert et al., 
2009). Quantification of mutant clusters demonstrated that KrasG12D cells 
increase in contractility and segregate from normal pancreatic cells. This is 
consistent with previous findings where Ras-transformed cells are repulsed by 
normal neighbours and adopt a contractile morphology (Porazinski et al., 2016). 
Loss of EphA2 in the mutant cell population was sufficient to significantly 
decrease contractility and segregation from surrounding normal cells. 
Furthermore, quantification of KrasG12D cells in vivo indicates that transformed 
acinar cells decrease in volume supporting the hypothesis that mutant cells in 
vivo are becoming contractile. It was also found that KrasG12D PDE cells could be 
extruded from the monolayer in an EphA2-dependent manner consistent with 
previous reports in vitro (Porazinski et al., 2016). Moreover, it supports the 
hypothesis that cell competition is occurring in healthy epithelial tissues to 
remove aberrant cells (Brown et al., 2017; Kon et al., 2017). 
  It is conceivable that extrusion of mutant cells could have a tumour-
suppressive or tumour-promoting role in vivo. Single transformed cells have been 
identified disseminating precursor lesions which can lead to metastasis (Hendley 
et al., 2016; Rhim et al., 2012). With KrasG12D mutant and Kras-wild type cells 
identified in precursor lesions it is conceivable that EphA2 signalling may drive 
extrusion of mutant cells from PanIN lesions. Extrusion of single cells has also 
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been shown to promote mutant cell growth (Leung and Brugge, 2012). Thus, this 
could suggest a tumour-promoting role for competitive interactions with inhibition 
of extrusion potentially inhibiting tumour growth and metastasis. 
 However, heterotypic interactions between KrasG12D cells and normal 
neighbours may also protect against tumour formation. If apical extrusion is 
occurring in vivo it could lead to mutant cells in the pancreatic ductal network. 
Presumably this would expose mutant cells to harsh conditions such as altered 
pH and could be cleared into the intestine and out via the gastrointestinal tract 
(Kon et al., 2017; Saitoh et al., 2017). Although apical extrusion was observed in 
PDE in vitro monolayers the direction of extrusion and effects of potential 
repulsion by normal neighbours within a 3D space of the pancreas tissue is less 
clear and requires further investigation. In summary, this chapter provides 
evidence than competitive interactions with normal cells are driving increased 
compactness of KrasG12D cells both in vitro and in vivo.  
 
5.3.2 Characterisation of EphA2/ephrin and downstream signalling in 
pancreatic cells in vitro 
 
 In order for aberrant cells to be eliminated they must first be detected by 
normal neighbouring cells. We have previously demonstrated that EphA2 is 
autonomously upregulated in Ras-transformed MDCK cell lines which promotes 
detection by normal neighbours (Porazinski et al., 2016). In this study levels of 
EphA2 appear to be higher in KrasG12D cells as observed by elevated levels 
observed between mutant cells surrounded by normal neighbours however, the 
localisation was primarily cytoplasmic when surrounded by normal neighbours or 
KrasG12D cells. Staining of EphA2 in MDCK cells is punctate when plated on 
collagen and membrane localised on glass. Therefore, the punctate EphA2 
staining of pancreatic cells could be a result of plating on top of collagen. 
Importantly, EphA2 levels were depleted in KRE cells indicating a loss of EphA2. 
Moreover, these cells were previously derived from animals with the same 
genetic disruption of EphA2 as KC-Eph mice supporting the in vivo model from 
the chapter 3. 
 As a requirement for EphA2 in KrasG12D cells had been observed for 
segregation from normal cells it was investigated whether the downstream 
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signalling pathway was similar to previous reports (Porazinski et al., 2016). 
Increased levels of phosphorylated Src were observed specifically in KrasG12D 
cells surrounded by normal neighbours supporting the hypothesis that EphA2 
signalling is activated in KrasG12D mutant cells. Although activation of pSrc 
requires further confirmation to confirm the accuracy of antibody staining. 
Moreover, use of stripe assay found that KrasG12D p53R172H mutant PDE cells 
were unable to efficiently migrate over pre-clustered ephrinA1 ligand. Further 
characterisation of ephrin-receptor interaction is required to as KP (KrasG12D 
p53R172H) cells may interact differently to KrasG12Dcells upon collision with 
EphrinA1 stripes. However, EphA2-deficient KrasG12D cells could efficiently 
migrate over stripes of pre-clustered ephrinA1. This suggests EphA2 is functional 
on KrasG12D PDE cells. 
 It was previously observed that levels of phosphorylated myosin light 
chain were elevated in Ras-transformed cell surrounded by normal neighbours 
(Hogan et al., 2009). Also, it was previously found that signalling via myosin-II 
was lost in Ras-transformed cells depleted of EphA2 when collided with normal 
cells (Porazinski et al., 2016), suggesting activation of actomyosin downstream 
of EphA2. In contrast to previous studies, this work found tentative evidence that 
elevated phosphorylated myosin-II was not observed in KrasG12D:normal cell 
interactions. Levels of active myosin-II were lower in KrasG12D cells than non-
transformed neighbours and appeared similar to monolayers of KrasG12D cells. 
This requires further characterisation in the form of a no secondary antibody 
control and staining only with a secondary antibody to check auto-fluorescence 
and non-specific staining respectively. However, this could suggest repulsion and 
cytoskeletal rearrangement in KrasG12D cells by normal neighbours could be 
different in primary pancreatic cells to MDCK cell lines and occurs via another 
pathway. Several other pathways have been associated downstream of EphA2 
to drive repulsion. For example, EphA2 can mediate actin cytoskeletal 
reorganisation via the Rac1/PAK pathway (Deroanne et al., 2003). Moreover, 
mDia1 and mDia3, members of the formin protein family, act downstream of 
EphA4-dependent axon repulsion (Toyoda et al., 2013) and so could also be 
acting downstream of EphA2 in repulsion of KrasG12D cells in primary pancreatic 
cells. Although active myosin-II was not elevated in KrasG12D cells surrounded by 
normal neighbours differential levels of phosphorylated myosin-II were observed 
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between mutant cells and the surrounding neighbours. Myosin-II can generate 
tension within a cell (Franke et al., 2005) and so this could indicate differential 
tension between normal and KrasG12D cells, which is important for cell sorting 
(Brodland, 2002; Krieg et al., 2008). In developing Drosophila a myosin-II cable 
forms at the boundary between different tissues (Monier et al., 2010). Therefore, 
although myosin-II does not appear to act downstream of EphA2 to drive 
repulsion, the contractile ring of myosin-II observed at the boundary between 
normal and KrasG12D cells is indicative of repulsion and segregation of mutant 
cells by normal neighbours. Therefore, further work is required to understand the 
role of myosin-II in KrasG12D pancreatic cells surrounded by normal neighbours. 
 In Eph-ephrin-mediated cell sorting cell-cell adhesion have been shown to 
be important (Steinberg, 2007) and EphA2 can weaken E-cadherin-mediated 
cell-adhesions (Fang et al., 2008). Previous work has demonstrated than 
endocytosis of E-cadherin via Rab-5 GTPase is vital for extrusion (Saitoh et al., 
2017). Moreover, E-cadherin is required within normal cells for extrusion of Ras-
transformed neighbours (Hogan et al., 2009). In PDE cells it was found that E-
cadherin was internalised in an EphA2 dependent manner. This could indicate 
that upon interaction with normal cells, E-cadherin in KrasG12D cells undergoes 
endocytosis by Rab-5 as observed in previous work (Saitoh et al., 2017), which 
is supported by the specific localisation of E-cadherin observed in PDE cells. 
Moreover, Eph-ephrin interactions can lead to adhesive forces between cells 
which must be overcome in order for cellular repulsion to occur. This can either 
occur through metalloproteinase cleavage of ephrin ligand (Hattori et al., 2000) 
or endocytosis of phosphorylated-Eph receptor and ligand into the receptor 
expressing cell (Marston et al., 2003). With EphA2 known to interact with E-
cadherin (Guo et al., 2014; Van Itallie et al., 2014; Zantek et al., 1999), it is 
possible that EphA2 and E-cadherin are endocytosed together which could 
explain the punctate EphA2 staining in mutant cells surrounded by normal 
neighbours. It is worth noting that active Eph signal transduction persists 
following endocytosis (Marston et al., 2003) and so repulsive signals would be 
maintained. In this chapter, EphA2 deficiency in KrasG12D cells was sufficient to 
allow formation of E-cadherin-based cell-cell contacts between normal and 
mutant cells. This is supported by previous studies where EphA2 has been 
demonstrated to drive E-cadherin loss from adherens junctions (Fang et al., 
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2008). Furthermore, staining for E-cadherin in vivo indicated loss of membrane 
E-cadherin between normal and KrasG12D cells suggesting a similar process may 
occur in vivo. Knockdown of E-cadherin in single cells in a normal epithelia has 
been demonstrated to be sufficient to drive extrusion (Vaughen and Igaki, 2016) 
inferring that loss of E-cadherin-based cell-cell contacts is an important step in 
the segregation of KrasG12D cells by normal neighbours. 
 The p120 catenin protein associates with E-cadherin at the cell membrane 
to stabilise E-cadherin, inhibit E-cadherin endocytosis and promote adherens 
junction formation (Ishiyama et al., 2010; Wildenberg et al., 2006). A decrease in 
p120 catenin at the membrane, specifically between KrasG12D and normal PDE 
cells was observed in cell mixing assay, which further supports the hypothesis 
that E-cadherin-based cell-cell contacts are lost at heterotypic cell-cell contacts. 
Loss of p120 catenin has also been shown to promote extrusion of KrasG12D cells 
from pancreatic PanIN lesions (Hendley et al., 2016), which suggests EphA2-
dependent junctional remodelling may occur in PanIN lesions. Moreover, 
extruding cells from PanIN lesions were found to have decreased E-cadherin and 
epithelial-mesenchymal transition (EMT) characteristics. With loss of E-cadherin 
a hallmark of EMT and metastasis (Wheelock et al., 2008), it is conceivable that 
heterotypic KrasG12D:normal cell interactions may promote neoplastic cell 
invasion. Although p120 catenin was internalised in KrasG12D cells surrounded by 
normal neighbours, membrane-localised p120 catenin was observed between 
KrasG12D cells. p120 catenin can bind other cadherins such as P-catenin 
(Albergaria et al., 2011) so could remain at the membrane during E-cadherin 
internalisation. Together, these data suggest that EphA2 is driving extrusion of 
mutant cells which results in loss of E-cadherin-based cell-cell contacts in mutant 
cells surrounded by normal neighbours. 
 The segregation and sorting of different cell populations has been 
extensively studied in development and homeostasis. With several hypotheses 
proposed for the segregation of cells; differential adhesion (Nose et al., 1988; 
Steinberg, 1963), induction of actomyosin contractility (Krieg et al., 2008) and 
Eph-ephrin signalling (Xu et al., 1999) which can alter both cadherin mediated 
adhesion (Hattori et al., 2000) and modulate the actin cytoskeleton (Marston et 
al., 2003). In this study, differences in myosin-II activity and a loss of E-cadherin-
based cell-cell contacts, which could imply differential tension and adhesion 
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between normal and mutant cells, respectively. Therefore, differential tension 
and adhesion could be leading to the observed segregation of mutant cells 
surrounded by normal neighbours. Loss of EphA2 in mutant cells resulted in a 
loss of contractile morphology when surrounded by normal neighbours and 
retention of transformed cells within normal monolayers. However, a smooth 
boundary was still observed at the interface of normal and mutant cells. This 
could suggest that repulsion of KrasG12D cells occurs via EphA2 but that other 
mechanisms contribute to segregation of mutant by normal pancreatic cells. 
Further characterisation of active myosin-II and use of the myosin-II inhibitor 
blebbistatin would further elucidate the segregation of EphA2-deficient Krasg12D 
cells by normal neighbours. In summary, the repulsion of KrasG12D mutant cells 
by normal neighbours occurs via an EphA2-dependent mechanism, resulting in 
loss of E-cadherin-based cell-cell contacts.  
  
5.4 Summary and Future Directions. 
 
Using the pancreatic ductal epithelial model in this chapter has further elucidated 
the mechanism of heterotypic cell-cell interaction between KrasG12D cells and 
normal neighbours at the level of the single cell. In summary, several conclusions 
can be made from the data presented in this chapter. Firstly, that KrasG12D cells 
segregate and are repulsed by normal neighbours which can result in extrusion. 
Secondly, that EphA2 is elevated in mutant cells and required for repulsion and 
extrusion. Finally, EphA2-dependent repulsion results in loss of E-cadherin-
based cell-cell contacts but does not appear to involve phosphorylated myosin-II 
in mutant cells. 
 Taken together, and in combination with previously published data, these 
results suggest that segregation of KrasG12D cells via EphA2 signalling could lead 
to the elimination of mutant cells. This raises several interesting questions 
regarding the maintenance of homeostasis in the pancreas by removal of 
aberrant cells. 
 Segregation or compacting of cells can have a variety of effects on a cell. 
In this chapter and other studies the contractile force is sufficient to drive 
extrusion of mutant cells (Hogan et al., 2009; Kon et al., 2017). The effect of this 
in vivo is still unclear; apical extrusion exposes cells to typically harsh 
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environments such as urine or digestive fluids and is in the opposite direction 
from metastasis and so could be considered cancer-preventative. Although the 
pathological consequences of apical extrusion are controversial (Leung and 
Brugge, 2012; Makohon-Moore et al., 2018) and heterotypic cell-cell interaction 
can also drive basal extrusion (Hogan et al., 2009). To address this issue, the 
fate of eliminated cells needs to be studied in vivo. Analysis of 3D reconstructions 
at later time points may identify extrusion events in vivo and provide information 
on the fate of transformed cells. This could also be carried out in EphA2-deficient 
animals to confirm that increased contractility of KrasG12D cells in vivo is occurring 
in an EphA2-dependent manner. This would support the hypothesis that EphA2-
deficieny is leading to retention of mutant cells by removing EphA2 dependent 
repulsion between normal and mutant cells. Furthermore, if extrusion of KrasG12D 
cells is promoting metastasis, analysis of the liver, the primary site of metastasis, 
or searching for circulating cancer cells using FACS for RFP cells could further 
elucidate this. 
 It is also important to further characterise the signalling cascade in vitro. 
The work in this chapter suggests that pSrc is activated and E-cadherin is 
internalised upon interaction of KrasG12D and normal cells in an EphA2 dependent 
manner. It has previously been demonstrated that pSrc is downstream of EphA2 
signalling (Porazinski et al., 2016), and that E-cadherin endocytosis plays an 
active role in apical extrusion of transformed cells (Saitoh et al., 2017). The 
requirement of these signals for extrusion in this system could be investigated 
with the use of pharmacological inhibitors of endocytosis such as chlorpromazine 
(Dutta and Donaldson, 2012; Saitoh et al., 2017). Analysis of pSrc in EphA2-
deficient KrasG12D cells could also confirm that SFK signalling is activated 
downstream of EphA2 as in previous work (Porazinski et al., 2016). With 
inhibition of pSrc shown to decrease Ras repulsion (Porazinski et al., 2016) and 
the extrusion of Src-transformed cells by non-transformed neighbours, inhibition 
of pSrc could further elucidate the molecular mechanism underlying EphA2-
dependent extrusion.  
 The contractility of a cell is regulated by the actin-myosin cytoskeleton 
which in turn are dynamically controlled by Rho-family GTPases (Lawson et al., 
2017). Further work could investigate whether Rho GTPases are important for 
the contractility observed in KrasG12D cells surrounded by normal neighbours. 
 164 
The role of Rho-family GTPases could be further elucidated using an active 
Rho pull-down. Furthermore, the addition of inhibitors would test the 
requirement of Rho-family GTPases in mutant cell contractility. This would 
further elucidate the molecular mechanism of repulsion of KrasG12D pancreatic 
cells by normal neighbours. 
 Intriguingly this work infers that endocytosis of E-cadherin and potentially 
EphA2 is occurring in Ras-transformed cells. EphA2 endocytosis is necessary to 
overcome the adhesive properties of Eph-ephrin interactions required for cell 
repulsion (Marston et al., 2003; Zimmer et al., 2003). As EphA2 can interact and 
localise with E-cadherin (Guo et al., 2014; Van Itallie et al., 2014) and 
internalisation of E-cadherin was observed it could infer that both are 
endocytosed. This could be explored further by investigating early endosome 
markers such as EEA1 (Simonsen et al., 1998). Caveolin-1 has also been 
involved in the internalisation of EphA2 (Vihanto et al., 2006). As caveolin-1 has 
been demonstrated to be required for Ras-transformed cell competition and 
extrusion (Kadeer et al., 2017; Ohoka et al., 2015), this could link EphA2 and 
other cell competition mechanisms. Further elucidation of the implications of E-
cadherin internalisation will improve our understanding of EphA2-dependent 
KrasG12D cell extrusion and may link EphA2 to other regulators of cell competition 
(Kadeer et al., 2017; Kajita et al., 2014; Ohoka et al., 2015). 
 Eph-ephrin signalling has been well characterised in other tissues such as 
intestine (Batlle et al., 2002) where EphB/EphrinB signalling mediates cell 
positioning. Understanding Eph-ephrin signalling in pancreas homeostasis may 
provide further understanding of how this signal is altered in disease. To this end 
functional characterisation of Eph and ephrin family members could begin with 
generating an expression profile for the different cell types within the pancreas. 
Indeed, little is known about the role of EphA2 except in pancreas development 
(Park et al., 2013). Thus, understanding the role of EphA2 in pancreas 
homeostasis may help elucidate how signalling changes upon emergence of 
KrasG12D transformed cell within a normal pancreatic epithelium.  
 In vitro cell culture systems are an invaluable tool for understanding cell 
biology and to characterise the underlying mechanisms of disease. However, 2D 
cell cultures can differ from the in vivo situation in a number of different ways, for 
example tissue culture conditions can select for clones that no longer model the 
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primary tumour (Boj et al., 2015; Lee et al., 2006). Moreover, 2D systems do not 
accurately recapitulate the complexity and organisation of a tissue with 
interactions limited between cells to only side-by-side contact which can alter cell 
morphology and adherens junctions (Soares et al., 2012). Recently, primary 
organoid models have been established for normal and neoplastic murine and 
human pancreatic tissue (Boj et al., 2015). Therefore, investigating heterotypic 
cell-cell interactions in normal human pancreatic tissue that is amenable to 
genetic manipulation could provide new insight into these processes and their 
relevance to human disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 166 
Chapter 6 General Discussion 
 
At the initial stages of carcinogenesis, mutant cells emerge within an epithelial 
layer. Competitive interactions between normal and transformed cells can lead 
to the elimination of mutant cells from the epithelium to protect from 
carcinogenesis (Alcolea et al., 2014; Hogan et al., 2009; Kon et al., 2017; Norman 
et al., 2012; Wagstaff et al., 2016). Strikingly, oncogenic cells such as Ras-
transformed cells can be eliminated by normal neighbours (Hogan et al., 2009; 
Kajita et al., 2014). In pancreatic ductal adenocarcinoma KrasG12D mutations are 
considered the initial transformation and are sufficient to drive malignant disease 
(Collins et al., 2012; Habbe et al., 2008; Hingorani et al., 2003). Although 
KrasG12D expressing cells (KrasG12D cells) initiate and drive the earliest stages of 
pancreatic cancer it is unclear if normal pancreatic cells can eliminate oncogenic 
cells. In this study, I have used low level, stochastic induction of KrasG12D 
mutation in vivo to model these interactions. I found that Ras-transformed cells 
adopt a contractile morphology and are eliminated from healthy tissue when 
present at low numbers. Using in vitro co-cultures, KrasG12D cells surrounded by 
normal neighbours become segregated, increase in compactness and are often 
extruded. I find that E-cadherin-based cell-cell contacts are downregulated and 
internalised in mutant cells when surrounded by normal neighbours in an EphA2-
dependent manner. Our evidence also suggests that normal cells suppress 
progression of Ras-transformed cells to an early disease state. Together, this 
study suggests that non-transformed pancreatic epithelial cells can eliminate 
KrasG12D cells from the tissue via EphA2 signalling (Figure 6.1). These data 
identify a novel putative tumour-suppressive mechanism in the adult pancreas 
that mutant cells must first overcome to drive tumourigenesis. Understanding the 
fate of eliminated cells and how cells are retained will further elucidate the role of 
cell competition in pancreatic cancer.   Moreover, this may provide insight into 
how risk factors promote disease and how pancreatic cancer spreads around the 
body. 
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Figure 6.1 Proposed mechanism of KrasG12D cell elimination from the pancreas. 
Upon mutational activation of Kras the altered cell is recognised by normal 
neighbours via EphA2 signalling. This leads to loss of cell-cell contacts (pink) and 
elimination of mutant cells. Retention and proliferation of the transformed cell will 
then lead to disease initiation. 
 168 
6.1 Extrusion of KrasG12D  cells via EphA2 signalling triggered 
by normal neighbours 
 
How mutant cells are identified by normal neighbours and how they trigger 
competitive interactions is an area of ongoing research. A growing body of work 
suggests a positive role for cell repulsion signals that classically have a role in 
axon guidance, have been identified in cell competition. For example, Slit-Robo2 
signalling drives extrusion of polarity deficient cells (Vaughen and Igaki, 2016), 
and we have identified EphA2 signalling as a mechanism of Ras-transformed cell 
repulsion and extrusion (Porazinski et al., 2016). Eph receptor tyrosine kinases 
regulate cell position by imposing repulsive signals and modulating adhesion 
between cells (Marston et al., 2003; Shamah et al., 2001). In pancreatic cancer, 
EphA2 is associated with early PanIN lesions and pre-mestastatic tumours 
(Mudali et al., 2006). In this thesis, I found that EphA2 is required for the detection 
and repulsion of KrasG12D cells from the pancreas. As KrasG12D cells were not 
triggered to become contractile by other Kras-transformed cells this suggests a 
requirement for normal neighbours to initiate repulsion via heterotypic 
interactions possibly via EphrinA1 ligand on non-transformed neighbours 
(Porazinski et al., 2016).  
 Using primary co-culture experiments an EphA2 dependent increase in 
cell contractility occurred in KrasG12D pancreatic cells when surrounded by 
normal neighbours. This work also indicated the possible upregulation of active 
Src as observed previously in MDCK cell cultures (Porazinski et al., 2016). 
Activation of Src can promote tumour invasion and metastasis by destabilisation 
of epithelial cell-cell junctions. This occurs via direct phosphorylation of E-
cadherin which promotes internalisation (Behrens et al., 1993; Lilien et al., 2005; 
Yap et al., 1998). Importantly, I found that E-cadherin was internalised in an 
EphA2 dependent manner specifically in KrasG12D cells surrounded by normal 
neighbours. This suggests activation of EphA2 is the initial event which triggers 
internalisation of E-cadherin possibly via Src activation. Src activation can also 
lead to RhoA GTPase activation which can disrupt adherens junctions via ROCK 
(Fang et al., 2008; Wójciak-Stothard et al., 2001). Finally, Eph receptor activation 
can lead to Rac1-dependent endocytosis of E-cadherin (Akhtar and Hotchin, 
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2001; Marston et al., 2003). Therefore, several possible mechanisms 
downstream of EphA2 could promote the loss of E-cadherin-based junctions. 
Figure 6.2 provides a summary of the proposed mechanisms by which EphA2 
could be regulating the internalisation of E-cadherin. The co-culture technique 
developed in this thesis in combination with specific inhibitors could be used in 
future studies to further elucidate the mechanism of KrasG12D cell extrusion and 
loss of E-cadherin via EphA2. It is important to understand the underlying 
mechanism as it could improve our understanding of how extrusion is overcome 
in vivo to promote pancreatic tumourigenesis. 
 In order for cells to be extruded they must lose contact with neighbouring 
cells. Using co-culture assays in vitro and mosaic expression of KrasG12D in vivo 
models I found evidence for the loss of E-cadherin in KrasG12D cells upon 
interaction with normal neighbours. Intriguingly, loss of E-cadherin can promote 
metastasis and is a key hallmark of epithelial-mesenchymal transition (Cano et 
al., 2000; Onder et al., 2008). Thus, it could be hypothesised that repulsion of 
KrasG12D cells by normal neighbours is promoting a metastatic phenotype in 
transformed cells. Future studies could test if extruded KrasG12D cells are more 
invasive than KrasG12D cells cultured next to KrasG12D cells. Although extrusion 
was not directly observed in vivo, analysis of further intermediate time points 
could capture pancreatic cells extruding. Another important implication in the loss 
of E-cadherin-based cell-cell junctions is the loss of cell polarity. Epithelial tissues 
display apical-basal polarity which is organised by polarity complexes physically 
associated with cell junction architecture. Consequently, loss of epithelial 
junctions confers a loss of polarity. This could be important for the direction of 
extrusion with loss of polarity potentially able to alter where oncogenic cells are 
extruded (Slattum & Rosenblatt, 2014). Apically extruded cells would be extruded 
in the lumen and could cleared through the ductal system (Kon et al., 2017), 
whereas basally extruded cells could invade and enter the circulation. 
Intriguingly, circulating tumour cells have been found in genetically engineered 
mouse models of pancreatic cancer circulating before primary tumours (Rhim et 
al., 2012). Moreover, pancreatic cancer is rarely diagnosed in humans without 
metastasis suggesting these tumours spread early (Das & Batra, 2015). Although 
I screened livers for RFP, robust RFP fluorescence was not detected in 
KrasG12D mice. This could be due to detection of RFP in the liver and future 
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experiments would need to stain for the pancreatic specific marker Pdx1. Another 
hypothesis is that cells require additional oncogenic transformations such as loss 
of p53 to promote survival after extrusion (Rhim et al., 2012). Recently, genetic 
analysis has demonstrated that spatially distal lesions share a common ancestral 
cell of origin suggesting precancerous cells spread and colonise the pancreas 
via the ductal network (Makohon-Moore et al., 2018). In 4/8 patients, a precursor 
cell had obtained one or two mutations to driver oncogenes such as Kras and 
spread through the pancreas to produce additional neoplastic lesions. Therefore, 
extrusion of KrasG12D cells by normal neighbours could drive the invasion and 
metastasis of pancreatic cancer from the earliest stages of tumourigenesis. 
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Figure 6.2: Proposed molecular mechanism of KrasG12D cell elimination from 
the pancreas. In KrasG12D mutant cells, EphA2 interacts with EphrinA1 on normal 
neighbouring cells which leads to activation of Src. Once active, Src can directly 
promote E-cadherin internalisation by phosphorylation and also activates RhoA 
GTPase. RhoA can activate ROCK which promotes E-cadherin internalisation. It 
has also been demonstrated that ROCK leads to Myosin-II activation and 
cytoskeletal rearrangements driving increased contractility. EphA2 can also activate 
another GTPase, Rac1, which can disrupt cell-cell contacts through endocytosis of 
E-cadherin. In summary, activation of EphA2 in KrasG12D cells by normal 
neighbours could trigger repulsion and loss of cell-cell contacts via activation of 
Rho GTPases and Src. Together, this promotes extrusion of mutant cells from 
normal pancreatic monolayers. Blue arrows indicate published studies and red 
arrows the findings of this thesis. 
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6.2 Evidence of a Cell community effect in pancreatic acinar 
cells 
 
In order to act efficiently cells are required to act in a coordinated manner to 
maintain homeostasis. Epithelial tissues are a tightly regulated system that must 
finely balance proliferation and cell turnover (Macara et al., 2014). It has long 
been established that cells acts as a coherent unit (Gurdon et al., 1993; Ho, 
1992). In the pancreas, there is evidence that wild type cells promote a 
differentiated state of surrounding mis-specified cells and inhibit acinar ductal 
metaplasia (ADM) (Krah et al., 2015). Yet how a cellular community reacts when 
a KrasG12D cell emerges is unclear. It has been proposed that single oncogenic 
cells must escape via extrusion from this tightly regulated system in order to 
proliferate (Leung and Brugge, 2012; Sasaki et al., 2018). From this and other 
work I hypothesised that sporadic expression of KrasG12D would be 
phenotypically silent when surrounded by normal neighbours but upon extrusion 
mutant cells could proliferate and undergo ADM (Dolberg and Bissell, 1984; 
Jonason et al., 1996; Leung and Brugge, 2012; Martincorena et al., 2015). With 
the limitations of examining single cell evolution in vivo, an acinar 3D culture 
system was used that recapitulates the organisation of the pancreas but in a 
tractable system. This allowed investigation of the fate of eliminated cells in vivo 
and testing of whether elimination promotes or suppreses disease. However, 
although KrasG12D cells appeared to adopt a contractile morphology and 
undergo cytoskeletal rearrangement when surrounded by non-transformed 
neighbours, elimination of mutant cells via extrusion was not apparent. This could 
be for several reasons; acinar cell culture is not robust with alterations to cell-cell 
junctions and cellular signalling such as calcium signalling known to be altered 
after 6 hours in culture (Amsterdam and Jamieson, 1974; Marciniak et al., 2013; 
Orabi et al., 2013). Therefore, further optimisation of acinar cell culture may be 
required in order to allow extrusion of mutant cells. This ruled out the possibility 
to investigate the progression of extruded KrasG12D cells through acinar-ductal 
metaplasia (ADM) or proliferation. Nonetheless, the effects of normal neighbours 
on Ras-transformed cells progressing through ADM could be investigated. It was 
found that small numbers of KrasG12D cells were suppressed from forming a 
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duct-like cyst in clusters of non-transformed cells. This supports the theory that 
expression of oncogenic mutations are not sufficient to predict the fate of 
sporadic aberrant cells (Dolberg and Bissell, 1984; Jonason et al., 1996; Leung 
and Brugge, 2012; Martincorena et al., 2015). However, single KrasG12D cells 
autonomously reprogrammed and expressed Sox9 when surrounded by normal 
neighbours (Zhou et al., 2018). This could suggest that normal neighbours slow 
the progression of ADM as Sox9 can be expressed in morphologically normal 
acinar cells before progression to a duct-like cyst in vivo (Kopp et al., 2012). 
Analysis of clusters with a high proportion of mutant cells demonstrated that 
clusters of acinar cells containing > 60% KrasG12D cells were able to overcome 
this inhibitory effect and efficiently progressed through ADM. Strikingly, in 
clusters with a large number of Ras-transformed cells, wild type cells were 
induced to progress through ADM, suggesting community effect with clusters of 
cells acting as a coherent unit (Gurdon et al., 1993). As non-transformed cells 
are known to make up a proportion of cells in human pancreatic intraepithelial 
neoplasia (PanIN) lesions (Kanda et al., 2012), this could suggest that mutant 
cells are recruiting normal neighbours at the earliest stages of pancreatic cancer. 
Future work could examine lesions containing Kras wild-type cells in vivo to 
investigate whether the presence of wild-type cells alters the fate of precursor 
lesions. 
 
 
6.3 Future Directions 
  
 Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a 5-
year survival rate of <5%. Over 80% of patients present with advanced, 
metastatic PDAC at diagnosis, ruling out surgical intervention. Current diagnostic 
techniques are expensive and invasive with no established screening technique 
demonstrated to be specific or sensitive enough to distinguish cancer from non-
cancer related disease. An understanding of the biology of disease initiation and 
progression is imperative to developing effective screening and diagnostic 
techniques (Ying et al., 2016). Moreover, further elucidation of how disease 
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develops and spread could identify novel targets for therapeutics and improve 
our understanding of how risk factors promote PDAC. 
 This study found supporting evidence that the pancreas epithelium has an 
intrinsic ability to eliminate KrasG12D mutant cells, similar to other systems 
(Brown et al., 2017; Hogan et al., 2009; Kon et al., 2017). Yet, virtually all PDAC 
tumours have KrasG12D mutations (Biankin et al., 2012). If elimination of Ras-
transformed cells is tumour suppressive it follows that there are mechanisms 
which overcome this process to permit disease initiation. The biggest risk factor 
for pancreatic cancer is age although the link between age and cancer risk not 
clear (Bosetti et al., 2014; Raimondi et al., 2009; Siegel et al., 2016). It has been 
demonstrated that the mechanical properties of tissue can change during aging 
(Phillip et al., 2015). With increasing stiffness strongly correlated with older 
epithelial cells in vitro and remodelling of the ECM observed in elderly individuals 
(Berdyyeva et al., 2005; Labat-Robert, 2004). Therefore, the intrinsic properties 
of normal epithelial cells or the surrounding microenvironment may reduce the 
efficiency of eliminating mutant neighbours. Altering the stiffness of the collagen 
matrix in vitro could further elucidate these changes; with matrix stiffness 
demonstrated to alter cell adhesive properties (Pelham & Wang, 1997) and could 
be studied by investigating cell competition in aged mice.  
 Obesity is a major risk factor for pancreatic cancer and has been 
increasing worldwide (Afshin 2012). Obesity can alter lipid metabolism, hormone 
secretion and induce chronic inflammation but it is unclear how obesity is 
involved in tumour initiation (Gonzalez-Muniesa 2017; Heymsfield and Wadden 
2017; Kopelman 2000; Rosenbaum 1997). Recently, evidence has suggested 
that obesity can suppress Ras-transformed cell extrusion from epithelial tissues 
(Sasaki et al., 2018). To further elucidate how obesity affects cell competition and 
disease initiation a high-fat diet in combination with this model could be used.   
 Another important risk factor for pancreatic cancer is pancreatitis 
(Freelove and Walling, 2006). Pancreatitis promotes an inflammatory state and 
it has been suggested that chronic inflammation inhibits the extrusion of Ras-
transformed cells in the intestine and pancreas (Sasaki et al., 2018). To better 
understand the relevance to disease initiation mosaic expression of KrasG12D 
could be combined with caerulein administration which recapitulates many 
aspects of pancreatitis (Niederau et al., 1985). It has also been reported that 
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pancreatitis results in a breakdown of adherens junctions so the segregation of 
mutant cells via internalisation E-cadherin may be altered (Lerch et al., 1997). 
Understanding how risk factors alter mutant cell elimination may help stratify 
patients and help inform diagnostic decisions and could be used to compliment 
developing diagnostic techniques. As if extrusion is a tumour suppressive 
mechanism this would suggest that identifying KrasG12D cells or oncogenic DNA 
in the circulatory system is a normal protective mechanism. 
 Extrusion of Ras-transformed cells was first observed using MDCK cell 
culture systems as a model of epithelial biology (Hogan et al., 2009). Evidence 
for extrusion was then identified in intestinal crypts (Kon et al., 2016), breast 
epithelia (Leung and Brugge, 2012) and more recently from CK19+ cells in the 
pancreas and lung (Sasuki et al., 2018). The work present here provides 
evidence for the elimination of KrasG12D cells from the pancreas building on 
previous cell competition studies using Hras (Kon et al., 2017; Saitoh et al., 
2017). It therefore could be hypothesised that extrusion is a general epithelial 
biological process in response to constitutive activation of RAS/MAPK pathway. 
Understanding the impact of extrusion on Ras-transformed cells from epithelial 
tissues in the body could provide insight into the earliest stages of multiple 
different cancer types. This could potentially also expand to malignancies not 
typically associated with Ras mutations such as breast cancer. Ras is negatively 
regulated by Ras GTPase-activating proteins (RasGAPs) that catalyse the 
hydrolysis of Ras-GTP to the inactivate Ras-GDP form. As such, RasGAPs are 
poised to function as tumour suppressors. Indeed, The RasGAP Nf1 is lost or 
suppressed in sporadic cancers such as glioblastoma (McGillicuddy et al., 2009; 
Williams Parsons et al., 2008), non-small cell lung cancer (Ding et al., 2008) 
neuroblastoma (Hölzel, 2010) and melanoma (Maertens et al., 2013). Moreover, 
the RAS/MAPK pathway is hyperactivated in >50% of breast cancers (von Lintig 
et al., 2000; Mueller et al., 2000; Sivaraman et al., 1997). With the RasGAP 
RASAL2 demonstrated to have a causal role in breast cancer development 
(McLaughlin et al., 2013). Therefore, extrusion could be happening in a wide 
range of epithelial cancers. 
 
 
 
 176 
List of References 
 
Abercrombie, M., and Heaysman, J.E.M. (1954). Observations on the social 
behaviour of cells in tissue culture. II. “Monolayering” of fibroblasts. Exp. Cell 
Res. 6, 293–306. 
 
Agrawal, N., Kango, M., Mishra, A., and Sinha, P. (1995). Neoplastic 
Transformation and Aberrant Cell–Cell Interactions in Genetic Mosaics of 
lethal(2)giant larvae (lgl),a Tumor Suppressor Gene of Drosophila. Dev. Biol. 
172, 218–229. 
 
Von Ahrens, D., Bhagat, T.D., Nagrath, D., Maitra, A., and Verma, A. (2017). 
The role of stromal cancer-associated fibroblasts in pancreatic cancer. J. 
Hematol. Oncol. 10. 
 
Akhtar, N., and Hotchin, N.A. (2001). RAC1 Regulates Adherens Junctions 
through Endocytosis of E-Cadherin. Mol. Biol. Cell. 
 
Albergaria, A., Ribeiro, A.S., Vieira, A.F., Sousa, B., Nobre, A.R., Seruca, R., 
Schmitt, F., and Paredes, J. (2011). P-cadherin role in normal breast 
development and cancer. Int. J. Dev. Biol. 
 
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2002). 
Molecular Biology of the Cell. 
 
Alcolea, M.P., and Jones, P.H. (2015). Cell competition: Winning out by losing 
notch. Cell Cycle 14, 9–17. 
 
Alcolea, M.P., Greulich, P., Wabik, A., Frede, J., Simons, B.D., and Jones, P.H. 
(2014). Differentiation imbalance in single oesophageal progenitor cells causes 
clonal immortalization and field change. Nat. Cell Biol. 16, 612–619. 
 
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, 
M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-
K-ras genes. Cell 53, 549–554. 
 
Amato, K.R., Wang, S., Tan, L., Hastings, A.K., Song, W., Lovly, C.M., Meador, 
C.B., Ye, F., Lu, P., Balko, J.M., et al. (2016). EPHA2 blockade overcomes 
acquired resistance to EGFR kinase inhibitors in lung cancer. Cancer Res. 76, 
305–318. 
 
Amoyel, M., Bach, E.A., Abrams, J.M., Abrams, J.M., White, K., Fessler, L.I., 
Steller, H., Agrawal, N., Kango, M., Mishra, A., et al. (2014). Cell competition: 
how to eliminate your neighbours. Development 141, 988–1000. 
 
Amsterdam, A., and Jamieson, J.D. (1974). Studies on dispersed pancreatic 
exocrine cells: I. dissociation technique and morphologic characteristics of 
separated cells. J. Cell Biol. 63, 1037–1056. 
 
 177 
Andres, A.C., Reid, H.H., Zurcher, G., Blaschke, R.J., Albrecht, D., and 
Ziemiecki, A. (1994). Expression of two novel eph-related receptor protein 
tyrosine kinases in mammary gland development and carcinogenesis. 
Oncogene 9, 1461–1467. 
 
Anton, K.A., Kajita, M., Narumi, R., Fujita, Y., and Tada, M. (2018). Src-
transformed cells hijack mitosis to extrude from the epithelium. BioRxiv 246199. 
 
Apodaca, G., Gallo, L.I., and Bryant, D.M. (2012). Role of membrane traffic in 
the generation of epithelial cell asymmetry. Nat. Cell Biol. 14, 1235–1243. 
 
Ardito, C.M., Grüner, B.M., Takeuchi, K.K., Lubeseder-Martellato, C., 
Teichmann, N., Mazur, P.K., DelGiorno, K.E., Carpenter, E.S., Halbrook, C.J., 
Hall, J.C., et al. (2012). EGF Receptor Is Required for KRAS-Induced 
Pancreatic Tumorigenesis. Cancer Cell 22, 304–317. 
 
Arvanitis, D., and Davy, A. (2008). Eph/ephrin signaling: Networks. Genes Dev. 
22, 416–429. 
 
Astin, J.W., Batson, J., Kadir, S., Charlet, J., Persad, R.A., Gillatt, D., Oxley, 
J.D., and Nobes, C.D. (2010). Competition amongst Eph receptors regulates 
contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat. 
Cell Biol. 12, 1194–1204. 
 
Avila, J.L., Troutman, S., Durham, A., and Kissil, J.L. (2012). Notch1 Is Not 
Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic 
Ductal Adenocarcinoma. PLoS One 7, e52133. 
 
Baer, R., Cintas, C., Dufresne, M., Cassant-Sourdy, S., Schönhuber, N., 
Planque, L., Lulka, H., Couderc, B., Bousquet, C., Garmy-Susini, B., et al. 
(2014). Pancreatic cell plasticity and cancer initiation induced by oncogenic 
Kras is completely dependent on wild-type PI 3-kinase p110α. Genes Dev. 28, 
2621–2635. 
 
Bailey, J.M., Hendley, A.M., Lafaro, K.J., Pruski, M.A., Jones, N.C., Alsina, J., 
Younes, M., Maitra, A., McAllister, F., Iacobuzio-Donahue, C.A., et al. (2016). 
P53 mutations cooperate with oncogenic Kras to promote adenocarcinoma 
from pancreatic ductal cells. Oncogene 35, 4282–4288. 
 
Baker, A.M., Huang, W., Wang, X.M.M., Jansen, M., Ma, X.J., Kim, J., 
Anderson, C.M., Wu, X., Pan, L., Su, N., et al. (2017). Robust RNA-based in 
situ mutation detection delineates colorectal cancer subclonal evolution. Nat. 
Commun. 8. 
 
Ballesteros-Arias, L., Saavedra, V., and Morata, G. (2014). Cell competition 
may function either as tumour-suppressing or as tumour-stimulating factor in 
Drosophila. Oncogene 33, 4377–4384. 
 
Bar-Sagi, D. (2001). A Ras by any other name. Mol. Cell. Biol. 21, 1441–1443. 
 178 
Bardeesy, N., and DePinho, R.A. (2002). Pancreatic cancer biology and 
genetics. Nat. Rev. Cancer 2, 897–909. 
 
Barreto, S.G., Carati, C.J., Toouli, J., and Saccone, G.T.P. (2010). The islet-
acinar axis of the pancreas: more than just insulin. Am. J. Physiol. Gastrointest. 
Liver Physiol. 299, 10–22. 
 
Barrios, A., Poole, R.J., Durbin, L., Brennan, C., Holder, N., and Wilson, S.W. 
(2003). Eph/Ephrin signaling regulates the mesenchymal-to-epithelial transition 
of the paraxial mesoderm during somite morphogenesis. Curr. Biol. 13, 1571–
1582. 
 
Batlle, E., and Wilkinson, D.G. (2012). Molecular mechanisms of cell 
segregation and boundary formation in development and tumorigenesis. Cold 
Spring Harb. Perspect. Biol. 4, 1 
 
Batlle, E., Henderson, J.T., Beghtel, H., Van den Born, M.M.W., Sancho, E., 
Huls, G., Meeldijk, J., Robertson, J., Van de Wetering, M., Pawson, T., et al. 
(2002). β-catenin and TCF mediate cell positioning in the intestinal epithelium 
by controlling the expression of EphB/EphrinB. Cell 111, 251–263. 
 
Batlle, E., Bacani, J., Begthel, H., Jonkeer, S., Gregorieff, A., Van De Born, M., 
Malats, N., Sancho, E., Boon, E., Pawson, T., et al. (2005). EphB receptor 
activity suppresses colorectal cancer progression. Nature 435, 1126–1130. 
 
Becker, A.E., Hernandez, Y.G., Frucht, H., and Lucas, A.L. (2014). Pancreatic 
ductal adenocarcinoma: Risk factors, screening, and early detection. World J. 
Gastroenterol. 20, 11182–11198. 
 
Behrens, G., Jochem, C., Schmid, D., Keimling, M., Ricci, C., and Leitzmann, 
M.F. (2015). Physical activity and risk of pancreatic cancer: a systematic review 
and meta-analysis. Eur. J. Epidemiol. 30, 279–298. 
 
Berdyyeva, T.K., Woodworth, C.D., and Sokolov, I. (2005). Human epithelial 
cells increase their rigidity with ageing in vitro: Direct measurements. Phys. 
Med. Biol. 50, 81. 
 
Berndt, J.D., Clay, M.R., Langenberg, T., and Halloran, M.C. (2008). Rho-
kinase and myosin II affect dynamic neural crest cell behaviors during epithelial 
to mesenchymal transition in vivo. Dev. Biol. 324, 236–244. 
 
Biankin, A. V., Waddell, N., Kassahn, K.S., Gingras, M.C., Muthuswamy, L.B., 
Johns, A.L., Miller, D.K., Wilson, P.J., Patch, A.M., Wu, J., et al. (2012). 
Pancreatic cancer genomes reveal aberrations in axon guidance pathway 
genes. Nature 491, 399–405. 
 
Bielmeier, C., Alt, S., Weichselberger, V., La Fortezza, M., Harz, H., Jülicher, 
F., Salbreux, G., and Classen, A.-K. (2016). Interface Contractility between 
Differently Fated Cells Drives Cell Elimination and Cyst Formation. Curr. Biol. 
26, 563–574. 
 179 
 
Böhni, R., Riesgo-Escovar, J., Oldham, S., Brogiolo, W., Stocker, H., Andruss, 
B.F., Beckingham, K., and Hafen, E. (1999). Autonomous control of cell and 
organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4. Cell 97, 
865–875. 
 
Boissier, P., Chen, J., and Huynh-Do, U. (2013). Epha2 signaling following 
endocytosis: Role of tiam1. Traffic 14, 1255–1271. 
 
Boj, S.F., Hwang, C. Il, Baker, L.A., Chio, I.I.C., Engle, D.D., Corbo, V., Jager, 
M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. (2015). Organoid models 
of human and mouse ductal pancreatic cancer. Cell. 160, 324-338. 
 
Bolouri, H., and Davidson, E.H. (2010). The gene regulatory network basis of 
the “community effect,” and analysis of a sea urchin embryo example. Dev. 
Biol. 340, 170-178. 
 
Bondar, T., and Medzhitov, R. (2010). p53-Mediated Hematopoietic Stem and 
Progenitor Cell Competition. Cell Stem Cell 6, 309–322. 
 
Bonnans, C., Chou, J., and Werb, Z. (2014). Remodelling the extracellular 
matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15, 786–801. 
 
Bosetti, C., Bertuccio, P., Negri, E., La Vecchia, C., Zeegers, M.P., and 
Boffetta, P. (2012). Pancreatic cancer: Overview of descriptive epidemiology. 
Mol. Carcinog. 51, 3–13. 
 
Bosetti, C., Rosato, V., Li, D., Silverman, D., Petersen, G.M., Bracci, P.M., 
Neale, R.E., Muscat, J., Anderson, K., Gallinger, S., et al. (2014). Diabetes, 
antidiabetic medications, and pancreatic cancer risk: an analysis from the 
International Pancreatic Cancer Case-Control Consortium. Ann. Oncol. 25, 
2065–2072. 
 
Bove, A., Gradeci, D., Fujita, Y., Banerjee, S., Charras, G., and Lowe, A.R. 
(2017). Local cellular neighbourhood controls proliferation in cell competition. 
Mol. Biol. Cell. 28, 3215-3228 
 
Bowling, S., Gregorio, A., Sancho, M., Pozzi, S., Aarts, M., Signore, M., 
Schneider, M., Barbera, J.P.M., Gil, J., and Rodríguez, T.A. (2018). P53 and 
mTOR signalling determine fitness selection through cell competition during 
early mouse embryonic development. Nat. Commun. 9, 1763. 
 
Braakhuis, B.J.M., Tabor, M.P., Kummer, J.A., Leemans, C.R., and Brakenhoff, 
R.H. (2003). A genetic explanation of slaughter’s concept of field cancerization: 
Evidence and clinical implications. Cancer Res. 63, 1727–1730. 
 
Brantley-Sieders, D.M. (2004). EphA2 receptor tyrosine kinase regulates 
endothelial cell migration and vascular assembly through phosphoinositide 3-
kinase-mediated Rac1 GTPase activation. J. Cell Sci. 117, 2037–2049. 
 
 180 
Brantley-Sieders, D.M., Zhuang, G., Hicks, D., Wei, B.F., Hwang, Y., Cates, 
J.M.M., Coffman, K., Jackson, D., Bruckheimer, E., Muraoka-Cook, R.S., et al. 
(2008). The receptor tyrosine kinase EphA2 promotes mammary 
adenocarcinoma tumorigenesis and metastatic progression in mice by 
amplifying ErbB2 signaling. J. Clin. Invest. 118, 64–78. 
 
Brembeck, F.H., Schreiber, F.S., Deramaudt, T.B., Craig, L., Rhoades, B., 
Swain, G., Grippo, P., Stoffers, D.A., Silberg, D.G., and Rustgi, A.K. (2003). 
The mutant K-ras oncogene causes pancreatic periductal lymphocytic 
infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer 
Res. 63, 2005–2009. 
 
Brodland, G.W. (2002). The Differential Interfacial Tension Hypothesis (DITH): 
A Comprehensive Theory for the Self-Rearrangement of Embryonic Cells and 
Tissues. J. Biomech. Eng. 124, 188. 
 
Bronner-Fraser, M. (1999). 9 Rostrocaudal Differences within the Somites 
Confer Segmental Pattern to Trunk Neural Crest Migration. Curr. Top. Dev. 
Biol. 47, 279–296. 
 
Brown, S., Pineda, C.M., Xin, T., Boucher, J., Suozzi, K.C., Park, S., Matte-
Martone, C., Gonzalez, D.G., Rytlewski, J., Beronja, S., et al. (2017). Correction 
of aberrant growth preserves tissue homeostasis. Nature 548, 334–337. 
 
Brumby, A.M., and Richardson, H.E. (2003). Scribble mutants cooperate with 
oncogenic Ras or Notch to cause neoplastic overgrowth in Drosophila. EMBO 
J. 22, 5769–5779. 
 
Brunicardi, F.C., Shavelle, D.M., and Andersen, D.K. (1995). Neural regulation 
of the endocrine pancreas. Int. J. Pancreatol. 18, 177–195. 
 
Cancer Research UK Pancreatic cancer statistics. 2017. 
https://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/pancreatic-cancer. 
 
Cano, A., Pérez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., Del 
Barrio, M.G., Portillo, F., and Nieto, M.A. (2000). The transcription factor Snail 
controls epithelial-mesenchymal transitions by repressing E-cadherin 
expression. Nat. Cell Biol. 
 
Canty, L., Zarour, E., Kashkooli, L., François, P., and Fagotto, F. (2017). 
Sorting at embryonic boundaries requires high heterotypic interfacial tension. 
Nat. Commun. 8, 157. 
 
Carriere, C., Seeley, E.S., Goetze, T., Longnecker, D.S., and Korc, M. (2007). 
The Nestin progenitor lineage is the compartment of origin for pancreatic 
intraepithelial neoplasia. Proc. Natl. Acad. Sci. 104, 4437–4442. 
 
Cayuso, J., Xu, Q., and Wilkinson, D.G. (2015). Mechanisms of boundary 
formation by Eph receptor and ephrin signaling. Dev. Biol. 401, 122–131. 
 181 
 
Chen, C.-L., Schroeder, M.C., Kango-Singh, M., Tao, C., and Halder, G. (2012). 
Tumor suppression by cell competition through regulation of the Hippo 
pathway. Proc. Natl. Acad. Sci. 109, 484–489. 
 
Chen, K.L., Zheng, X.L., Li, Y., Yang, L., Zhou, Z.G., Zhou, X.Y., Zhou, B., 
Wang, R., Jiang, J.J., Chen, L.H., et al. (2009). An improved primary culture 
system of pancreatic duct epithelial cells from Wistar rats. Cytotechnology 60, 
23–31. 
 
Chiba, T., Ishihara, E., Miyamura, N., Narumi, R., Kajita, M., Fujita, Y., Suzuki, 
A., Ogawa, Y., and Nishina, H. (2016). MDCK cells expressing constitutively 
active Yes-associated protein (YAP) undergo apical extrusion depending on 
neighboring cell status. Sci. Rep. 6. 
 
Clavería, C., Giovinazzo, G., Sierra, R., and Torres, M. (2013). Myc-driven 
endogenous cell competition in the early mammalian embryo. Nature. 500, 39–
44. 
 
Collins, M.A., Bednar, F., Zhang, Y., Brisset, J., Galbán, S., Galbán, C.J., 
Rakshit, S., Flannagan, K.S., Adsay, N.V., Pasca di Magliano, M., et al. (2012). 
Oncogenic Kras is required for both the initiation and maintenance of pancreatic 
cancer in mice. J. Clin. Invest. 122, 639-653. 
 
Collins, M.A., Yan, W., Sebolt-Leopold, J.S., and Pasca Di Magliano, M. (2014). 
MAPK signaling is required for dedifferentiation of acinar cells and development 
of pancreatic intraepithelial neoplasia in mice. Gastroenterology 146. 
 
Collisson, E.A., Trejo, C.L., Silva, J.M., Gu, S., Korkola, J.E., Heiser, L.M., 
Charles, R.P., Rabinovich, B.A., Hann, B., Dankort, D., et al. (2012). A Central 
role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal 
adenocarcinoma. Cancer Discov. 2, 685–693. 
 
Cortina, C., Palomo-Ponce, S., Iglesias, M., Fernández-Masip, J.L., Vivancos, 
A., Whissell, G., Humà, M., Peiró, N., Gallego, L., Jonkheer, S., et al. (2007). 
EphB-ephrin-B interactions suppress colorectal cancer progression by 
compartmentalizing tumor cells. Nat. Genet. 39, 1376–1383. 
 
Cowan, C.A., and Henkemeyer, M. (2001). The SH2/SH3 adaptor Grb4 
transduces B-ephrin reverse signals. Nature 413, 174–179. 
 
Cox, A.D., and Der, C.J. (2010). Ras history: The saga continues. Small 
GTPases 1, 2–27. 
Crawford, H.C., Scoggins, C.R., Kay Washington, M., Matrisian, L.M., and 
Leach, S.D. (2002). Matrix metalloproteinase-7 is expressed by pancreatic 
cancer precursors and regulates acinar-to-ductal metaplasia in exocrine 
pancreas. J. Clin. Invest. 109, 1437-1444. 
 
 182 
Cubilla, A.L., and Fitzgerald, P.J. (1976). Morphological Lesions Associated 
with Human Primary Invasive Nonendocrine Pancreas Cancer. Cancer Res. 36, 
2690–2698. 
 
D’Amico, T.A., Aloia, T.A., Moore, M.B.H., Conlon, D.H., Herndon, J.E., Kinch, 
M.S., and Harpole, D.H. (2001). Predicting the sites of metastases from lung 
cancer using molecular biologic markers. Ann. Thorac. Surg. 72, 1144–1148. 
 
Dail, M., Richter, M., Godement, P., and Pasquale, E.B. (2006). Eph receptors 
inactivate R-Ras through different mechanisms to achieve cell repulsion. J. Cell 
Sci. 119, 1244–1254. 
 
Dang, C. V. (2012). MYC on the path to cancer. Cell 149, 22–35. 
 
Davis, S., Gale, N.W., Aldrich, T.H., Maisonpierre, P.C., Lhotak, V., Pawson, T., 
Goldfarb, M., and Yancopoulos, G.D. (1994). Ligands for EPH-related receptor 
tyrosine kinases that require membrane attachment or clustering for activity. 
Science. 266, 816–819. 
 
Deroanne, C., Vouret-Craviari, V., Wang, B., and Pouysségur, J. (2003). 
EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading 
via the Rac/PAK pathway. J. Cell Sci. 116, 1367–1376. 
 
Deutsch, M., Rosenstein, M.M., and Ramanathan, R.K. (1999). Pancreatic 
cancer in a young adult after treatment for Hodgkin’s disease. Clin. Oncol. (R. 
Coll. Radiol). 11, 280–282. 
 
DiGiuseppe, J.A., Hruban, R.H., Offerhaus, G.J., Clement, M.J., van den Berg, 
F.M., Cameron, J.L., and van Mansfeld, A.D. (1994). Detection of K-ras 
mutations in mucinous pancreatic duct hyperplasia from a patient with a family 
history of pancreatic carcinoma. Am. J. Pathol. 144, 889–895. 
 
Ding, L., Getz, G., Wheeler, D.A., Mardis, E.R., McLellan, M.D., Cibulskis, K., 
Sougnez, C., Greulich, H., Muzny, D.M., Morgan, M.B., et al. (2008). Somatic 
mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–
1075. 
 
Dolberg, D.S., and Bissell, M.J. (1984). Inability of Rous sarcoma virus to cause 
sarcomas in the avian embryo. Nature. 309, 522 
 
Dolenšek, J., Rupnik, M.S., and Stožer, A. (2015). Structural similarities and 
differences between the human and the mouse pancreas. Islets 7. 
 
Le Douarin, N., and Kalcheim, C. (1999). The Neural Crest. Cambridge 
University Press. 
 
Duffy, M.J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V.L., Klapdor, R., 
Nicolini, A., Topolcan, O., and Heinemann, V. (2010). Tumor markers in 
pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. 
Ann. Oncol. 21, 441–447. 
 183 
 
Dutta, D., and Donaldson, J.G. (2012). Search for inhibitors of endocytosis. 
Cell. Logist. 2, 203–208. 
 
Duxbury, M.S., Ito, H., Zinner, M.J., Ashley, S.W., and Whang, E.E. (2004). 
EphA2: A determinant of malignant cellular behavior and a potential therapeutic 
target in pancreatic adenocarcinoma. Oncogene 23, 1448–1456. 
 
Eagle, H., and Levine, E.M. (1967). Growth regulatory effects of cellular 
interaction. Nature 213, 1102–1106. 
 
Ehrlicher, A.J., Nakamura, F., Hartwig, J.H., Weitz, D.A., and Stossel, T.P. 
(2011). Mechanical strain in actin networks regulates FilGAP and integrin 
binding to filamin A. Nature 478, 260–263. 
 
Eilers, M., and Eisenman, R.N. (2008). Myc’s broad reach. Genes Dev. 22, 
2755–2766. 
 
Eisener-Dorman, A.F., Lawrence, D.A., and Bolivar, V.J. (2009). Cautionary 
insights on knockout mouse studies: The gene or not the gene? Brain. Behav. 
Immun. 23, 318–324. 
 
Eisenhoffer, G.T., Loftus, P.D., Yoshigi, M., Otsuna, H., Chien, C. Bin, Morcos, 
P.A., and Rosenblatt, J. (2012). Crowding induces live cell extrusion to maintain 
homeostatic cell numbers in epithelia. Nature 484, 546–549. 
 
Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, 
M., Arbeiter, A., Klein, S., Kong, B., et al. (2013). Selective requirement of 
PI3K/PDK1 signaling for kras oncogene-driven pancreatic cell plasticity and 
cancer. Cancer Cell 23, 406–420. 
 
Fagotto, F., Rohani, N., Touret, A.S., and Li, R. (2013). A Molecular Base for 
Cell Sorting at Embryonic Boundaries: Contact Inhibition of Cadherin Adhesion 
by Ephrin/Eph-Dependent Contractility. Dev. Cell. 27, 72-87. 
 
Fagotto, F., Winklbauer, R., and Rohani, N. (2014). Ephrin-Eph signaling in 
embryonic tissue separation. Cell Adhes. Migr. 8, 308-326 
 
Fan, H.-Y., Shimada, M., Liu, Z., Cahill, N., Noma, N., Wu, Y., Gossen, J., and 
Richards, J.S. (2008). Selective expression of KrasG12D in granulosa cells of 
the mouse ovary causes defects in follicle development and ovulation. 
Development 135, 2127–2137. 
 
Fang, W.B., Ireton, R.C., Zhuang, G., Takahashi, T., Reynolds, A., and Chen, J. 
(2008). Overexpression of EPHA2 receptor destabilizes adherens junctions via 
a RhoA-dependent mechanism. J. Cell Sci. 121, 358–368. 
 
Feil, R., Brocard, J., Mascrez, B., LeMeur, M., Metzger, D., and Chambon, P. 
(1996). Ligand-activated site-specific recombination in mice. Proc. Natl. Acad. 
Sci. 93, 10887–10890. 
 184 
 
Feldmann, G., Mishra, A., Hong, S.M., Bisht, S., Strock, C.J., Ball, D.W., 
Goggins, M., Maitra, A., and Nelkin, B.D. (2010). Inhibiting the cyclin-dependent 
kinase CDK5 blocks pancreatic cancer formation and progression through the 
suppression of Ras-Ral signaling. Cancer Res. 70, 4460–4469. 
 
Feng, Y., Santoriello, C., Mione, M., Hurlstone, A., and Martin, P. (2010). Live 
imaging of innate immune cell sensing of transformed cells in zebrafish larvae: 
Parallels between tumor initiation and wound inflammation. PLoS Biol. 8. 
 
Fero, D., Wang, K.C., Nguyen, P., Hur, S.S., Hu, Y., and Li, Y.S. (2011). 
Ephrin-a1 regulates cell remodeling and migration. Cell. Mol. Bioeng. 4, 648–
655. 
 
Ferreira, R.M.M., Sancho, R., Messal, H.A., Nye, E., Spencer-Dene, B., Stone, 
R.K., Stamp, G., Rosewell, I., Quaglia, A., and Behrens, A. (2017). Duct- and 
Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor 
Progression and Marker Expression. Cell Rep. 21, 968-978 
 
Forbes, S.A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, 
C.G., Ward, S., Dawson, E., Ponting, L., et al. (2017). COSMIC: Somatic 
cancer genetics at high-resolution. Nucleic Acids Res. 45, 777-783 
 
Franke, J.D., Montague, R.A., and Kiehart, D.P. (2005). Nonmuscle myosin II 
generates forces that transmit tension and drive contraction in multiple tissues 
during dorsal closure. Curr. Biol. 15, 2208–2221. 
 
Freelove, R., and Walling, A.D. (2006). Pancreatic cancer: Diagnosis and 
management. Am. Fam. Physician 73, 485–492. 
 
Frier, B.M., Saunders, J.H., Wormsley, K.G., and Bouchier, I.A. (1976). 
Exocrine pancreatic function in juvenile-onset diabetes mellitus. Gut 17, 685–
691. 
 
Frisch, S.M., and Francis, H. (1994). Disruption of epithelial cell-matrix 
interactions induces apoptosis. J. Cell Biol. 124, 619–626. 
 
Froldi, F., Ziosi, M., Garoia, F., Pession, A., Grzeschik, N.A., Bellosta, P., 
Strand, D., Richardson, H.E., Pession, A., and Grifoni, D. (2010). The lethal 
giant larvae tumour suppressor mutation requires dMyc oncoprotein to promote 
clonal malignancy. BMC Biol. 8. 
 
Fuchs, Y., and Steller, H. (2015). Live to die another way: Modes of 
programmed cell death and the signals emanating from dying cells. Nat. Rev. 
Mol. Cell Biol. 16, 329–344. 
 
Gallo, G. (2006). RhoA-kinase coordinates F-actin organization and myosin II 
activity during semaphorin-3A-induced axon retraction. J. Cell Sci. 119, 3413–
3423. 
 
 185 
Gateff, E. (1978). Malignant neoplasms of genetic origin in Drosophila 
melanogaster. Science (80-. ). 200, 1448–1459. 
 
Gidekel Friedlander, S.Y., Chu, G.C., Snyder, E.L., Girnius, N., Dibelius, G., 
Crowley, D., Vasile, E., DePinho, R.A., and Jacks, T. (2009). Context-
dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer 
Cell 16, 379–389. 
 
Gong, J., Körner, R., Gaitanos, L., and Klein, R. (2016). Exosomes mediate cell 
contact-independent ephrin-Eph signaling during axon guidance. J. Cell Biol. 
214, 35–44. 
 
Gopinathan, A., Morton, J.P., Jodrell, D.I., and Sansom, O.J. (2015). GEMMs 
as preclinical models for testing pancreatic cancer therapies. Dis. Model. Mech. 
8, 1185–1200. 
 
Grapin-Botton, A. (2005). Ductal cells of the pancreas. Int. J. Biochem. Cell 
Biol. 37, 504–510. 
 
Grippo, P.J., Nowlin, P.S., Demeure, M.J., Longnecker, D.S., and Sandgren, 
E.P. (2003). Preinvasive pancreatic neoplasia of ductal phenotype induced by 
acinar cell targeting of mutant Kras in transgenic mice. Cancer Res. 63, 2016–
2019. 
 
Gu, G., Dubauskaite, J., and Melton, D.A. (2002). Direct evidence for the 
pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct 
progenitors. Development. 129, 2447-2457. 
 
Gu, Y., Forostyan, T., Sabbadini, R., and Rosenblatt, J. (2011). Epithelial cell 
extrusion requires the sphingosine-1-phosphate receptor 2 pathway. J. Cell 
Biol. 193, 667–676. 
 
Gu, Y., Shea, J., Slattum, G., Firpo, M.A., Alexander, M., Golubovskaya, V.M., 
and Rosenblatt, J. (2015). Defective apical extrusion signaling contributes to 
aggressive tumor hallmarks. Elife 2015. e04069. 
 
Guerra, C., Schuhmacher, A.J., Cañamero, M., Grippo, P.J., Verdaguer, L., 
Pérez-Gallego, L., Dubus, P., Sandgren, E.P., and Barbacid, M. (2007). 
Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal 
Adenocarcinoma by K-Ras Oncogenes in Adult Mice. Cancer Cell 11, 291–302. 
 
Guerra, C., Collado, M., Navas, C., Schuhmacher, A.J., Hernández-Porras, I., 
Cañamero, M., Rodriguez-Justo, M., Serrano, M., and Barbacid, M. (2011). 
Pancreatitis-Induced Inflammation Contributes to Pancreatic Cancer by 
Inhibiting Oncogene-Induced Senescence. Cancer Cell 19, 728–739. 
 
Gumbiner, B.M. (1996). Cell adhesion: The molecular basis of tissue 
architecture and morphogenesis. Cell 84, 345–357. 
 
 186 
Gundry, C., Marco, S., Rainero, E., Miller, B., Dornier, E., Mitchell, L., Caswell, 
P.T., Campbell, A.D., Hogeweg, A., Sansom, O.J., et al. (2017). 
Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent 
EphA2 trafficking to promote cell:cell repulsion. Nat. Commun. 8, 14646. 
 
Guo, Z., Neilson, L.J., Zhong, H., Murray, P.S., Zanivan, S., and Zaidel-Bar, R. 
(2014). E-cadherin interactome complexity and robustness resolved by 
quantitative proteomics. Sci. Signal. 7. 
 
Gurdon, J.B., Kato, K., and Lemaire, P. (1993). The community effect, 
dorsalization and mesoderm induction. Curr. Opin. Genet. Dev. 3, 662-667 
 
Habbe, N., Shi, G., Meguid, R.A., Fendrich, V., Esni, F., Chen, H., Feldmann, 
G., Stoffers, D.A., Konieczny, S.F., Leach, S.D., et al. (2008). Spontaneous 
induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell 
targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci. 105, 18913–
18918. 
 
Hall, P.A., and Lemoine, N.R. (1992). Rapid acinar to ductal transdifferentiation 
in cultured human exocrine pancreas. J. Pathol. 166, 97–103. 
 
Hattori, M., Osterfield, M., and Flanagan, J.G. (2000). Regulated cleavage of a 
contact-mediated axon repellent. Science. 289, 1360–1365. 
 
Hendley, A.M., Wang, Y.J., Polireddy, K., Alsina, J., Ahmed, I., Lafaro, K.J., 
Zhang, H., Roy, N., Savidge, S.G., Cao, Y., et al. (2016). p120 catenin 
suppresses basal epithelial cell extrusion in invasive pancreatic neoplasia. 
Cancer Res. 76, 3351–3363. 
 
Herbach, N., Bergmayr, M., Göke, B., Wolf, E., and Wanke, R. (2011). 
Postnatal development of numbers and mean sizes of pancreatic islets and 
Beta-Cells in healthy mice and giprdntransgenic diabetic mice. PLoS One 6. 
e22814. 
 
Hezel, A.F., Gurumurthy, S., Granot, Z., Swisa, A., Chu, G.C., Bailey, G., Dor, 
Y., Bardeesy, N., and DePinho, R.A. (2008). Pancreatic Lkb1 Deletion Leads to 
Acinar Polarity Defects and Cystic Neoplasms. Mol. Cell. Biol. 28, 2414–2425. 
 
Hill, W., and Hogan, C. (2017). Normal epithelial cells trigger EphA2-dependent 
RasV12 cell repulsion at the single cell level. Small GTPases 1–6. 
 
Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz, 
M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. (2003a). 
Preinvasive and invasive ductal pancreatic cancer and its early detection in the 
mouse. Cancer Cell 4, 437–450. 
 
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, 
R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H and 
KrasG12D cooperate to promote chromosomal instability and widely metastatic 
pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483. 
 187 
 
Hirai, H., Maru, Y., Hagiwara, K., Nishida, J., and Takaku, F. (1987). A novel 
putative tyrosine kinase receptor encoded by the eph gene. Science. 238, 
1717–1720. 
 
Hiramoto-Yamaki, N., Takeuchi, S., Ueda, S., Harada, K., Fujimoto, S., Negishi, 
M., and Katoh, H. (2010). Ephexin4 and EphA2 mediate cell migration through 
a RhoG-dependent mechanism. J. Cell Biol. 190, 461–477. 
 
Ho, R.K. (1992). Cell movements and cell fate during zebrafish gastrulation. 
Dev. Suppl. 73, 65–73. 
 
Hobbs, G.A., Der, C.J., and Rossman, K.L. (2016). RAS isoforms and 
mutations in cancer at a glance. J. Cell Sci. 129, 1287–1292. 
 
Hoess, R., Abremski, K., and Sternberg, N. (1984). The nature of the interaction 
of the P1 recombinase Cre with the recombining site loxP. Cold Spring Harb. 
Symp. Quant. Biol. 49, 761–768. 
 
Hogan, C., Dupré-Crochet, S., Norman, M., Kajita, M., Zimmermann, C., 
Pelling, A.E., Piddini, E., Baena-López, L.A., Vincent, J.-P., Itoh, Y., et al. 
(2009). Characterization of the interface between normal and transformed 
epithelial cells. Nat. Cell Biol. 11, 460–467. 
 
Hölzel, M. (2010). NF1 is a tumor suppressor in neuroblastoma that determines 
retinoic acid response and disease outcome. Nat. Rev. Cancer 10, 601. 
 
Hornberger, M.R., Dütting, D., Ciossek, T., Yamada, T., Handwerker, C., Lang, 
S., Weth, F., Huf, J., Weßel, R., Logan, C., et al. (1999). Modulation of EphA 
receptor function by coexpressed EphrinA ligands on retinal ganglion cell 
axons. Neuron 22, 731–742. 
 
Houbracken, I., and Bouwens, L. (2017). Acinar cells in the neonatal pancreas 
grow by self-duplication and not by neogenesis from duct cells. Sci. Rep. 7, 
12643. 
 
Houbracken, I., De Waele, E., Lardon, J., Ling, Z., Heimberg, H., Rooman, I., 
and Bouwens, L. (2011). Lineage tracing evidence for transdifferentiation of 
acinar to duct cells and plasticity of human pancreas. Gastroenterology. 141, 
731-741. 
 
Hruban, R.H., Takaori, K., Klimstra, D.S., Adsay, N.V., Albores-Saavedra, J., 
Biankin, A. V., Biankin, S.A., Compton, C., Fukushima, N., Furukawa, T., et al. 
(2004). An illustrated consensus on the classification of pancreatic 
intraepithelial neoplasia and intraductal papillary mucinous neoplasms. In 
American Journal of Surgical Pathology. 977–987. 
 
Huch, M., Bonfanti, P., Boj, S.F., Sato, T., Loomans, C.J.M., Van De Wetering, 
M., Sojoodi, M., Li, V.S.W., Schuijers, J., Gracanin, A., et al. (2013). Unlimited 
 188 
in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-
spondin axis. EMBO J. 32, 2708–2721. 
 
Hunter, S.G., Zhuang, G., Brantley-Sieders, D., Swat, W., Cowan, C.W., and 
Chen, J. (2006). Essential Role of Vav Family Guanine Nucleotide Exchange 
Factors in EphA Receptor-Mediated Angiogenesis. Mol. Cell. Biol. 26, 4830–
4842. 
 
Huynh-Do, U., Stein, E., Lane, A.A., Liu, H., Cerretti, D.P., and Daniel, T.O. 
(1999). Surface densities of ephrin-B1 determine EphB1-coupled activation of 
cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J. 18, 
2165–2173. 
 
Igaki, T., Pagliarini, R.A., and Xu, T. (2006). Loss of Cell Polarity Drives Tumor 
Growth and Invasion through JNK Activation in Drosophila. Curr. Biol. 16, 
1139–1146. 
 
Ionescu-Tirgoviste, C., Gagniuc, P.A., Gubceac, E., Mardare, L., Popescu, I., 
Dima, S., and Militaru, M. (2015). A 3D map of the islet routes throughout the 
healthy human pancreas. Sci. Rep. 5, 14634. 
 
Ireton, R.C., Davis, M.A., Van Hengel, J., Mariner, D.J., Barnes, K., Thoreson, 
M.A., Anastasiadis, P.Z., Matrisian, L., Bundy, L.M., Sealy, L., et al. (2002). A 
novel role for p120 catenin in E-cadherin function. J. Cell Biol. 159, 465-476. 
 
Ishiyama, N., Lee, S.H., Liu, S., Li, G.Y., Smith, M.J., Reichardt, L.F., and Ikura, 
M. (2010). Dynamic and Static Interactions between p120 Catenin and E-
Cadherin Regulate the Stability of Cell-Cell Adhesion. Cell 141, 117–128. 
 
Van Itallie, C.M., Tietgens, A.J., Aponte, A., Fredriksson, K., Fanning, A.S., 
Gucek, M., and Anderson, J.M. (2014). Biotin ligase tagging identifies proteins 
proximal to E-cadherin, including lipoma preferred partner, a regulator of 
epithelial cell–cell and cell–substrate adhesion. J. Cell Sci. 127, 885–895. 
 
Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., 
Jacks, T., and Tuveson, D.A. (2001). Analysis of lung tumor initiation and 
progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 
3243–3248. 
 
Jain, R., and Lammert, E. (2009). Cell-cell interactions in the endocrine 
pancreas. Diabetes, Obes. Metab. 11, 159–167. 
 
Javaherian, S., D’Arcangelo, E., Slater, B., Zulueta-Coarasa, T., Fernandez-
Gonzalez, R., and McGuigan, A.P. (2015). An in vitro model of tissue boundary 
formation for dissecting the contribution of different boundary forming 
mechanisms. Integr. Biol. 7, 298-312. 
 
Jensen, J.N., Cameron, E., Garay, M.V.R., Starkey, T.W., Gianani, R., and 
Jensen, J. (2005). Recapitulation of elements of embryonic development in 
adult mouse pancreatic regeneration. Gastroenterology. 128, 728-741. 
 189 
 
Ji, B., Tsou, L., Wang, H., Gaiser, S., Chang, D.Z., Daniluk, J., Bi, Y., Grote, T., 
Longnecker, D.S., and Logsdon, C.D. (2009). Ras Activity Levels Control the 
Development of Pancreatic Diseases. Gastroenterology. 137, 1072-1082. 
 
Johnson, P.W., Stankova, J., Dexter, D., and Roder, J.C. (1990). The in vivo 
clearance of Ha-ras transformants by natural killer cells. Clin. Exp. Metastasis 
8, 13–25. 
 
Jonason, A.S., Kunala, S., Price, G.J., Restifo, R.J., Spinelli, H.M., Persing, 
J.A., Leffell, D.J., Tarone, R.E., and Brash, D.E. (1996). Frequent clones of 
p53-mutated keratinocytes in normal human skin. Proc. Natl. Acad. Sci. 93, 
14025-14029. 
 
Jones, S., Zhang, X., Parsons, D.W., Lin, J.C.-H., Leary, R.J., Angenendt, P., 
Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008). Core signaling 
pathways in human pancreatic cancers revealed by global genomic analyses. 
Science 321, 1801–1806. 
 
Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. (1994). Insulin-promoter-
factor 1 is required for pancreas development in mice. Nature 371, 606–609. 
 
Jørgensen, C., Sherman, A., Chen, G.I., Pasculescu, A., Poliakov, A., Hsiung, 
M., Larsen, B., Wilkinson, D.G., Linding, R., and Pawson, T. (2009). Cell-
specific information processing in segregating populations of Eph receptor 
ephrin-expressing cells. Science. 326, 1502–1509. 
 
Kadeer, A., Maruyama, T., Kajita, M., Morita, T., Sasaki, A., Ohoka, A., 
Ishikawa, S., Ikegawa, M., Shimada, T., and Fujita, Y. (2017). Plectin is a novel 
regulator for apical extrusion of RasV12-transformed cells. Sci. Rep. 7, 44328. 
 
Kajita, M., and Fujita, Y. (2015). EDAC: Epithelial defence against cancer - Cell 
competition between normal and transformed epithelial cells in mammals. J. 
Biochem. 158, 15-23. 
 
Kajita, M., Hogan, C., Harris, A.R., Dupre-Crochet, S., Itasaki, N., Kawakami, 
K., Charras, G., Tada, M., and Fujita, Y. (2010). Interaction with surrounding 
normal epithelial cells influences signalling pathways and behaviour of Src-
transformed cells. J. Cell Sci. 123, 171–180. 
 
Kajita, M., Sugimura, K., Ohoka, A., Burden, J., Suganuma, H., Ikegawa, M., 
Shimada, T., Kitamura, T., Shindoh, M., Ishikawa, S., et al. (2014). Filamin acts 
as a key regulator in epithelial defence against transformed cells. Nat. 
Commun. 5, 4428. 
 
Kanda, M., Matthaei, H., Wu, J., Hong, S.M., Yu, J., Borges, M., Hruban, R.H., 
Maitra, A., Kinzler, K., Vogelstein, B., et al. (2012). Presence of somatic 
mutations in most early-stage pancreatic intraepithelial neoplasia. 
Gastroenterology. 142, 730-733. 
 
 190 
Kania, A., and Klein, R. (2016). Mechanisms of ephrin–Eph signalling in 
development, physiology and disease. Nat. Rev. Mol. Cell Biol. 17, 240–256. 
 
Karim, F.D., and Rubin, G.M. (1998). Ectopic expression of activated Ras1 
induces hyperplastic growth and increased cell death in Drosophila imaginal 
tissues. Development 125, 1–9. 
 
Kataoka, H., Igarashi, H., Kanamori, M., Ihara, M., Wang, J.D., Wang, Y.J., Li, 
Z.Y., Shimamura, T., Kobayashi, T., Maruyama, K., et al. (2004). Correlation of 
EPHA2 overexpression with high microvessel count in human primary 
colorectal cancer. Cancer Sci. 95, 136–141. 
 
Kawaguchi, K., Kageyama, R., and Sano, M. (2017). Topological defects 
control collective dynamics in neural progenitor cell cultures. Nature 545, 327–
331. 
 
Kimura, T., Sakisaka, T., Baba, T., Yamada, T., and Takai, Y. (2006). 
Involvement of the Ras-Ras-activated Rab5 guanine nucleotide exchange 
factor RIN2-Rab5 pathway in the hepatocyte growth factor-induced endocytosis 
of E-cadherin. J. Biol. Chem. 281, 10598–10609. 
 
Kippert, A., Fitzner, D., Helenius, J., and Simons, M. (2009). Actomyosin 
contractility controls cell surface area of oligodendrocytes. BMC Cell Biol. 10, 
71. 
 
Knöll, B., Weinl, C., Nordheim, A., and Bonhoeffer, F. (2007). Stripe assay to 
examine axonal guidance and cell migration. Nat. Protoc. 2, 1216–1224. 
 
Kon, S., Ishibashi, K., Katoh, H., Kitamoto, S., Shirai, T., Tanaka, S., Kajita, M., 
Ishikawa, S., Yamauchi, H., Yako, Y., et al. (2017). Cell competition with normal 
epithelial cells promotes apical extrusion of transformed cells through metabolic 
changes. Nat. Cell Biol. 19, 530–541. 
 
Kopp, J.L., von Figura, G., Mayes, E., Liu, F.-F., Dubois, C.L., Morris, J.P., Pan, 
F.C., Akiyama, H., Wright, C.V.E., Jensen, K., et al. (2012). Identification of 
Sox9-Dependent Acinar-to-Ductal Reprogramming as the Principal Mechanism 
for Initiation of Pancreatic Ductal Adenocarcinoma. Cancer Cell 22, 737–750. 
 
Krah, N.M., De La O, J.-P., Swift, G.H., Hoang, C.Q., Willet, S.G., Chen Pan, 
F., Cash, G.M., Bronner, M.P., Wright, C.V., MacDonald, R.J., et al. (2015). The 
acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal 
adenocarcinoma. Elife 4, e07125. 
 
Krieg, M., Arboleda-Estudillo, Y., Puech, P.H., Käfer, J., Graner, F., Müller, 
D.J., and Heisenberg, C.P. (2008). Tensile forces govern germ-layer 
organization in zebrafish. Nat. Cell Biol. 10, 429–436. 
 
Kujoth, G.C., Hiona, A., Pugh, T.D., Someya, S., Panzer, K., Wohlgemuth, S.E., 
Hofer, T., Seo, A.Y., Sullivan, R., Jobling, W.A., et al. (2005). Mitochondrial 
 191 
DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science. 
309, 481–484. 
 
Kuo, C.S., and Krasnow, M.A. (2015). Formation of a Neurosensory Organ by 
Epithelial Cell Slithering. Cell 163, 394–405. 
 
De La Cova, C., Abril, M., Bellosta, P., Gallant, P., and Johnston, L.A. (2004). 
Drosophila myc regulates organ size by inducing cell competition. Cell 117, 
107–116. 
 
De La Cova, C., Senoo-Matsuda, N., Ziosi, M., Wu, D.C., Bellosta, P., Quinzii, 
C.M., and Johnston, L.A. (2014). Supercompetitor status of drosophila Myc 
cells requires p53 as a Fitness sensor to reprogram metabolism and promote 
viability. Cell Metab. 19, 470–483. 
 
Labat-Robert, J. (2004). Cell-matrix interactions in aging: Role of receptors and 
matricryptins. Ageing Res. Rev. 3, 233-247. 
 
Landen, C.N., Lu, C., Han, L.Y., Coffman, K.T., Bruckheimer, E., Halder, J., 
Mangala, L.S., Merritt, W.M., Lin, Y.G., Gao, C., et al. (2006). Efficacy and 
antivascular effects of EphA2 reduction with an agonistic antibody in ovarian 
cancer. J. Natl. Cancer Inst. 98, 1558–1570. 
 
Langenberg, T., and Brand, M. (2005). Lineage restriction maintains a stable 
organizer cell population at the zebrafish midbrain-hindbrain boundary. 
Development 132, 3209–3216. 
 
Lankisch, P.G., Manthey, G., Otto, J., Koop, H., Talaulicar, M., Willms, B., and 
Creutzfeldt, W. (1982). Exocrine pancreatic function in insulin-dependent 
diabetes mellitus. Digestion 25, 211–216. 
 
Lecuit, T., and Yap, A.S. (2015). E-cadherin junctions as active mechanical 
integrators in tissue dynamics. Nat. Cell Biol. 17, 533–539. 
 
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M., Pastorino, S., 
Purow, B.W., Christopher, N., Zhang, W., et al. (2006). Tumor stem cells 
derived from glioblastomas cultured in bFGF and EGF more closely mirror the 
phenotype and genotype of primary tumors than do serum-cultured cell lines. 
Cancer Cell 9, 391–403. 
 
Lerch, M.M., Lutz, M.P., Weidenbach, H., Muller-Pillasch, F., Gress, T.M., 
Leser, J., and Adler, G. (1997). Dissociation and reassembly of adherens 
junctions during experimental acute pancreatitis. Gastroenterology 113, 1355–
1366. 
 
Leung, C.T., and Brugge, J.S. (2012). Outgrowth of single oncogene-
expressing cells from suppressive epithelial environments. Nature 482, 410–
413. 
 
 192 
Levayer, R., Hauert, B., and Moreno, E. (2015). Cell mixing induced by myc is 
required for competitive tissue invasion and destruction. Nature 524, 476–480. 
 
Li, J., Ma, Q., Liu, H., Guo, K., Li, F., Li, W., Han, L., Wang, F., and Wu, E. 
(2011). Relationship between neural alteration and perineural invasion in 
pancreatic cancer patients with hyperglycemia. PLoS One 6. e17385. 
 
Liang, K., Liu, F., Fan, J., Sun, D., Liu, C., Lyon, C.J., Bernard, D.W., Li, Y., 
Yokoi, K., Katz, M.H., et al. (2017). Nanoplasmonic Quantification of Tumor-
derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and 
Treatment Monitoring. Nat. Biomed. Eng. 1, 21. 
 
Lim, K.H., Baines, A.T., Fiordalisi, J.J., Shipitsin, M., Feig, L.A., Cox, A.D., Der, 
C.J., and Counter, C.M. (2005). Activation of RalA is critical for Ras-induced 
tumorigenesis of human cells. Cancer Cell 7, 533–545. 
 
von Lintig, F.C., Dreilinger, A.D., Varki, N.M., Wallace, A.M., Casteel, D.E., and 
Boss, G.R. (2000). Ras activation in human breast cancer. Breast Cancer Res. 
Treat. 62, 51–62. 
 
Liou, G.-Y., Döppler, H., Necela, B., Krishna, M., Crawford, H.C., Raimondo, 
M., and Storz, P. (2013a). Macrophage-secreted cytokines drive pancreatic 
acinar-to-ductal metaplasia through NF-κB and MMPs. J. Cell Biol. 202, 563–
577. 
 
Liou, G.-Y., Döppler, H., Braun, U.B., Panayiotou, R., Scotti Buzhardt, M., 
Radisky, D.C., Crawford, H.C., Fields, A.P., Murray, N.R., Wang, Q.J., et al. 
(2015). Protein kinase D1 drives pancreatic acinar cell reprogramming and 
progression to intraepithelial neoplasia. Nat. Commun. 6, 6200. 
 
Liou, G.-Y., Bastea, L., Fleming, A., Döppler, H., Edenfield, B.H., Dawson, 
D.W., Zhang, L., Bardeesy, N., and Storz, P. (2017). The Presence of 
Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage 
Populations and Mediates Pancreatic Tumorigenesis. Cell Rep. 19, 1322–1333. 
 
Liou, G.Y., Döppler, H., Necela, B., Krishna, M., Crawford, H.C., Raimondo, M., 
and Storz, P. (2013b). Macrophage-secreted cytokines drive pancreatic acinar-
to-ductal metaplasia through NF-κB and MMPs. J. Cell Biol. 202, 563–577. 
 
Liu, J., Willet, S.G., Bankaitis, E.D., Xu, Y., Wright, C.V.E., and Gu, G. (2013). 
Non-parallel recombination limits cre-loxP-based reporters as precise indicators 
of conditional genetic manipulation. Genesis 51, 436–442. 
 
Liu, J., Akanuma, N., Liu, C., Naji, A., Halff, G.A., Washburn, W.K., Sun, L., and 
Wang, P. (2016). TGF-β1 promotes acinar to ductal metaplasia of human 
pancreatic acinar cells. 6, 30904. 
 
Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A.B., and Lüttges, J. (2005). 
Frequency of K-ras Mutations in Pancreatic Intraductal Neoplasias Associated 
 193 
with Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis: A Meta-
Analysis. Neoplasia. 7, 17-23. 
 
Lopez-Garcia, C., Klein, A.M., Simons, B.D., and Winton, D.J. (2010). Intestinal 
stem cell replacement follows a pattern of neutral drift. Science. 330, 822-825. 
 
Lu, X., Xu, T., Qian, J., Wen, X., and Wu, D. (2002). Detecting K-ras and p53 
gene mutation from stool and pancreatic juice for diagnosis of early pancreatic 
cancer. Chin. Med. J. (Engl). 115, 1632–1636. 
 
Lu, Z., Ghosh, S., Wang, Z., and Hunter, T. (2003). Downregulation of caveolin-
1 function by EGF leads to the loss of E-cadherin, increased transcriptional 
activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell 4, 499–
515. 
 
Luche, H., Weber, O., Nageswara Rao, T., Blum, C., and Fehling, H.J. (2007). 
Faithful activation of an extra-bright red fluorescent protein in “knock-in” Cre-
reporter mice ideally suited for lineage tracing studies. Eur. J. Immunol. 37, 43–
53. 
 
Macara, I.G., Guyer, R., Richardson, G., Huo, Y., and Ahmed, S.M. (2014). 
Epithelial homeostasis. Curr. Biol. 24, 815-825. 
 
Macrae, M., Neve, R.M., Rodriguez-Viciana, P., Haqq, C., Yeh, J., Chen, C., 
Gray, J.W., and McCormick, F. (2005). A conditional feedback loop regulates 
Ras activity through EphA2. Cancer Cell 8, 111–118. 
 
Maddipati, R., and Stanger, B.Z. (2015). Pancreatic cancer metastases harbor 
evidence of polyclonality. Cancer Discov. CD-15. 
 
Maertens, O., Johnson, B., Hollstein, P., Frederick, D.T., Cooper, Z.A., 
Messiaen, L., Bronson, R.T., McMahon, M., Granter, S., Flaherty, K., et al. 
(2013). Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 
3, 338–349. 
 
Magami, Y., Azuma, T., Inokuchi, H., Kawai, K., and Hattori, T. (1990). 
Turnover of acinar cells in mouse pancreas. J. Gastroenterol. 25, 514. 
 
Magami, Y., Azuma, T., Inokuchi, H., Moriyasu, F., Kawai, K., and Hattori, T. 
(2002). Heterogeneous cell renewal of pancreas in mice: [3H]-thymidine 
autoradiographic investigation. Pancreas 24, 153–160. 
 
Magnuson, M.A., and Osipovich, A.B. (2013). Pancreas-specific Cre driver lines 
and considerations for their prudent use. Cell Metab. 18, 9–20. 
 
Makohon-Moore, A., and Iacobuzio-Donahue, C.A. (2016). Pancreatic cancer 
biology and genetics from an evolutionary perspective. Nat. Rev. Cancer. 16, 
553. 
 
 194 
Makohon-Moore, A.P., Matsukuma, K., Zhang, M., Reiter, J.G., Gerold, J.M., 
Jiao, Y., Sikkema, L., Attiyeh, M.A., Yachida, S., Sandone, C., et al. (2018). 
Precancerous neoplastic cells can move through the pancreatic ductal system. 
Nature. 1. 
 
Mamada, H., Sato, T., Ota, M., and Sasaki, H. (2015). Cell competition in 
mouse NIH3T3 embryonic fibroblasts is controlled by the activity of Tead family 
proteins and Myc. J. Cell Sci. 128, 790–803. 
 
Marciniak, A., Selck, C., Friedrich, B., and Speier, S. (2013). Mouse pancreas 
tissue slice culture facilitates long-term studies of exocrine and endocrine cell 
physiology in situ. PLoS One 8. e78706. 
 
Marinari, E., Mehonic, A., Curran, S., Gale, J., Duke, T., and Baum, B. (2012). 
Live-cell delamination counterbalances epithelial growth to limit tissue 
overcrowding. Nature 484, 542–545. 
 
Marston, D.J., Dickinson, S., and Nobes, C.D. (2003). Rac-dependent trans-
endocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat. Cell Biol. 
5, 879–888. 
 
Martín, F.A., Herrera, S.C., and Morata, G. (2009). Cell competition, growth and 
size control in the Drosophila wing imaginal disc. Development 136, 3747–
3756. 
 
Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S., 
Wedge, D.C., Fullam, A., Alexandrov, L.B., Tubio, J.M., et al. (2015). High 
burden and pervasive positive selection of somatic mutations in normal human 
skin. Science. 348, 880–886. 
 
Martins, V.C., Busch, K., Juraeva, D., Blum, C., Ludwig, C., Rasche, V., 
Lasitschka, F., Mastitsky, S.E., Brors, B., Hielscher, T., et al. (2014). Cell 
competition is a tumour suppressor mechanism in the thymus. Nature 509, 
465–470. 
 
Matsuda, Y., Furukawa, T., Yachida, S., Nishimura, M., Seki, A., Nonaka, K., 
Aida, J., Takubo, K., Ishiwata, T., Kimura, W., et al. (2017). The prevalence and 
clinicopathological characteristics of high-grade pancreatic intraepithelial 
neoplasia autopsy study evaluating the entire pancreatic parenchyma. 
Pancreas. 46, 658-664. 
 
Mayo, S.C., Nathan, H., Cameron, J.L., Olino, K., Edil, B.H., Herman, J.M., 
Hirose, K., Schulick, R.D., Choti, M.A., Wolfgang, C.L., et al. (2012). 
Conditional survival in patients with pancreatic ductal adenocarcinoma resected 
with curative intent. Cancer 118, 2674–2681. 
 
McGillicuddy, L.T., Fromm, J.A., Hollstein, P.E., Kubek, S., Beroukhim, R., De 
Raedt, T., Johnson, B.W., Williams, S.M.G., Nghiemphu, P., Liau, L.M., et al. 
(2009). Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in 
Gliomagenesis. Cancer Cell 16, 44–54. 
 195 
 
McLaughlin, S.K., Olsen, S.N., Dake, B., De Raedt, T., Lim, E., Bronson, R.T., 
Beroukhim, R., Polyak, K., Brown, M., and Kuperwasser, C. (2013). The 
RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell 
24, 365–378. 
 
Means, A.L., Meszoely, I.M., Suzuki, K., Miyamoto, Y., Rustgi, A.K., Coffey, 
R.J., Wright, C.V., Stoffers, D.A., and Leach, S.D. (2005). Pancreatic epithelial 
plasticity mediated by acinar cell transdifferentiation and generation of nestin-
positive intermediates. Development. 132, 3767-3776. 
 
Menendez, J., Perez-Garijo, A., Calleja, M., and Morata, G. (2010). A tumor-
suppressing mechanism in Drosophila involving cell competition and the Hippo 
pathway. Proc. Natl. Acad. Sci. 107, 14651–14656. 
 
Merino, M.M., Rhiner, C., Portela, M., and Moreno, E. (2013). “Fitness 
fingerprints” mediate physiological culling of unwanted neurons in drosophila. 
Curr. Biol. 23, 1300-1309. 
 
Meyer, N., and Penn, L.Z. (2008). Reflecting on 25 years with MYC. Nat. Rev. 
Cancer 8, 976–990. 
 
Meyer, S.N., Amoyel, M., Bergantiños, C., De La Cova, C., Schertel, C., Basler, 
K., and Johnston, L.A. (2014). An ancient defense system eliminates unfit cells 
from developing tissues during cell competition. Science. 346, 1258236. 
 
Miao, H., Burnett, E., Kinch, M., Simon, E., and Wang, B. (2000). Activation of 
EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase 
dephosphorylation. Nat. Cell Biol. 2, 62–69. 
 
Miao, H., Wei, B.R., Peehl, D.M., Li, Q., Alexandrou, T., Schelling, J.R., Rhim, 
J.S., Sedor, J.R., Burnett, E., and Wang, B. (2001). Activation of EphA receptor 
tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell Biol. 3, 527–530. 
 
Miao, H., Li, D.Q., Mukherjee, A., Guo, H., Petty, A., Cutter, J., Basilion, J.P., 
Sedor, J., Wu, J., Danielpour, D., et al. (2009). EphA2 Mediates Ligand-
Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and 
Invasion via a Reciprocal Regulatory Loop with Akt. Cancer Cell 16, 9–20. 
 
Mills, J.C., and Sansom, O.J. (2015). Reserve stem cells: Differentiated cells 
reprogram to fuel repair, metaplasia, and neoplasia in the adult gastrointestinal 
tract. Sci. Signal. 8, re8. 
Minami, K. (2013). Searching for stem cells in the adult pancreas: A futile 
effort? J. Diabetes Investig. 4, 331–333. 
 
Monier, B., Pélissier-Monier, A., Brand, A.H., and Sanson, B. (2010). An 
actomyosin-based barrier inhibits cell mixing at compartmental boundaries in 
Drosophila embryos. Nat. Cell Biol. 12, 60–65. 
 
 196 
Montecucco, F., Mach, F., Lenglet, S., Vonlaufen, A., Gomes Quinderé, A.L., 
Pelli, G., Burger, F., Galan, K., Dallegri, F., Carbone, F., et al. (2014). 
Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse 
acute pancreatitis. Eur. J. Clin. Invest. 44, 940-950 
Morata, G., and Ripoll, P. (1975). Minutes: Mutants of Drosophila autonomously 
affecting cell division rate. Dev. Biol. 42, 211–221. 
 
Moreno, E. (2008). Is cell competition relevant to cancer? Nat. Rev. Cancer 8, 
141–147. 
Moreno, E., and Basler, K. (2004). dMyc transforms cells into super-
competitors. Cell 117, 117–129. 
 
Moreno, E., Basler, K., and Morata, G. (2002). Cells compete for 
decapentaplegic survival factor to prevent apoptosis in Drosophila wing 
development. Nature 416, 755–759. 
 
Morris, J.P., Wang, S.C., and Hebrok, M. (2010a). KRAS, Hedgehog, Wnt and 
the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. 
Rev. Cancer 10, 683–695. 
 
Morris, J.P., Cano, D.A., Sekine, S., Wang, S.C., and Hebrok, M. (2010b). β-
catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer 
precursor lesions in mice. J. Clin. Invest. 120, 508–520. 
 
Morton, J.P., Timpson, P., Karim, S.A., Ridgway, R.A., Athineos, D., Doyle, B., 
Jamieson, N.B., Oien, K.A., Lowy, A.M., Brunton, V.G., et al. (2010). Mutant 
p53 drives metastasis and overcomes growth arrest/senescence in pancreatic 
cancer. Proc. Natl. Acad. Sci. 107, 246–251. 
 
Mudali, S. V, Fu, B., Lakkur, S.S., Luo, M., Embuscado, E.E., and Iacobuzio-
Donahue, C.A. (2006). Patterns of EphA2 protein expression in primary and 
metastatic pancreatic carcinoma and correlation with genetic status. Clin. Exp. 
Metastasis 23, 357–365. 
 
Mueller, H., Flury, N., Eppenberger-Castori, S., Kueng, W., David, F., and 
Eppenberger, U. (2000). Potential prognostic value of mitogen-activated protein 
kinase activity for disease-free survival of primary breast cancer patients. Int. J. 
Cancer 89, 384–388. 
 
Nakayama, D., Magami, Y., Azuma, T., Inokuchi, H., Furukawa, M., Ohyashiki, 
J., Yoshimoto, T., Mizuguchi, J., Moriyasu, F., Kawai, K., et al. (2003). Turnover 
of acinar and islet cells in the pancreas of monosodium glutamate-treated 
obese mice. Obes. Res. 11, 87–94. 
 
Neesse, A., Algül, H., Tuveson, D.A., and Gress, T.M. (2015). Stromal biology 
and therapy in pancreatic cancer: A changing paradigm. Gut 64, 1476–1484. 
 
Nemashkalo, A., Ruzo, A., Heemskerk, I., and Warmflash, A. (2017). 
Morphogen and community effects determine cell fates in response to BMP4 
signaling in human embryonic stem cells. Development. 153239. 
 197 
 
Neto-Silva, R.M., de Beco, S., and Johnston, L.A. (2010). Evidence for a 
growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, 
the drosophila homolog of Yap. Dev. Cell 19, 507–520. 
 
Niederau, C., Ferrell, L.D., and Grendell, J.H. (1985). Caerulein-Induced Acute 
Necrotizing Pancreatitis in Mice; Protective Effects of Proglumide Benzotript, 
and Secretin. Gastroenterology. 88, 1192-1204. 
 
Noberini, R., Rubio de la Torre, E., and Pasquale, E.B. (2012). Profiling Eph 
receptor expression in cells and tissues. Cell Adh. Migr. 6, 102–156. 
 
Noren, N.K., and Pasquale, E.B. (2004). Eph receptor-ephrin bidirectional 
signals that target Ras and Rho proteins. Cell. Signal. 16, 655–666. 
 
Norman, M., Wisniewska, K.A., Lawrenson, K., Garcia-Miranda, P., Tada, M., 
Kajita, M., Mano, H., Ishikawa, S., Ikegawa, M., Shimada, T., et al. (2012). Loss 
of Scribble causes cell competition in mammalian cells. J. Cell Sci. 125, 59–66. 
 
Nose, A., Nagafuchi, A., and Takeichi, M. (1988). Expressed recombinant 
cadherins mediate cell sorting in model systems. Cell 54, 993–1001. 
 
Oertel, M., Menthena, A., Chen, Y.-Q., and Shafritz, D.A. (2006). Properties of 
Cryopreserved Fetal Liver Stem/Progenitor Cells That Exhibit Long-Term 
Repopulation of the Normal Rat Liver. Stem Cells 24, 2244–2251. 
 
Offield, M.F., Jetton, T.L., Labosky, P.A., Ray, M., Stein, R.W., Magnuson, 
M.A., Hogan, B.L., and Wright, C. V (1996). PDX-1 is required for pancreatic 
outgrowth and differentiation of the rostral duodenum. Development 122, 983–
995. 
 
Ohoka, A., Kajita, M., Ikenouchi, J., Yako, Y., Kitamoto, S., Kon, S., Ikegawa, 
M., Shimada, T., Ishikawa, S., and Fujita, Y. (2015). EPLIN is a crucial regulator 
for extrusion of RasV12-transformed cells. J. Cell Sci. 128, 781–789. 
 
Oliver, E.R., Saunders, T.L., Tarle, S.A., and Glaser, T. (2004). Ribosomal 
protein L24 defect in Belly spot and tail (Bst), a mouse Minute. Development 
131, 3907–3920. 
 
Onder, T.T., Gupta, P.B., Mani, S.A., Yang, J., Lander, E.S., and Weinberg, 
R.A. (2008). Loss of E-cadherin promotes metastasis via multiple downstream 
transcriptional pathways. Cancer Res. 
 
Orabi, A.I., Muili, K.A., Wang, D., Jin, S., Perides, G., and Husain, S.Z. (2013). 
Preparation of Pancreatic Acinar Cells for the Purpose of Calcium Imaging, Cell 
Injury Measurements, and Adenoviral Infection. J. Vis. Exp. 77. 
 
Palmer, A., Zimmer, M., Erdmann, K.S., Eulenburg, V., Porthin, A., Heumann, 
R., Deutsch, U., and Klein, R. (2002). EphrinB phosphorylation and reverse 
 198 
signaling: Regulation by Src kinases and PTP-BL phosphatase. Mol. Cell 9, 
725–737. 
 
Parfitt, G.J., Xie, Y., Reid, K.M., Dervillez, X., Brown, D.J., and Jester, J. V. 
(2012). A Novel Immunofluorescent Computed Tomography (ICT) Method to 
Localise and Quantify Multiple Antigens in Large Tissue Volumes at High 
Resolution. PLoS One. 7, e53245. 
 
Park, J.E., Son, A.I., and Zhou, R. (2013). Roles of EphA2 in development and 
disease. Genes. 4, 334-357. 
 
Park, M.K., Lee, M., and Petersen, O.H. (2004). Morphological and functional 
changes of dissociated single pancreatic acinar cells: Testing the suitability of 
the single cells as a model for exocytosis and calcium signaling. Cell Calcium. 
35, 367-379. 
 
Parsons, B.L., and Meng, F. (2009). K-RAS mutation in the screening, 
prognosis and treatment of cancer. Biomark. Med. 3, 757–769. 
 
Pasquale, E.B. (2010). Eph receptors and ephrins in cancer: Bidirectional 
signalling and beyond. Nat. Rev. Cancer 10, 165–180. 
 
Pasquale, E.B., Aasheim, H.C., Munthe, E., Funderud, S., Smeland, E.B., 
Beiske, K., Logtenberg, T., Alfaro, D., Garcia-Ceca, J.J., Cejalvo, T., et al. 
(2008). Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 
38–52. 
 
Penzo-Méndez, A.I., Chen, Y.J., Li, J., Witze, E.S., and Stanger, B.Z. (2015). 
Spontaneous cell competition in immortalized mammalian cell lines. PLoS One 
10. e0132437. 
 
Phillip, J.M., Aifuwa, I., Walston, J., and Wirtz, D. (2015). The Mechanobiology 
of Aging. Annu. Rev. Biomed. Eng. 17, 113–141. 
 
Pierreux, C.E., Cordi, S., Hick, A.C., Achouri, Y., Ruiz de Almodovar, C., 
Prévot, P.P., Courtoy, P.J., Carmeliet, P., and Lemaigre, F.P. (2010). Epithelial: 
Endothelial cross-talk regulates exocrine differentiation in developing pancreas. 
Dev. Biol. 347, 216-227. 
 
Pommier, A., Anaparthy, N., Memos, N., Kelley, Z.L., Gouronnec, A., Yan, R., 
Auffray, C., Albrengues, J., Egeblad, M., Iacobuzio-Donahue, C.A., et al. 
(2018). Unresolved endoplasmic reticulum stress engenders immune-resistant, 
latent pancreatic cancer metastases. Science. 1–15. 
 
Porazinski, S., de Navascués, J., Yako, Y., Hill, W., Jones, M.R., Maddison, R., 
Fujita, Y., and Hogan, C. (2016). EphA2 Drives the Segregation of Ras-
Transformed Epithelial Cells from Normal Neighbors. Curr. Biol. 26, 3220–
3229. 
 
 199 
Poruk, K.E., Gay, D.Z., Brown, K., Mulvihill, J.D., Boucher, K.M., Scaife, C.L., 
Firpo, M.A., and Mulvihill, S.J. (2013). The clinical utility of CA 19-9 in 
pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr. Mol. 
Med. 13, 340–351. 
 
Prévot, P.-P., Simion, A., Grimont, A., Colletti, M., Khalaileh, A., Van den Steen, 
G., Sempoux, C., Xu, X., Roelants, V., Hald, J., et al. (2012). Role of the ductal 
transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia. 
Gut 61, 1723–1732. 
 
Prior, I.A., Lewis, P.D., and Mattos, C. (2012). A comprehensive survey of ras 
mutations in cancer. Cancer Res. 72, 2457–2467. 
 
Prober, D.A., and Edgar, B.A. (2000). Ras1 promotes cellular growth in the 
Drosophila wing. Cell 100, 435–446. 
 
Raff, M.C. (1992). Social controls on cell survival and cell death. Nature 356, 
397–400. 
 
Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., and 
Matrisian, L.M. (2014). Projecting Cancer Incidence and Deaths to 2030: The 
Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United 
States. Cancer Res. 74, 2913 LP-2921. 
 
Raimondi, S., Maisonneuve, P., and Lowenfels, A.B. (2009). Epidemiology of 
pancreatic cancer: an overview. Nat. Rev. Gastroenterol. Hepatol. 6, 699. 
 
Reichert, M., Takano, S., Heeg, S., Bakir, B., Botta, G.P., and Rustgi, A.K. 
(2013). Isolation, culture and genetic manipulation of mouse pancreatic ductal 
cells. Nat. Protoc. 8, 1354–1365. 
 
Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., 
Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al. (2012). EMT 
and dissemination precede pancreatic tumor formation. Cell 148, 349–361. 
 
Rhim, A.D., Thege, F.I., Santana, S.M., Lannin, T.B., Saha, T.N., Tsai, S., 
Maggs, L.R., Kochman, M.L., Ginsberg, G.G., Lieb, J.G., et al. (2014). 
Detection of circulating pancreas epithelial cells in patients with pancreatic 
cystic lesions. Gastroenterology 146, 647–651. 
 
Rhiner, C., López-Gay, J.M., Soldini, D., Casas-Tinto, S., Martín, F.A., 
Lombardía, L., and Moreno, E. (2010). Flower forms an extracellular code that 
reveals the fitness of a cell to its neighbors in Drosophila. Dev. Cell 18, 985–
998. 
 
Rodrigues, A.B., Zoranovic, T., Ayala-Camargo, A., Grewal, S., Reyes-Robles, 
T., Krasny, M., Wu, D.C., Johnston, L.A., and Bach, E.A. (2012). Activated 
STAT regulates growth and induces competitive interactions independently of 
Myc, Yorkie, Wingless and ribosome biogenesis. Development 139, 4051–
4061. 
 200 
 
Rodriguez-Boulan, E., and Macara, I.G. (2014). Organization and execution of 
the epithelial polarity programme. Nat. Rev. Mol. Cell Biol. 15, 225–242. 
 
Roh-Johnson, M., Shemer, G., Higgins, C.D., McClellan, J.H., Werts, A.D., 
Tulu, U.S., Gao, L., Betzig, E., Kiehart, D.P., and Goldstein, B. (2012). 
Triggering a cell shape change by exploiting preexisting actomyosin 
contractions. Science. 335, 1232–1235. 
 
Rohani, N., Canty, L., Luu, O., Fagotto, F., and Winklbauer, R. (2011). 
EphrinB/EphB signaling controls embryonic germ layer separation by contact-
induced cell detachment. PLoS Biol. e1000597. 
 
Rosenblatt, J., Raff, M.C., and Cramer, L.P. (2001). An epithelial cell destined 
for apoptosis signals its neighbors to extrude it by an actin- and myosin-
dependent mechanism. Curr. Biol. 11, 1847–1857. 
 
Saito, T., Masuda, N., Miyazaki, T., Kanoh, K., Suzuki, H., Shimura, T., Asao, 
T., and Kuwano, H. (2004). Expression of EphA2 and E-cadherin in colorectal 
cancer: Correlation with cancer metastasis. Oncol. Rep. 11, 605–611. 
 
Saitoh, S., Maruyama, T., Yako, Y., Kajita, M., Fujioka, Y., Ohba, Y., Kasai, N., 
Sugama, N., Kon, S., Ishikawa, S., et al. (2017). Rab5-regulated endocytosis 
plays a crucial role in apical extrusion of transformed cells. Proc. Natl. Acad. 
Sci. 114, E2327–E2336. 
 
Saka, Y., Lhoussaine, C., Kuttler, C., Ullner, E., and Thiel, M. (2011). 
Theoretical basis of the community effect in development. BMC Syst. Biol. 5, 
54. 
 
Sancho, M., Di-Gregorio, A., George, N., Pozzi, S., Sánchez, J.M., Pernaute, 
B., and Rodríguez, T.A. (2013). Competitive interactions eliminate unfit 
embryonic stem cells at the onset of differentiation. Dev. Cell 26, 19–30. 
 
Sasaki, A., Nagatake, T., Egami, R., Gu, G., Takigawa, I., Ikeda, W., Nakatani, 
T., Kunisawa, J., and Fujita, Y. (2018). Obesity Suppresses Cell-Competition-
Mediated Apical Elimination of RasV12-Transformed Cells from Epithelial 
Tissues. Cell Rep. 23, 974-982. 
 
Sausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R.J., Barrett, M.T., 
Anagnostou, V., Parpart-Li, S., Murphy, D., Li, Q.K., et al. (2015). Clinical 
implications of genomic alterations in the tumour and circulation of pancreatic 
cancer patients. Nat. Commun. 6, 7686. 
 
Saw, T.B., Doostmohammadi, A., Nier, V., Kocgozlu, L., Thampi, S., Toyama, 
Y., Marcq, P., Lim, C.T., Yeomans, J.M., and Ladoux, B. (2017). Topological 
defects in epithelia govern cell death and extrusion. Nature 544, 212–216. 
 
Schnekenburger, J., Mayerle, J., Krüger, B., Buchwalow, I., Weiss, F.U., 
Albrecht, E., Samoilova, V.E., Domschke, W., and Lerch, M.M. (2005). Protein 
 201 
tyrosine phosphatase κ and SHP-1 are involved in the regulation of cell-cell 
contacts at adherens junctions in the exocrine pancreas. Gut 54, 1445–1455. 
 
Scholzen, T., and Gerdes, J. (2000). The Ki-67 protein: From the known and 
the unknown. J. Cell. Physiol. 182, 311–322. 
 
Senoo-Matsuda, N., and Johnston, L. a (2007). Soluble factors mediate 
competitive and cooperative interactions between cells expressing different 
levels of Drosophila Myc. Proc. Natl. Acad. Sci. 104, 18543-18548. 
 
Seymour, P.A., Freude, K.K., Tran, M.N., Mayes, E.E., Jensen, J., Kist, R., 
Scherer, G., and Sander, M. (2007). SOX9 is required for maintenance of the 
pancreatic progenitor cell pool. Proc. Natl. Acad. Sci. 104, 1865-1870. 
 
Shamah, S.M., Lin, M.Z., Goldberg, J.L., Estrach, S., Sahin, M., Hu, L., 
Bazalakova, M., Neve, R.L., Corfas, G., Debant, A., et al. (2001). EphA 
receptors regulate growth cone dynamics through the novel guanine nucleotide 
exchange factor ephexin. Cell. 105, 233-244. 
 
Shi, G., DiRenzo, D., Qu, C., Barney, D., Miley, D., and Konieczny, S.F. (2013). 
Maintenance of acinar cell organization is critical to preventing Kras-induced 
acinar-ductal metaplasia. Oncogene 32, 1950–1958. 
 
Shiozawa, Y., Pedersen, E.A., Havens, A.M., Jung, Y., Mishra, A., Joseph, J., 
Kim, J.K., Patel, L.R., Ying, C., Ziegler, A.M., et al. (2011). Human prostate 
cancer metastases target the hematopoietic stem cell niche to establish 
footholds in mouse bone marrow. J. Clin. Invest. 121, 1298–1312. 
 
Shraiman, B.I. (2005). Mechanical feedback as a possible regulator of tissue 
growth. Proc. Natl. Acad. Sci. 102, 3318–3323. 
 
Siegel, R.L., Miller, K.D., and Jemal, A. (2016a). Cancer statistics, 2016. CA. 
Cancer J. Clin. 66, 7–30. 
 
Simonsen, A., Lippé, R., Christoforidis, S., Gaullier, J.M., Brech, A., Callaghan, 
J., Toh, B.H., Murphy, C., Zerial, M., and Stenmark, H. (1998). EEA1 links 
PI(3)K function to Rab5 regulation of endosome fusion. Nature. 394, 494. 
 
Simpson, P. (1979). Parameters of cell competition in the compartments of the 
wing disc of Drosophila. Dev. Biol. 69, 182–193. 
 
Simpson, P., and Morata, G. (1981). Differential mitotic rates and patterns of 
growth in compartments in the Drosophila wing. Dev. Biol. 85, 299–308. 
 
Sivaraman, V.S., Wang, H., Nuovo, G.J., and Malbon, C.C. (1997). 
Hyperexpression of mitogen-activated protein kinase in human breast cancer. 
J. Clin. Invest. 99, 1478–1483. 
 
Slaghter, D.P., Southwick, H.W., and Smejkal, W. (1953). Field canerisation in 
oral stratified squamous epithelium. Cancer 6, 963–968. 
 202 
 
Slattum, G., Gu, Y., Sabbadini, R., and Rosenblatt, J. (2014). Autophagy in 
oncogenic K-Ras promotes basal extrusion of epithelial cells by degrading S1P. 
Curr. Biol. 24, 19–28. 
 
Smith, F.M., Vearing, C., Lackmann, M., Treutlein, H., Himanen, J., Chen, K., 
Saul, A., Nikolov, D., and Boyd, A.W. (2004). Dissecting the EphA3/Ephrin-A5 
interactions using a novel functional mutagenesis screen. J. Biol. Chem. 279, 
9522–9531. 
 
Snippert, H.J., van der Flier, L.G., Sato, T., van Es, J.H., van den Born, M., 
Kroon-Veenboer, C., Barker, N., Klein, A.M., van Rheenen, J., Simons, B.D., et 
al. (2010). Intestinal crypt homeostasis results from neutral competition 
between symmetrically dividing Lgr5 stem cells. Cell. 143, 134-144. 
 
Soares, C.P., Midlej, V., de Oliveira, M.E.W., Benchimol, M., Costa, M.L., and 
Mermelstein, C. (2012). 2D and 3D-organized cardiac cells shows differences 
in cellular morphology, adhesion junctions, presence of myofibrils and protein 
expression. PLoS One 7. e38147. 
 
Solanas, G., Cortina, C., Sevillano, M., and Batlle, E. (2011). Cleavage of E-
cadherin by ADAM10 mediates epithelial cell sorting downstream of EphB 
signalling. Nat. Cell Biol. 13, 1100–1109. 
 
Sousa, C.M., and Kimmelman, A.C. (2014). The complex landscape of 
pancreatic cancer metabolism. Carcinogenesis. 35, 1441-1450. 
 
St Johnston, D., and Ahringer, J. (2010). Cell polarity in eggs and epithelia: 
Parallels and diversity. Cell 141, 757–774. 
 
Steinberg, M.S. (1963). Reconstruction of tissues by dissociated cells. Some 
morphogenetic tissue movements and the sorting out of embryonic cells may 
have a common explanation. Science. 141, 401–408. 
 
Steinberg, M.S. (2007). Differential adhesion in morphogenesis: a modern view. 
Curr. Opin. Genet. Dev. 17, 281–286. 
 
Stoker, M., and Rubin, H. (1967). Density dependent inhibition of cell growth in 
culture. Nature 215, 171–172. 
 
Stopczynski, R.E., Normolle, D.P., Hartman, D.J., Ying, H., DeBerry, J.J., 
Bielefeldt, K., Rhim, A.D., DePinho, R.A., Albers, K.M., and Davis, B.M. (2014). 
Neuroplastic changes occur early in the development of pancreatic ductal 
adenocarcinoma. Cancer Res. 2050. 
 
Storz, P. (2017). Acinar cell plasticity and development of pancreatic ductal 
adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 14, 296–304. 
 
Stromnes, I.M., DelGiorno, K.E., Greenberg, P.D., and Hingorani, S.R. (2014). 
Stromal re-engineering to treat pancreas cancer. Carcinogenesis 35. 
 203 
 
Suijkerbuijk, S.J.E., Kolahgar, G., Kucinski, I., and Piddini, E. (2016). Cell 
competition drives the growth of intestinal adenomas in Drosophila. Curr. Biol. 
26, 428–438. 
 
Tamori, Y., and Deng, W.M. (2013). Tissue Repair through Cell Competition 
and Compensatory Cellular Hypertrophy in Postmitotic Epithelia. Dev. Cell 25, 
350–363. 
 
Tamori, Y., Bialucha, C.U., Tian, A.G., Kajita, M., Huang, Y.C., Norman, M., 
Harrison, N., Poulton, J., Ivanovitch, K., Disch, L., et al. (2010). Involvement of 
Lgl and mahjong/VprBP in cell competition. PLoS Biol. 8. e1000422. 
 
Tape, C.J., Ling, S., Dimitriadi, M., McMahon, K.M., Worboys, J.D., Leong, 
H.S., Norrie, I.C., Miller, C.J., Poulogiannis, G., Lauffenburger, D.A., et al. 
(2016). Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal 
Reciprocation. Cell. 165, 910-920. 
 
Thiery, J.P., Acloque, H., Huang, R.Y.J., and Nieto, M.A. (2009). Epithelial-
Mesenchymal Transitions in Development and Disease. Cell 139, 871–890. 
 
Tobita, K., Kijima, H., Dowaki, S., Kashiwagi, H., Ohtani, Y., Oida, Y., 
Yamazaki, H., Nakamura, M., Ueyama, Y., Tanaka, M., et al. (2003). Epidermal 
growth factor receptor expression in human pancreatic cancer: Significance for 
liver metastasis. Int. J. Mol. Med. 11, 305-309. 
 
Toyoda, Y., Shinohara, R., Thumkeo, D., Kamijo, H., Nishimaru, H., Hioki, H., 
Kaneko, T., Ishizaki, T., Furuyashiki, T., and Narumiya, S. (2013). EphA4-
dependent axon retraction and midline localization of Ephrin-B3 are disrupted in 
the spinal cord of mice lacking mDia1 and mDia3 in combination. Genes to 
Cells. 18, 873-885. 
 
Trajkovic-Arsic, M., Kalideris, E., and Siveke, J.T. (2013). The role of insulin 
and IGF system in pancreatic cancer. J. Mol. Endocrinol. 50, 67-74. 
 
Trepat, X., and Sahai, E. (2018). Mesoscale physical principles of collective cell 
organization. Nat. Phys. 1. 
 
Tuveson, D.A., Shaw, A.T., Willis, N.A., Silver, D.P., Jackson, E.L., Chang, S., 
Mercer, K.L., Grochow, R., Hock, H., Crowley, D., et al. (2004). Endogenous 
oncogenic K-rasG12Dstimulates proliferation and widespread neoplastic and 
developmental defects. Cancer Cell 5, 375–387. 
 
Twigg, S.R.F., Kan, R., Babbs, C., Bochukova, E.G., Robertson, S.P., Wall, 
S.A., Morriss-Kay, G.M., and Wilkie, A.O.M. (2004). Mutations of ephrin-B1 
(EFNB1), a marker of tissue boundary formation, cause craniofrontonasal 
syndrome. Proc. Natl. Acad. Sci. U. S. A. 101, 8652–8657. 
 
Tyler, D.M., Li, W., Zhuo, N., Pellock, B., and Baker, N.E. (2007). Genes 
affecting cell competition in drosophila. Genetics 175, 643–657. 
 204 
 
Vaughen, J., and Igaki, T. (2016). Slit-Robo Repulsive Signaling Extrudes 
Tumorigenic Cells from Epithelia. Dev. Cell 39, 683–695. 
 
Verdu, J., Buratovicht, M.A., Wilder, E.L., and Birnbaum, M.J. (1999). Cell-
autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat. 
Cell Biol. 1, 500–506. 
 
Vihanto, M.M., Vindis, C., Djonov, V., Cerretti, D.P., and Huynh-Do, U. (2006). 
Caveolin-1 is required for signaling and membrane targeting of EphB1 receptor 
tyrosine kinase. J. Cell Sci. 119, 2299-2309. 
 
Villa del Campo, C., Clavería, C., Sierra, R., and Torres, M. (2014). Cell 
competition promotes phenotypically silent cardiomyocyte replacement in the 
mammalian heart. Cell Rep. 8, 1741–1751. 
 
Villasenor, A., Chong, D.C., Henkemeyer, M., and Cleaver, O. (2010). Epithelial 
dynamics of pancreatic branching morphogenesis. Development. 137, 4295-
4305. 
 
Vincent, J.P., Kolahgar, G., Gagliardi, M., and Piddini, E. (2011). Steep 
Differences in Wingless Signaling Trigger Myc-Independent Competitive Cell 
Interactions. Dev. Cell 21, 366–374. 
 
Vooijs, M., Jonkers, J., and Berns, A. (2001). A highly efficient ligand-regulated 
Cre recombinase mouse line shows that LoxP recombination is position 
dependent. EMBO Rep. 2, 292-297. 
 
Waddell, N., Pajic, M., Patch, A.M., Chang, D.K., Kassahn, K.S., Bailey, P., 
Johns, A.L., Miller, D., Nones, K., Quek, K., et al. (2015). Whole genomes 
redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501. 
 
Wagstaff, L., Goschorska, M., Kozyrska, K., Duclos, G., Kucinski, I., Chessel, 
A., Hampton-O’Neil, L., Bradshaw, C.R., Allen, G.E., Rawlins, E.L., et al. 
(2016a). Mechanical cell competition kills cells via induction of lethal p53 levels. 
Nat. Commun. 7, 11373. 
 
Wahl, S., Barth, H., Ciossek, T., Aktories, K., and Mueller, B.K. (2000). Ephrin-
A5 induces collapse of growth cones by activating Rho and Rho kinase. J. Cell 
Biol. 149, 263–270. 
 
Wakayama, Y., Miura, K., Sabe, H., and Mochizuki, N. (2011). EphrinA1-EphA2 
signal induces compaction and polarization of Madin-Darby canine kidney cells 
by inactivating Ezrin through negative regulation of RhoA. J. Biol. Chem. 286, 
44243–44253. 
 
Walker-Daniels, J., Coffman, K., Azimi, M., Rhim, J.S., Bostwick, D.G., Snyder, 
P., Kerns, B.J., Waters, D.J., and Kinch, M.S. (1999). Overexpression of the 
EphA2 tyrosine kinase in prostate cancer. Prostate 41, 275–280. 
 
 205 
Wang, H.U., and Anderson, D.J. (1997). Eph family transmembrane ligands can 
mediate repulsive guidance of trunk neural crest migration and motor axon 
outgrowth. Neuron 18, 383–396. 
 
Watanabe, H., Ishibashi, K., Mano, H., Kitamoto, S., Sato, N., Hoshiba, K., 
Kato, M., Matsuzawa, F., Takeuchi, Y., Shirai, T., et al. (2018). Mutant p53-
Expressing Cells Undergo Necroptosis via Cell Competition with the 
Neighboring Normal Epithelial Cells. Cell Rep. 23, 3721–3729. 
 
Watanabe, T., Sato, Y., Saito, D., Tadokoro, R., and Takahashi, Y. (2009). 
EphrinB2 coordinates the formation of a morphological boundary and cell 
epithelialization during somite segmentation. Proc. Natl. Acad. Sci. 106, 7467–
7472. 
 
Wheelock, M.J., Shintani, Y., Maeda, M., Fukumoto, Y., and Johnson, K.R. 
(2008). Cadherin switching. J. Cell Sci. 121, 727–735. 
 
Wildenberg, G.A., Dohn, M.R., Carnahan, R.H., Davis, M.A., Lobdell, N.A., 
Settleman, J., and Reynolds, A.B. (2006). p120-Catenin and p190RhoGAP 
Regulate Cell-Cell Adhesion by Coordinating Antagonism between Rac and 
Rho. Cell 127, 1027–1039. 
 
Wilentz, R.E., Geradts, J., Maynard, R., Offerhaus, G.J.A., Kang, M., Goggins, 
M., Yeo, C.J., Kern, S.E., and Hruban, R.H. (1998). Inactivation of the p16 
(INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear 
expression. Cancer Res. 58, 4740–4744. 
 
Wilentz, R.E., Iacobuzio-Donahue, C.A., Argani, P., McCarthy, D.M., Parsons, 
J.L., Yeo, C.J., Kern, S.E., and Hruban, R.H. (2000). Loss of expression of 
Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation 
occurs late in neoplastic progression. Cancer Res. 60, 2002–2006. 
 
Williams Parsons, D., Jones, S., Zhang, X., Cheng-Ho Lin, J., Leary, R.J., 
Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G.L., et al. (2008). An 
Integrated Genomic Analysis of Human Glioblastoma Multiforme I An Integrated 
Genomic Analysis of Human Glioblastoma Multiforme. Source Sci. New Ser. 
321, 1807–1812. 
 
Witkiewicz, A.K., McMillan, E.A., Balaji, U., Baek, G.H., Lin, W.C., Mansour, J., 
Mollaee, M., Wagner, K.U., Koduru, P., Yopp, A., et al. (2015). Whole-exome 
sequencing of pancreatic cancer defines genetic diversity and therapeutic 
targets. Nat. Commun. 6. 
 
Wójciak-Stothard, B., Potempa, S., Eichholtz, T., and Ridley, A.J. (2001). Rho 
and Rac but not Cdc42 regulate endothelial cell permeability. J. Cell Sci. 
 
Wollny, D., Zhao, S., Everlien, I., Lun, X., Brunken, J., Brüne, D., Ziebell, F., 
Tabansky, I., Weichert, W., Marciniak-Czochra, A., et al. (2016). Single-Cell 
Analysis Uncovers Clonal Acinar Cell Heterogeneity in the Adult Pancreas. 
Dev. Cell 39, 289–301. 
 206 
 
Woods, D.F., and Bryant, P.J. (1991). The discs-large tumor suppressor gene 
of Drosophila encodes a guanylate kinase homolog localized at septate 
junctions. Cell 66, 451–464. 
 
Wu, S.K., Gomez, G.A., Michael, M., Verma, S., Cox, H.L., Lefevre, J.G., 
Parton, R.G., Hamilton, N.A., Neufeld, Z., and Yap, A.S. (2014). Cortical F-actin 
stabilization generates apical-lateral patterns of junctional contractility that 
integrate cells into epithelia. Nat. Cell Biol. 16, 167–178. 
 
Wu, S.K., Lagendijk, A.K., Hogan, B.M., Gomez, G.A., and Yap, A.S. (2015). 
Active contractility at E-cadherin junctions and its implications for cell extrusion 
in cancer. Cell Cycle 14, 315–322. 
 
Xu, N.J., and Henkemeyer, M. (2009). Ephrin-B3 reverse signaling through 
Grb4 and cytoskeletal regulators mediates axon pruning. Nat. Neurosci. 12, 
268–276. 
 
Xu, M., Jung, X., Hines, O.J., Eibl, G., and Chen, Y. (2018). Obesity and 
Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by 
Weight Loss. Pancreas 47, 158–162. 
 
Xu, Q., Mellitzer, G., Robinson, V., and Wilkinson, D.G. (1999). In vivo cell 
sorting in complementary segmental domains mediated by Eph receptors and 
ephrins. Nature 399, 267–271. 
 
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., 
Hruban, R.H., Eshleman, J.R., Nowak, M.A., et al. (2010). Distant metastasis 
occurs late during the genetic evolution of pancreatic cancer. Nature 467, 
1114–1117. 
 
Yakubovskaya, M.S., Spiegelman, V., Luo, F.C., Malaev, S., Salnev, A., 
Zborovskaya, I., Gasparyan, A., Polotsky, B., Machaladze, Z., Trachtenberg, 
A.C., et al. (1995). High frequency of K- ras mutations in normal appearing lung 
tissues and sputum of patients with lung cancer. Int. J. Cancer 63, 810–814. 
 
Yamaguchi, J., Yokoyama, Y., Kokuryo, T., Ebata, T., and Nagino, M. (2017). 
Cells of origin of pancreatic neoplasms. Surg. Today 0, 1–9. 
 
Yan, L., McFaul, C., Howes, N., Leslie, J., Lancaster, G., Wong, T., Threadgold, 
J., Evans, J., Gilmore, I., Smart, H., et al. (2005). Molecular analysis to detect 
pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128, 
2124–2130. 
 
Yeddula, N., Xia, Y., Ke, E., Beumer, J., and Verma, I.M. (2015). Screening for 
tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic 
KRas in promoting lung adenocarcinoma. Proc. Natl. Acad. Sci. 112, E6476–
E6485. 
 
 207 
Yin, Y., Yamashita, Y., Noda, H., Okafuji, T., Go, M.J., and Tanaka, H. (2004). 
EphA receptor tyrosine kinases interact with co-expressed ephrin-A ligands in 
cis. Neurosci. Res. 48, 285–296. 
 
Ying, H., Dey, P., Yao, W., Kimmelman, A.C., Draetta, G.F., Maitra, A., and 
Depinho, R.A. (2016). Genetics and biology of pancreatic ductal 
adenocarcinoma. Genes Dev. 30, 355-385. 
 
Zantek, N.D., Azimi, M., Fedor-Chaiken, M., Wang, B., Brackenbury, R., and 
Kinch, M.S. (1999). E-cadherin regulates the function of the EphA2 receptor 
tyrosine kinase. Cell Growth Differ. 10, 629–638. 
 
Zelinski, D.P., Zantek, N.D., Stewart, J.C., Irizarry, A.R., and Kinch, M.S. 
(2001). EphA2 overexpression causes tumorigenesis of mammary epithelial 
cells. Cancer Res. 61, 2301–2306. 
 
Zhang, K., Myllymäki, S.M., Gao, P., Devarajan, R., Kytölä, V., Nykter, M., Wei, 
G.H., and Manninen, A. (2017). Oncogenic K-Ras upregulates ITGA6 
expression via FOSL1 to induce anoikis resistance and synergizes with αV-
Class integrins to promote EMT. Oncogene 36, 5681–5694. 
 
Zhou, H., Qin, Y., Ji, S., Ling, J., Fu, J., Zhuang, Z., Fan, X., Song, L., Yu, X., 
and Chiao, P.J. (2018). SOX9 activity is induced by oncogenic Kras to affect 
MDC1 and MCMs expression in pancreatic cancer. Oncogene. 37, 912. 
 
Zhu, L., Shi, G., Schmidt, C.M., Hruban, R.H., and Konieczny, S.F. (2007). 
Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic 
Intraepithelial Neoplasia. Am. J. Pathol. 171, 263–273. 
 
Zhu, Z., Kleeff, J., Friess, H., Wang, L., Zimmermann, A., Yarden, Y., Büchler, 
M.W., and Korc, M. (2000). Epiregulin is up-regulated in pancreatic cancer and 
stimulates pancreatic cancer cell growth. Biochem. Biophys. Res. Commun. 
273, 1019-1024. 
 
Zhuang, G., Brantley-Sieders, D.M., Vaught, D., Yu, J., Xie, L., Wells, S., 
Jackson, D., Muraoka-Cook, R., Arteaga, C., and Chen, J. (2010). Elevation of 
receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. 
Cancer Res. 70, 299–308. 
 
Zimmer, M., Palmer, A., Köhler, J., and Klein, R. (2003). EphB-ephrinB bi-
directional endocytosis terminates adhesion allowing contact mediated 
repulsion. Nat. Cell Biol. 5, 869–878. 
 
Ziosi, M., Baena-López, L.A., Grifoni, D., Froldi, F., Pession, A., Garoia, F., 
Trotta, V., Bellosta, P., Cavicchi, S., and Pession, A. (2010). dMyc functions 
downstream of yorkie to promote the supercompetitive behavior of hippo 
pathway mutant Cells. PLoS Genet. 6. 
 
 
 
